Drug, bio-affecting and body treating compositions inventions 08/09

20090214419 - Self-assembled biodegradable polymersomes: The invention concerns a block copolymer of polyethylene oxide and polycaprolactone, the polyethylene oxide having a number average molecular weight from about 2.0 to about 3.8 kD, the block copolymer having a fraction of polyethylene oxide of from about 11.8 to 18.8 percent by weight. The invention also concerns polymersomes... Agent: Woodcock Washburn LLP

20090214422 - dna encoding a novel rg1 polypeptide: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides,... Agent: Mandel & Adriano

20090214421 - Antibody directed against pap2a and use thereof for diagnostic and therapeutic purposes: The present invention aims at developing a gene delivery system which has a high selectivity to a target cell and can introduce and express a gene with high efficiency, particularly developing such a system for use in a gene delivery therapy using a viral vector. The present invention provides a... Agent: Foley And Lardner LLP Suite 500

20090214420 - Method of diagnosis and treatment and agents useful for same: The present invention relates generally to a method of screening for the level of neoplastic cell death in a subject. More particularly, the present invention provides a method of screening for the level of neoplastic cell death by detecting the level of expression of telomerase protein and/or gene by dead... Agent: Scully, Scott, Murphy & Presser, P.c.

20090214423 - Selective targeting of tumor vasculature using radiolabelled antibody molecules: A specific binding member that binds human ED-B, wherein the specific binding member is labelled with an isotope selected from the group consisting of 76Br, 77Br, 123I, 124I, 131I and 211At and comprises an antigen-binding site that comprises an antibody VH domain and an antibody VL domain, wherein the antibody... Agent: Millen, White, Zelano & Branigan, P.c.

20090214424 - Human glycoprotein hormone superagonists and uses thereof: The present invention provides improved methods of imaging, targeted therapy and detection and diagnostics using modified glycoprotein hormones having increased activity over wild-type hormones.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090214425 - Tumor therapy with replication competent sindbis viral vectors: Disclosed herein are methods for treating a mammal harboring a solid tumor which expresses higher levels of High Affinity Laminin Receptors (LAMR) than normal cells of the same lineage comprising systematically administering to a mammal in need of such treatment a therapeutically effective amount of a Replication Competent (RC) Sindbis... Agent: Darby & Darby P.c.

20090214426 - Assay method: The present invention is related to the field of pharmacy. The present invention more particularly discloses a method of determining the emotional, sensory, physiological, social and cognitive effects of a pain condition in a non human animal and further discloses a method for preclinically identifying pharmaceutical therapeutics which improve the... Agent: Pfizer Inc. Patent Department

20090214428 - Human monoclonal antibodies against hendra and nipah viruses: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for... Agent: Morgan Lewis & Bockius LLP

20090214429 - Methods and compositions related to targeting tumors and wounds: Disclosed are compositions and methods useful for targeting tumors, sites of injury and blood clots. The compositions and methods are based on peptide sequences that selectively bind to and home to tumors, sites of injury and blood clots in animals. The disclosed targeting is useful for delivering therapeutic and detectable... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090214427 - Novel peptides: s

20090214430 - Polypeptide specifically bound to phosphatidylserine and the use thereof: The present invention relates to a polypeptide specifically bound to phosphatidylserine and use thereof, and more particularly to a polypeptide having an amino acid sequence designated as sequence number 1 and specifically bound to phosphatidylserine, a phosphatidylserine detecting composition containing the polypeptide as an active ingredient, a detecting method of... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090214431 - Identification of ergothioneine transporter and therapeutic uses thereof: The transporter that translocates ergothioneine has been identified. Described are methods for identifying and obtaining compounds capable of modulating ergothioneine transport as well as the use of such compounds for the treatment of diseases ergothioneine may be involved in such as autoimmune diseases, in particular rheumatoid arthritis, as well as... Agent: Mckee, Voorhees & Sease, P.L.C

20090214433 - Hyperpolarized solid materials with long spin relaxation times for use as imaging agents in magnetic resonance imaging: An imaging agent is disclosed for use in nuclear magnetic resonance imaging. The imaging agent includes a first substance and a second substance. The first substance includes at least one atom having non-zero nuclear spin providing a polarized magnetic orientation. The second substance is bound to the first substance and... Agent: Choate, Hall & Stewart LLP

20090214432 - Radicals and their use as paramagnetic agents in a dnp process: The invention relates to new radicals, their use as paramagnetic agents in a method for the dynamic nuclear polarisation and a method for the dynamic nuclear polarisation of compounds comprising carboxyl groups.... Agent: Ge Healthcare, Inc.

20090214441 - Lipophilic chelates and their use in imaging: The invention relates to chelate compounds which can be used in MRI, the chelates being intended to be conveyed by lipophilic transporters, such as lipid nanoparticles or liposomes. The invention also relates to compounds comprising, in association, these chelates and these transporters, if appropriate connected via chemical bonding groups, and... Agent: Birch Stewart Kolasch & Birch

20090214437 - In vivo mitochondrial labeling using positively-charged nitroxide enhanced and gadolinium chelate enhanced magnetic resonance imaging: A system and method for acquiring MR imaging data from a subject includes administering positively-charged nitroxides or gadolinium chelates for in vivo mitochondrial labeling, acquiring MR imaging data from the subject, and reconstructing an image of the subject having enhanced contrast in areas including metabolic and/or mitotic activity.... Agent: Quarles & Brady LLP

20090214438 - Methods and compositions for the preparation and use of toxin conjugates: The present invention relates to methods for the preparation of toxin conjugates that are useful in vaccination and other therapies and diagnostics. In particular, methods are provided that involve a [3+2] cycloaddition between a first reactive unsaturated group on a toxin moiety and a second reactive unsaturated group on a... Agent: Young & Thompson

20090214439 - Fluorinated carbohydrates and their use in tumor visualization, tissue engineering, and cancer chemotherapy: The present invention relates to fluorine-containing monosaccharides that are useful for forming extracellular fluorinated glycoconjugates. Methods of forming extracellular fluorinated glycoconjugates comprise the steps of contacting a cell with a fluorine-containing monosaccharide, and incubating the cell under conditions whereby the cell internalizes the fluorine-containing monosaccharide, or a derivative thereof, on... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090214440 - Method and device for examining a biological tissue: The invention relates to a method and a device for analyzing a biological tissue, whereby a luminescence light of a luminescence substance is detected. The aim of the invention is to increase the precision and reliability of the analysis. To this end, a permutation symmetry imbalance is generated in the... Agent: Siemens Corporation Intellectual Property Department

20090214436 - Dichromic fluorescent compounds: The present invention provides dichromic fluorescent compounds, as well as processes for making and methods for using the dichromic fluorescent compounds.... Agent: Polsinelli Shughart Pc

20090214434 - Method of detecting and treating allogenic cells responsible for endometriosis: There are presently provided methods for identifying an ectopic allogenic cell in a mammalian host, the methods comprising obtaining a first internal soft tissue image, administering an effective amount of iodine to potentiate the host's immune response to aberrant ectopic tissue, obtaining one or more subsequent internal soft tissue images... Agent: Klarquist Sparkman, LLP

20090214435 - Recombinant vector expressing mdr1 shrna and thymidine kinase and use thereof: A recombinant vector capable of expressing MDR1 shRNA and thymidine kinase, and a use thereof. More specifically, provided is a recombinant vector capable of efficiently expressing MDR1 shRNA and thymidine kinase in a host cell, a transfectant cell comprising the same recombinant vector, a composition for treating neoplastic diseases, comprising... Agent: Iphorgan, Ltd.

20090214442 - Oral transmucosal nicotine dosage form: Described herein are oral transmucosal solid dosage forms useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the dosage forms transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such, and manufacture... Agent: Ross J. Oehler Cephalon, Inc.

20090214443 - Method for retarding systemic delivery rate for easily absorbable active agents: Drugs such as hormones, which are easily absorbable through the stratum corneum into the vascular network, are administered to the skin of a patient in an absorption retarding matrix material, thereby retarding the rate at which the drug penetrates into and through the skin.... Agent: Nutter Mcclennen & Fish LLP

20090214444 - Poly aromatic sodium channel blockers: u

20090214445 - Delivery systems for managing release of functional ingredients in an edible composition: A delivery system for inclusion in an edible composition is formulated to have at least one ingredient encapsulated with an encapsulating material. The delivery system and the resulting edible composition may include other ingredients to create a desired release profile for the at least one ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090214446 - Cyclodextrin inclusion complexes and methods of preparing same: Cyclodextrin inclusion complexes, guest stabilizing systems, and methods for preparing and using the same. Some embodiments of the present invention provide a method for making a guest stabilizing system. The method can include mixing cyclodextrin, a solvent and a guest to form a cyclodextrin inclusion complex. The method can further... Agent: Michael Best & Friedrich LLP

20090214447 - Preparation of cationic nanoparticles and personal care compositions comprising said nanoparticles: The present invention is directed to cationic nanoparticles, methods to make them, and the use of compositions containing said nanoparticles in personal care compositions or formulations. The nanoparticles are useful in personal care applications and impart antimicrobial properties to home and personal care products containing them. These cationic nanoparticles also... Agent: Joann Villamizar Ciba Corporation/patent Department

20090214448 - Structures and compositions increasing the stability of peroxide actives: A tooth whitening system is provided. The tooth whitening system includes a carrier, first and second substrates, and first and second tooth whitening compositions.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090214450 - Oral treatment compositions and related methods of manufacture: An oral treatment composition that includes a carrier, an active agent and a silicon dioxide compound. The active agent can be a variety of compositions, such as dental whitening or bleaching agents, desensitizing agents, antimicrobials, anti-plaque agents, remineralizing agents, anti-tartar agents, mouth fresheners, and anesthetics. Optionally, a processing aid can... Agent: Warner Norcross & Judd LLP

20090214449 - Preparation of precipitated silicas useful as fillers in silicon matrices: Carboxylic acids are employed during the preparation of precipitated silica or a suspension of precipitated silica to provide precipitated silicas with low water uptake, which are useful, for example, as reinforcing fillers for silicon matrices.... Agent: Buchanan, Ingersoll & Rooney Pc

20090214451 - Oral hygiene compositions: Oral hygiene compositions suitable for use as dentifrice compositions comprising a silicon abrasive agent are provided.... Agent: Nixon & Vanderhye, Pc

20090214452 - Arginine heteromers for topical administration: The invention is directed to a strategy for providing therapeutic or cosmetic benefit to skin by topically applying arginine chemically bound to a second (non-oligo arginine) compound in order to increase transepithelial delivery of arginine through a combination of increased solubility and flux across the skin. The arginine heteromers of... Agent: King & Spalding

20090214453 - Use of transmission dyes for protecting human skin from browning and ageing: Disclosed is the use of an aqueous dispersion comprising (a) a micronized sparingly soluble organic compound which has a UV-Vis spectrum with a maximum from 380 to 420 nm; and (b) an anionic dispersing agent for protecting the human skin from browning and skin aging.... Agent: Joann Villamizar Ciba Corporation/patent Department

20090214454 - Method for skin whitening using (2z, 8z) - matricaria acid methyl ester: The present invention relates to a method for inhibiting melanin generation or a method for skin whitening using an active fraction of Erigeron breviscapus extract or matricaria acid methyl ester isolated from the same. The active fraction obtained by solvent fractionation from Erigeron breviscapus whole plant extract and (2Z,8Z)-matricaria acid... Agent: Lucas & Mercanti, LLP

20090214455 - Process for making up or caring for keratin materials, comprising the application of compounds a and b, at least one of which is silicone-based: The invention relates to a cosmetic process for coating keratin materials, which consists in applying to the said keratin materials at least one compound A and at least one compound B, at least one of the compounds A and B being a silicone compound, the said compounds A and B... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090214456 - Pigment dispersion composition comprising and ester blend and manufacture thereof: A composition comprising a pigment dispersed in a liquid ester blend vehicle is disclosed, wherein the amount of pigment dispersed in the vehicle is substantially greater than previous pigment dispersions and the dispersion has improved flow properties to facilitate incorporation into a cosmetic formulation. The ester blend contains tridecyl trimellitate... Agent: Marshall, Gerstein & Borun LLP

20090214457 - Antiperspirant composition based on dicarboxylic acid diesters of a c6-c18 dicarboxylic acid with c12-c22 fatty alcohols: A composition for cosmetic compositions which contains (a) at least one dicarboxylic acid diester of a C6-C13 dicarboxylic acid with a C12-22 fatty alcohol; (b) at least one oil component. The composition provides excellent antiperspirant and deodorant sticks when combined with an antiperspirant or deodorizing composition. Addition of a pigment... Agent: Fox Rothschild LLP

20090214459 - Method of using certain cationic polymers as antioxidants or free-radical scavengers: c

20090214458 - Cosmetic composition comprising at least one specific silicone copolymer, at least one volatile solvent and at least one certain silicone resin: The present disclosure relates to a keratin fiber treatment composition comprising at least one copolymer comprising at least one silicone resin and at least one fluid silicone, at least one volatile solvent, and at least one silicone resin having at least one trifunctional unit of the formula (R)SiO3/2 (T unit).... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090214460 - Composition comprising a monomer compound exhibiting an optical property, method making use of said composition, a monomer compound and a polymer containing said monomer compound and the use thereof: The invention relates to a cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, at least one type of polymer containing at least one type of novel monomer compound exhibiting optical properties. Said invention also relates to a cosmetic method for making up or treating keratinous materials, in particular... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090214461 - Polymer particle dispersion, cosmetic composition comprising it and cosmetic process using it: Another aspect of the present disclosure relates to a dispersion of polymer particles in a liquid silicone medium, and also to a cosmetic process for making up, cleansing, protecting against the sun, shaping, dyeing or caring for keratin materials, such as the body or facial skin, the nails, the hair... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090214462 - Cockcroach jelly bait: The present invention provides jelly bait for carrying insecticide to kill cockroaches. The jelly bait benefits from maintaining its softness for longer periods of time, which results in higher successful rates in luring and then killing cockroaches. The jelly bait can be injected with a syringe into the crevices or... Agent: Jianq Chyun Intellectual Property Office

20090214464 - Compounds for flaviviridae treatment: Disclosed are non-immunosuppressive cyclophilin-binding cyclosporins, e.g. of formula I, Ia or II as defined herein, having useful properties in the prevention or treatment of Flaviviridae infections and Flaviviridae induced disorders.... Agent: Mccarter & English, LLP Wilmington Basil S. Krikelis

20090214470 - Eye-drop vaccine containing copolymer 1 for therapeutic immunization: The invention provides an eye-drop vaccine for therapeutic immunization of a mammal comprising Copolymer 1, a Copolymer 1-related peptide, or a Copolymer 1-related polypeptide, for treating neuronal degeneration caused by an injury or disease, disorder or condition in the central nervous system (CNS) or peripheral nervous system (PNS), for preventing... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090214463 - Latent phase viral interleukin-10-(vii-10) and uses thereof: The present invention relates to a purified nucleic acid sequence encoding a homologue of human interleukin 10 (IL-10), wherein said IL-10 homologue is expressed during the latent phase of infection by a virus of the herpesvirideae group. The present invention also relates to uses of this polypeptide, in particular for... Agent: Knobbe Martens Olson & Bear LLP

20090214468 - Localized insulin delivery for bone healing: A method of promoting bone healing in a non-diabetic patient in need thereof by locally administering a therapeutically effective amount of insulin to the patient. A drug delivery device, which includes insulin and a pharmaceutically acceptable carrier, wherein the device is adapted for localized administration of insulin to a patient... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090214469 - Methods and compositions for the treatment of sepsis: Methods for the treatment of sepsis are disclosed.... Agent: Dann, Dorfman, Herrell & Skillman

20090214466 - Methods of alleviating disorders and their associated pain: The invention relates generally to the field of treatment of headache, post-laminectomy syndrome, and other disorders associated with localized pain. The compositions and methods described herein are useful for alleviating both the disorders and the pain associated therewith.... Agent: Duane Morris LLP - Philadelphia Ip Department

20090214467 - Methods of protecting against apoptosis using lipopeptides: The use of lipopeptides as inducers of NF-κB for the protection of mammals from the effects of apoptosis is described.... Agent: Polsinelli Shughart Pc

20090214465 - Quinoxaline derivatives as antitumor agents: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.... Agent: Ropes & Gray LLP

20090214471 - Use of pegylated il-10 to treat cancer: Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.... Agent: Schering-plough Biopharma Legal Department

20090214473 - Combination chaperonin 10 and beta-interferon therapy for multiple sclerosis: A method of treating multiple sclerosis (MS) is provided which includes the step of administering a pharmaceutically-effective amount of chaperonin 10 and IFN-beta. Also provided are pharmaceutical compositions and a kit for treating MS, which include chaperonin 10 and IFN-beta.... Agent: Morrison & Foerster LLP

20090214472 - Interferon-beta polymer conjugates: Biologically-active, interferon-beta 1b-polymer conjugate compositions are disclosed. The polymer portion is preferably a polyalkylene oxide polymer having a molecular weight of at least about 12 kDa. Methods of making and using the same are also disclosed.... Agent: Lucas & Mercanti, LLP

20090214474 - Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development: The present invention relates to prevention of congenital deformations. The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events and gene expression during prenatal development, post-natal development, and... Agent: Irving M. Fishman C/o Cohen, Tauber, Spievak & Wagner

20090214475 - Extractability and bioavailability of the natural antioxidant astaxanthin from a green alga, haematococcus pluvialis: As the richest source of astaxanthin, a natural antioxidant and coloring agent, the unicellular green alga, Haematococcus pluvialis, is being commercially exploited. A major constraint in the Haematococcus production system, however, is the thick, rigid cell walls associated with astaxanthin-rich cysts (or aplanospores). The thick walls prevent the extraction of... Agent: Fulbright & Jaworski L.l.p.

20090214477 - Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis: The invention relates to novel targets in the screening for compounds useful in the treatment and/or prophylaxis of a disease selected from the group comprising cardiovascular diseases, disorders of lipid metabolism or atherosclerosis. The invention relates to novel compounds for use as a medicament for diseases or conditions involving a... Agent: Hahn & Voight Pllc

20090214478 - Method of treating ocular diseases by gene therapy: A method for the treatment of diseases associated with mutations in ABCA4 gene by administering, to a subject in need thereof, an adeno-associated viral vector encoding an ABCR protein; genetic constructs and adeno-associated viral vectors for use in this method.... Agent: Arent Fox LLP

20090214476 - Novel mannose-specific adhesins and their use: The present invention relates to novel mannose-specific adhesins, and variants thereof, as well as nucleic acid sequences encoding these. The invention also relates to host cells expressing nucleic acids encoding the mannose-specific adhesins or variants thereof, as well as to pharmaceutical or nutraceutical compositions comprising the mannose-specific adhesins and/or host... Agent: Jay S. Cinamon Abelman, Frayne And Schwab

20090214496 - Bmx/etk tyrosine kinase gene therapy materials and methods: The present invention relates to materials and methods for the treatment of arterial diseases having impaired arteriogenesis and angiogenesis. More particularly, the invention provides materials and methods for treating arterial disease using a gene therapy vector expressing Bmx tyrosine kinase.... Agent: Marshall, Gerstein & Borun LLP

20090214494 - Cancer vaccines and therapeutic methods: Compositions and methods of producing improved cancer vaccines are described. In addition, methods of identifying tumor associated antigens are also described.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090214495 - Vascular endothelial growth factor-d (vegf)-d and functionally fragments thereof for bone repairing: The invention refers to use of VEGF-D or fragments thereof for the preparation of a medicament for therapy and/or prevention of bone diseases, to compositions comprising the same, vectors for gene therapy, to cells expressing VEGF-D.... Agent: Steinfl & Bruno

20090214498 - Antimicrobial peptides and bacterial strains that produce them: The present invention relates generally to the field of health promoting agents, in particular antimicrobial agents and provides antimicrobial peptides and bacterial strains that provide the antimicrobial peptides. In one aspect, the invention provides a biologically pure culture of Lactobacillus acidophilus, strain DPC6026, a sample of which has been deposited... Agent: Chalker Flores, LLP

20090214499 - Feline probiotic bifidobacteria: According to the invention there is provided a strain of lactic acid bacteria of the genus Bifidobacteria obtainable by isolation from resected and washed feline gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Bifidobacteria of the present invention are also provided.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090214497 - Novel acid tolerant lactobacillus sakei probio-65 with the ability of growth suppression of pathogenic microorganisms and the anti-allergic effect: Disclosed are a novel tactic acid bacterium, Lactobacillus sakei Probio-65, and the use thereof. The L. sakei Probio-65 strain has acid tolerance, bile acid tolerance and antibiotic resistance, inhibits the growth of harmful pathogenic microorganisms in the body and the intestine of animals, and has immunuenhancing activity. In particular, the... Agent: Casimir Jones, S.c.

20090214502 - Green mold inhibitor: The present invention provides a novel biocontrol agent for the prevention and/or reduction of mold during mushroom production. In particular, the invention utilizes Bacillus spp. as a natural, organic agent for the control of mold caused by Trichoderma spp.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090214503 - New bacillus subtilis strain atcc® pta-8805, bioproducts containing said strain and use of the same to control the fungus rhizoctonia solani, an important plant pathogen that attacks economically relevant crops: The present application is directed to a new Bacillus subtilis strain deposited under the access number ATCC® PTA-8805, to bioproduct formulations comprising viable cells of the new strain, which can be encapsulated or in a concentrated liquid form, and to the use of these bioproducts to biologically control and decrease... Agent: Merchant & Gould Pc

20090214501 - Gel-based cosmetic and wound-healing formulation and method: Disclosed are gel-based cosmetic and wound-healing formulations, methods for making said formulations, and a method for simultaneously treating and concealing injuries to human skin. In one exemplary embodiment, the cosmetic and wound-healing formulation comprises live yeast cell extract, pigment, and a gel.... Agent: Zarian Midgley & Johnson Pllc

20090214500 - Prevention and treatment of osteochondrosis in animals and humans: The present invention relates to compositions and methods for preventing and treating osteochondrosis by administration of supplemental boron containing compounds to animals and humans. The supplemental boron containing compounds are provided in animal feed compositions or as supplements for animal feed. Also provided by this invention are animal feed compositions... Agent: Morrison & Foerster LLP

20090214479 - Attenuated reovirus: Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable... Agent: Fulbright & Jaworski L.l.p.

20090214493 - Cardiac muscle regeneration using mesenchymal stem cells: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid.... Agent: Mcandrews Held & Malloy, Ltd

20090214490 - Human embryonic stem cell methods and podxl expression: A method of identifying an undifferentiated human embryonic stem cell in a sample which may contain such cells, the method comprising identifying the cell or cells within the sample that express podocalyxin-like protein (PODXL) on their surface. A method of isolating an undifferentiated human embryonic stem cell from a sample... Agent: Knobbe Martens Olson & Bear LLP

20090214492 - Isolated stromal cells for use in the treatment of diseases of the central nervous system: Methods of treating a human patient having a disease, disorder or condition of the central nervous system are disclosed. The methods include obtaining a bone marrow sample from a human donor, isolating stromal cells from the bone marrow sample, and administering the isolated stromal cells to the central nervous system... Agent: Seed Intellectual Property Law Group Pllc

20090214491 - Method of using mitotically inactivated stem cells for damaged tissue repair: The present invention is directed to the use of mitotically and/or lethally inactivated stem cells for the repair of damaged organs and/or tissues. Stem cells are mitotically and/or lethally inactivated and transplanted into damaged tissue. Any form of ex vivo inactivation of stem cells may be used such that the... Agent: Fitch Even Tabin & Flannery

20090214488 - Methods and compositions for treating basement membrane disorders: The invention features methods and compositions for the treatment of basement membrane diseases and disorders, such as Alport's syndrome.... Agent: Clark & Elbing LLP

20090214480 - Novel cancer antigen peptide and the use thereof: Novel peptides useful as a therapeutic and/or prophylactic agent of cancers, as well as medical uses thereof, are described. Each of these peptides have a consecutive amino acid sequence within a specific region of YKL-40 antigen expressing on the cell surface of brain tumor cells, that is, within the region... Agent: Birch Stewart Kolasch & Birch

20090214489 - Peptides and compounds that bind to a receptor: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide... Agent: Philip S. Johnson Johnson & Johnson

20090214483 - Progenitor cells and uses thereof: Methods for preparing progenitor cells are described where epithelial cells are induced to undergo epithelial-mesenchymal transition as a result of exposure to an inducing agent or introduction of a gene therein that induces epithelial-mesenchymal transition. Progenitor cells resulting therefrom have use in cell-based therapies, among other utilities.... Agent: Pearl Cohen Zedek Latzer, LLP

20090214486 - Serum response factor and myocardin control alzheimer cerebral amyloid angiopathy: Cerebral amyloid angiopathy is involved in Alzheimer dementia through reduction in arterial blood flow that may impair protein synthesis, which is required for learning and memory, and lower the threshold for ischemic injury. Elevated serum response factor (SRF) or myocardin (MYOCD) activity in subjects afflicted by or at risk for... Agent: Nixon & Vanderhye, Pc

20090214484 - Stem cell therapy for the treatment of central nervous system disorders: The invention provides a method for treating CNS disorders by administering a neural stem cell composition and a mesenchymal stem cell composition on opposing sides of the blood brain barrier. The neural stem cell composition is administered to the central nervous system, while the mesenchymal stem cell composition is administered... Agent: Stemedica Cell Technologies, Inc

20090214485 - Stem cell therapy for the treatment of diabetic retinopathy and diabetic optic neuropathy: The invention comprises methods and stem cell compositions for the treatment of diabetic retinopathy and other degenerative diseases of the eye. The invention is practiced in two stages with the first stage comprising the administration of neural stem cells to the eye, and the second stage comprising the administration of... Agent: Stemedica Cell Technologies, Inc

20090214482 - Transgenic mammals expressing human preproinsulin: Transgenic mammals which express human preproinsulin, methods and reagents for producing the transgenic mammals, and therapeutic methods of providing patients with insulin and C-peptide using tissues and cells from the transgenic mammals.... Agent: Banner & Witcoff, Ltd.

20090214481 - Treatment of ischemia using stem cells: The invention features a method for treating or preventing ischemia in a mammal by administering unrestricted somatic stem cells (USSCs) to the mammal.... Agent: Clark & Elbing LLP

20090214487 - Use of mesenchymal stem cells for treating genetic diseases and disorders: A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.... Agent: Mcandrews Held & Malloy, Ltd

20090214504 - Methods and compositions for topical treatment of medical conditions including wounds and inflammation: A method for treating a patient suffering from a wound, ulcer, or inflammation includes providing a topical formulation comprising a carrier and a combination of active ingredients that includes at least one retinoid and at least one blood vessel dilator, and applying the topical formulation to the skin of the... Agent: Vista Ip Law Group LLP/bsc - Neuromodulation

20090214505 - Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active... Agent: K&l Gates LLP

20090214506 - Use of tfpi to treat severe bacterial infections: Methods for prophylactically or therapeutically treating a patient at risk of developing or diagnosed as having a severe bacterial infection involving administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous... Agent: Novartis Corporate Intellectual Property

20090214507 - Method of treating preventing, inhibiting or reducing damage to cardiac tissue: A method of treatment for treating, preventing, inhibiting or reducing damage to coronary tissue includes inducing at least one of a physiological function selected from: up-regulation of or increasing ILK activity in the coronary tissue, up-regulation of or increasing Akt activity in the coronary tissue, down-regulation of or reducing cardiomyocyte... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20090214509 - Novel bacillus thuringiensis gene with lepidopteran activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic... Agent: Pioneer Hi-bred International, Inc.

20090214508 - Vegf-activated fas ligands: The present invention provides fusion proteins comprising an extracellular domain of a VEGF receptor and a death ligand. The fusion proteins bind to VEGF and to death receptors on tumor cells thereby inhibiting VEGF activation of VEGF receptors and inducing apoptosis in the tumor cells. Fusion proteins of the present... Agent: Townsend And Townsend And Crew, LLP

20090214510 - Broad spectrum antiviral compositions: The instant invention provides compositions and methods for the treatment of viral infections caused by enveloped viruses comprising phospholipase nucleic acid molecules or polypeptides, or fusion molecules comprising phospholipase molecules or functional fragments thereof.... Agent: Edwards Angell Palmer & Dodge LLP

20090214511 - Digestible compositions of inulin for managing blood glucose levels: Digestible compositions of inulin for managing blood glucose levels in a patient are disclosed. The compositions can include an inulin, a sucrose and an amylase, wherein the inulin is configured to lower blood glucose in the patient and wherein the sucrose is presented in sufficient amount to at least partially... Agent: Trung Hong Tran

20090214512 - Methods of treating skin disease, scalp disease, sensitive skin or suppressing hair loss with microbubble washing compositions: The present invention provides a microbubble washing composition for washing a human body or an animal, a microbubble washing method using the microbubble washing composition, and a microbubble washing apparatus suitable for carrying out the method are provided which are capable of safely removing sebum and old keratin adhering to... Agent: Birch Stewart Kolasch & Birch

20090214513 - Mammalian expression systems: The present invention features mammalian expression systems with improved production yields, and method of using these systems to produce desired proteins. In one embodiment, the expression systems of the present invention comprise genetically-engineered mammalian host cells cultured in a medium that contains an effective amount of heparin or heparin-like molecules.... Agent: Wyeth Patent Law Group

20090214521 - Bone morphogenetic protein-2 in the treatment and diagnosis of cancer: The present invention pertains to the use of BMP-2, which is overexpressed in most common cancers, as 1) a target for cancer treatment therapies and 2) a means to diagnose cancer. The therapeutic component of this invention involves administering to a patient a composition that inhibits bone morphogenetic-2 activity. Such... Agent: Perkins Coie LLP

20090214519 - Compositions and methods for treating inflammation: The present invention relates to compositions to treat inflammation (LIGHT pathway) related disorders, and specifically liver inflammation or hepatitis. The invention also relates to methods treating LIGHT pathway related disorders. The invention further relates to kits for treating LIGHT pathway related disorders in a subject. The invention further relates to... Agent: Edwards Angell Palmer & Dodge LLP

20090214517 - Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease: Microarray analysis, confirmed by RT-PCT, demonstrated that mRNA derived from cancerous tissues hybridized specifically and preferentially to human nectin 4, semaphorin 4b, IgSF9, and KIAA0152. Microarray analysis also demonstrated that RNA from malignant bladder, pancreas, and stomach tissue hybridized specifically to human nectin 4, semaphorin 4b, IgSF9, and KIAA0152, all... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090214514 - Gus3 neuropeptides for regulating hypothalamic function: The present invention relates to use of GUS3 neuropeptides or functional variants in a medicament. The invention furthermore relates to specific medical uses of such neuropeptides, for regulating hypothalamic function.... Agent: Darby & Darby P.c.

20090214516 - Inhibitors of reglll proteins as asthma therapeutics: Methods of screening for agents for treating asthma are provided. The methods involve screening for agents that decrease the production or activity of a RegIII protein that has been discovered herein to play a role in producing the symptoms and pathological complications involved in asthma. Methods of treating asthma, as... Agent: Wilmerhale/wyeth

20090214518 - Methods and compositions for treating solid tumors and enhancing tumor vaccines: The present invention provides methods of treating and enhancing efficacy of immunotherapy for a solid tumor in a subject, comprising the step of contacting the subject with a compound or composition that modulates the expression or activity of ETRB, ET-1, ICAM-1, or another protein found herein to play a role... Agent: Pearl Cohen Zedek Latzer, LLP

20090214515 - Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins: The subject invention relates to the cloning, expression and isolation of recombinant forms of beta-amyloid protein containing a N-terminal methionine (or one or more amino acids) as well as to methods of using this recombinant protein in the production of therapeutic antibodies, in the identification of therapeutic small molecules, and... Agent: Paul D. Yasger Abbott Laboratories

20090214522 - Process for concentration of antibodies and therapeutic products thereof: The present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process for preparing highly concentrated antibody compositions, and highly concentrated antibody products.... Agent: Morrison & Foerster LLP

20090214520 - Soluble clca-1 and antagonists to clca-1: The invention relates to methods of treating a disease or condition, wherein expression or activity of soluble CLCA1 is up-regulated, by administering inhibitors of soluble CLCA1. The invention also relates to methods of isolating soluble CLCA1 from a bodily fluid.... Agent: Wyeth/finnegan Henderson, LLP

20090214532 - Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons: The methods and compositions of the invention are based on a method for measuring nociceptive responses in vertebrates, including humans and other mammals utilizing a newly discovered thermoreceptor belonging to the Transient Receptor Potential (TRP) family of non-selective cation channels that participates in thermosensation and pain. This receptor, designated ANKTM1,... Agent: Dla Piper LLP (us)

20090214527 - Combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis: The invention relates to a new combination of an anti-MAdCAM antibody with an anti-fibrotic agent, such as a protease inhibitor, preferably a caspase inhibitor. The invention also relates to pharmaceutical compositions comprising the combination of the invention, and the use of the combination for the treatment of liver fibrosis.... Agent: Pfizer Inc. Patent Department

20090214528 - Host cell lines for production of antibody constant region with enhanced effector function: Host cell lines for biopharmaceutical production of antibodies, antibody fragments or antibody-derived fusion proteins are selected as having the capability of inducing improved cellular effector functions, e.g., Fc-medicated effector functions. The host cells are derived from the rat myeloma cell line YB2/0 and are adapted to growth in chemically-defined medium.... Agent: Philip S. Johnson Johnson & Johnson

20090214529 - Kinesin inhibitors: This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat a kinesin Eg5 protein-mediated disorder.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090214524 - Methods and compositions for regulating cell cycle checkpoints: The invention relates to regulation of cell cycle checkpoints, and the application of such regulation in the treatment of disease, particularly cancer.... Agent: Wolf Greenfield & Sacks, P.c.

20090214531 - Methods and compositions for treating and preventing bacterial infections: The invention features methods and compositions for treating or preventing Gram-negative bacterial infections.... Agent: Clark & Elbing LLP

20090214533 - Methods for converting or inducing protective immunity: The invention is based in part on the finding that suppressing regulatory T cell function is needed in order to convert passive immunity into active antigen-specific immunity. Generally, the methods of the invention comprise at least the combination of: (1) increasing the amount of immune complexes in the subject, wherein... Agent: Wilmerhale/columbia University

20090214530 - Modified cpg oligodeoxynucleotide with improved immunoregulatory function: The present invention relates to a modified CpG oligodeoxynucleotide (ODN) which is prepared by coupling a consecutive sequence of deoxyribothymine (dT) to the 3′-terminus of CpG ODN having immunoregularory function, thereby improving immunoactivity of splenocytes, macrophages and peripheral mononuclear cells, and therefore, can be effectively used as a vaccine adjuvant... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090214525 - Novel anti-igf-ir antibodies and uses thereof: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid... Agent: Birch Stewart Kolasch & Birch

20090214523 - Novel anti-il13 antibodies and uses thereof: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in... Agent: Nikolaos C. George Jones Day

20090214526 - Optimized fc variants and methods for their generation: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20090214534 - Bispecific domain antibodies targeting serum albumin and glp-1 or pyy: Drug fusions and conjugates that contain an incretin therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The conjugates and fusion have a longer in vivo half life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090214539 - B-cell reduction using cd37-specific and cd20-specific binding molecules: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further... Agent: Seed Intellectual Property Law Group Pllc

20090214536 - Cacna1e in cancer diagnosis, detection and treatment: This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the CACNA1E gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating... Agent: Novartis Vaccines And Diagnostics Inc.

20090214535 - Pharmaceutical compositions containing sc(fv)2: The present inventor discovered stabilizing agents/stabilizing conditions for suppressing isomerization reactions of sc(Fv)2. It was also discovered that the above-mentioned isomerization reactions can be suppressed through use of freeze-dried formulations. As disclosed herein, by applying the discovered stabilizing agents/stabilizing conditions or the freeze-dried formulation, the isomerization reaction of an sc(Fv)2-type... Agent: Fish & Richardson Pc

20090214537 - Serum resistance factors of gram positive bacteria: A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.... Agent: Novartis Vaccines And Diagnostics Inc.

20090214538 - Use of complement inhibitors to treat ocular diseases: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole... Agent: Nikolaos C. George Jones Day

20090214541 - Combination therapy using anti-egfr and anti-her2 antibodies: The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20090214540 - Protein involved in cancer: The present invention relates to new uses of PSK-1 in the diagnosis, screening, treatment and prophylaxis of ovarian and lung cancer. The invention also provides compositions comprising PSK-1, including vaccines, antibodies that are immunospecific for PSK-1 and agents which interact with or modulate the expression or activity of PSK-1 or... Agent: Klauber & Jackson

20090214544 - Method of treating cd30 positive lymphomas: Methods for treating lymphomas characterized by expression of CD30 using anti-CD30 antibodies and steroids in combination are disclosed.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090214545 - Method of treating or preventing an il-1 related disease or condition: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof. An IL-1β binding antibody or IL-1β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15... Agent: K&l Gates LLP

20090214543 - Methods for treating cancer using an immuno-toxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer associated protease site cleaved by mmp-2 or mmp-9: The present invention provides a modified toxin having an ETA moiety that has the furin site replaced with a cancer-associated protease site. The present invention also provides modified immunotoxins having a ligand that binds to a cancer cell attached to an ETA moiety that has the furin site replaced with... Agent: Dann, Dorfman, Herrell & Skillman

20090214542 - Novel therapeutic targets in cancer: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel... Agent: Novartis Vaccines And Diagnostics, Inc. Corporate Intellectual Property-r338

20090214556 - Antibodies and related molecules that bind to 161p2f10b proteins: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B... Agent: Agensys C/o Morrison & Foerster LLP

20090214549 - Antigenic epitopes of inteleukin-21, related antibodies and their use in medical field: The present invention relates to antigenic epitopes of interleukin-21, related antibodies and their use in medical field, in particular for the treatment of immune-inflammatory diseases characterized by an enhanced production and/or activity of IL-21, such as for example chronic inflammatory bowel diseases (IBD), celiac disease and psoriasis.... Agent: Goodwin Procter LLP Patent Administrator

20090214547 - Binding member towards pneumolysin: The present invention relates to an anti-haemolytic binding member comprising at least one binding domain capable of specifically binding Pneumolysin, in particular to a binding member having at least two biding domains, to the use of said binding members in diagnostic methods as well as for treatment. In a preferred... Agent: Baker Botts L.l.p.

20090214553 - Complete human monoclonal igg4lambda specific for ctla-4 and uses thereof for detection of soluble ctla-4 and isolation of regulatory cells: The present invention provides a CTLA-4 non-blocking agent of a complete human antibody nature, thus is non-immunogenic in a human. The immunoassay method using such a non-blocking agent measures the CTLA-4 content in a sample of a human subject. The present invention further provides a novel method for isolating human... Agent: Sinorica, Llc

20090214551 - High affinity hiv t cell receptors: The present invention provides TCRs having an affinity (KD) of less than or equal to 1 μM, and/or an off-rate (koff) of 1×10−3S−1 or slower, for the SLYNTVATL-HLA-A*0201 complex provided that when the said TCR is presented by cell and comprises SEQ ID NOS:1 and 2, the cell is not... Agent: Banner & Witcoff, Ltd.

20090214550 - Identification of surface-associated antigens for tumor diagnosis and therapy: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides... Agent: Keown & Zucchero, LLP

20090214552 - Novel egg receptors for sperm proteins: The present invention relates to novel egg membrane protein receptors and to methods of inhibiting the interaction of sperm proteins with egg proteins. The invention further relates to methods of preventing and inhibiting sperm-egg binding, sperm-egg fusion, and fertilization. The invention further relates to the egg membrane proteins MET and... Agent: University Of Virginia Patent Foundation

20090214546 - Novel therapeutic targets in cancer: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present... Agent: Novartis Vaccines And Diagnostics, Inc. Corporate Intellectual Property-r338

20090214555 - Proteoglycan splice variants as therapeutics and diagnostics for amyloid diseases: The identification of novel Syndecan-2 splice variants and their use in the diagnosis and therapeutic intervention of Alzheimer's disease and other amyloid diseases. In addition the use of new animal models expressing or devoid of syndecan-2 splice variants to effectively screen and identify potential therapeutic compounds for Alzheimer's disease.... Agent: Proteotech, Inc.

20090214548 - Tgr3-like protein receptor: There are provided proteins containing a domain corresponding to the C-terminal half of a ZP domain similar to that identified in TGF-beta Receptor III and the use of the proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of diseases. In particular, the present... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090214554 - Truncated memapsin 2 compositions and treatments: The present invention provides novel methods of reducing memapsin 2 β-secretase activity in a subject, decreasing levels of β-amyloid peptide in the brain of a subject, treating Alzheimer's disease and/or reducing the size and/or number of β-amyloid plaques in the brain of a subject. The methods may include the step... Agent: Morrison & Foerster LLP

20090214557 - Biologically active antibodies recognizing a cell surface molecule selectively expressed on living mouse natural type one (i) interferon producing cells: An isolated and characterized monoclonal antibody (“440c”) prepared by immunizing Wistar/CRL rats subcutaneously with purified rat bone marrow IPC, fusing popliteal lymph nodes of the rats with SP2/0 myeloma spleen cells and differentially selecting for hybridome supernatants that successfully stain bone marrow derived IPC and fractions thereof using CD11c+ spleen... Agent: Patrick W. Rasche Armstrong Teasdale LLP

20090214558 - Novel madcam antibodies: The invention provides new, improved anti-MAdCAM antibodies. Uses of these antibodies in medicine are also included, in particular for the treatment of inflammatory conditions such as inflammatory bowel disease.... Agent: Pfizer Inc

20090214560 - Binding molecules to the human ox40 receptor: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods... Agent: Dickstein Shapiro LLP

20090214559 - Therapeutic human anti-il-1r1 monoclonal antibody: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090214561 - Treatment method: The invention provides methods of treating autoimmune diseases by administration of a complete therapeutically effective amount of a CD20 specific antagonist as a single intravenous infusion. Retreatment may follow by the administration of a complete therapeutically effective amount of the CD20 specific antagonist by a single intravenous infusion, 4 to... Agent: Fulbright & Jaworski, LLP

20090214564 - Anti-ephrinb2 antibodies and methods using same: The invention provides anti-EphrinB2 antibodies, and compositions comprising and methods of using these antibodies.... Agent: Genentech, Inc.

20090214565 - Anti-interferon alpha monoclonal antibodies and methods for use: The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity... Agent: Brinks, Hofer, Gilson & Lione

20090214562 - Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection: The present invention encompasses a therapeutic combination composition of a β-glucan EGF receptor antagonist. This therapeutic combination composition is useful for the treatment of diseases including proliferative disorders and immune dysfunction.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090214563 - Treatment for antiphospholipid-syndrome-related pregnancy complications: The present application provides compositions and methods for treating antiphospholipid-syndrome-related pregnancy complications with tissue factor antagonists.... Agent: Morrison & Foerster LLP

20090214566 - Protective anti-glucan antibodies with preference for beta-1,3- glucans: Anti-β-1,3-glucan antibodies have been found to be protective against systemic fungal infection with Candida albicans. The present invention provides monoclonal antibodies that bind to β-1,3-glucan, hybridoma cell lines producing the antibodies, compositions comprising the antibodies and methods of using such antibodies for treatment of microbial infections, particularly against Candida albicans... Agent: Robins & Pasternak

20090214567 - Immunoglobulin fraction and process therefor: The invention relates to the production of compositions containing IgA for use as a food additive. More specifically, it relates to a process to prepare an IgA-enriched milk product extract composition and to such compositions.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090214568 - Method of treating or preventing an il-1 related disease or condition: Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof. An IL-1β binding antibody or IL-1β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15... Agent: K&l Gates LLP

20090214569 - Use of hiv envelope/cd4 complexes for the generation antibodies: The instant invention provides antibodies, vaccines, and immunogenic compositions, for the treatment and prevention of HIV infection. The invention further provides kits comprising the antibodies, vaccines and immunogenic compositions, of the invention.... Agent: Edwards Angell Palmer & Dodge LLP

20090214570 - Methods and compositions for immunizing against chlamydia infection: The present invention relates, in part, to methods and compositions for immunizing against infection by Chlamydia trachomatis. The methods and compositions rely, in part, on administering an immunogenic composition comprising one or more peptides derived from C. trachomatis major outer membrane protein (MOMP) to a subject to be immunized. In... Agent: Jones Day

20090214571 - Colon cancer related gene tom34: Objective methods for detecting and diagnosing colon cancer are described herein. In one embodiment, the diagnostic method involves determining the expression level of TOM34 that discriminates between colon cancer cells and normal cells. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of colon... Agent: Townsend And Townsend And Crew, LLP

20090214572 - Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders: The invention features methods and compositions for treating and preventing angiogenic disorders and endothelial cells disorders using HspA12B antagonist and HspA12B agonist compounds, respectively.... Agent: Clark & Elbing LLP

20090214573 - Modulation of bne development: Methods and compositions for modulating bone development are described.... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20090214574 - Anti-cd16 binding molecules: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. FcγRIIIA), and in particular binding molecules that specifically bind the A form FcγRIII but do not bind to the B form of... Agent: Wilson Sonsini Goodrich & Rosati

20090214575 - Annexin ii and uses thereof: The present invention in particular relates to the discovery that the expression of Annexin II is involved in apoptosis induced by oxidative stress, and that anti-sense Annexin II RNA and Annexin II siRNA protected the cells from this apoptosis. Thus Annexin II inhibitors prevent the damage caused by said ischemic... Agent: Cooper & Dunham, LLP

20090214576 - Tyrosine kinase inhibitor compositions and methods for manufacturing and using them in the treatment of disease: The invention is the method of using the soluble modified receptor erbB3 to treat breast cancer by competitively inhibiting ligands, such as heregulin, from binding to erbB3 tyrosine kinase receptors on cell surfaces.... Agent: K&l Gates LLP

20090214578 - Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone: Immunostimulatory single-stranded oligoribonucleotides (ssORN) with phosphodiester backbones induce TLR7-independent and MyD88-dependent immune activation. These immunostimulatory ssORN are useful to induce a ThI-like immune response in a subject, to induce an antigen-specific immune response in a subject, and to treat a subject having a cancer, an infectious disease, an allergic condition,... Agent: Wolf Greenfield & Sacks, P.c.

20090214577 - Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof: DNA plasmids containing sequences coding for different fragments of 185neu oncoprotein which are able to induce an immune response against p185neu-overexpressing tumors, and pharmaceutical compositions thereof are described.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.a.

20090214579 - Promoter for introducing a gene into a lymphocyte or blood cell and application thereof: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression... Agent: King & Spalding LLP

20090214581 - Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides: The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for... Agent: Townsend And Townsend And Crew, LLP

20090214582 - Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof: The present invention provides a method of classifying an epitope displayed by a polypeptide; a method of determining the presence of an epitope on a polypeptide encoded by a test nucleotide sequence; and a method of generating a nucleotide sequence encoding a polypeptide that exhibits a selected epitope. The present... Agent: Bozicevic, Field & Francis LLP

20090214580 - Peptide mixtures with immunomodulatory activity: The present invention is related to complex peptide mixtures with immunomodulatory effects and methods for their use. The invention is further directed toward treatments of diseases through the modulation of the immune system with complex peptide mixtures. The invention is also directed to methods for improving the characteristics of complex... Agent: Knobbe Martens Olson & Bear LLP

20090214583 - Epitope-enhancement of a human cd4 hiv epitope: Virus-specific CD4+T cell help and CD8+ cytotoxic T cell responses are critical for the maintenance of effective immunity in chronic viral infections. The importance of the CD4+T cells has been documented in HIV infection. A T1-specific CD4+T cell line from a healthy volunteer immunized with a canarypox vector expressing gp120... Agent: Townsend And Townsend And Crew, LLP

20090214584 - Characterization of novel lpxtg-containing proteins of staphylococcus epidermidis: The present invention is directed toward isolated Staphylococcus epidermidis surface (Ses) A-F proteins, monoclonal and polyclonal antibodies directed against SesA-F proteins, vaccines comprising SesA-F proteins and diagnostic devices. The present invention is further directed to method of diagnosing an individual with Staphylococcus epidermidis comprising obtaining a sample from the individual... Agent: Dinsmore & Shohl LLP

20090214585 - Medicament, particularly an anti-cancer medicament, for treatment using immunotherapy, particularly autologous: The invention relates to a medicament characterized in that it comprises at least one solid biocompatible support, preferably in powder form, on which at least one active substance, preferably selected among biological materials and/or biological molecules, is adsorbed or on which it is to be adsorbed, preferably without requiring a... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090214586 - Combination vaccines with whole cell pertussis antigen: Vaccines have been studied that comprise (a) D-T-Pw-HepB-Hib antigens and (b) one or more meningococcal conjugate antigens. A number of improvements and variations of these vaccines have been discovered. The vaccines can be prepared extemporaneously at the time of use by mixing together two components: (a) a first component comprising... Agent: Novartis Vaccines And Diagnostics Inc.

20090214587 - Recombinant virus and use thereof: The present invention provides a recombinant virus which is efficacious and highly safe in preventing the onset of SARS infection and a vaccine for SARS coronavirus containing the same. The recombinant virus of the invention can express a SARS coronavirus gene.... Agent: Darby & Darby P.c.

20090214588 - Vaccines against aids comprising cmv/r-nucleic acid constructs: The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided.... Agent: Knobbe, Martens, Olson & Bear, LLP

20090214589 - Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine: Use of a recombinant lentiviral vector comprising a polynucleotide fragment encoding at least one protein of a virus of the family Flaviviridae or an immunogenic peptide of at least 8 amino acids of said protein, for preparing a pharmaceutical composition intended for the prevention and/or the treatment of a Flaviviridae... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090214590 - Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof: The present invention provides novel virus vaccines with augmented, e.g., enhanced and/or extended immunogenicity. The virus vaccines of the invention comprise an envelope-bound immunomodulatory protein, e.g., a cytokine, chemokine or costimulatory molecule. The immunomodulatory protein serves as an adjuvant to augment, e.g., enhance or extend the immunogenicity of the virus... Agent: Darby & Darby P.c.

20090214591 - Immunogens for vaccines against antigenically variable pathogens and diseases: The present invention provides compositions and methods for the therapeutic and/or prophylactic treatment of pathogen infections and/or disease states. The compositions may comprise variable epitope libraries (VELs), containing antigenic epitopes with one or more amino acid substitutions in the native epitope sequence. In preferred embodiments, the substituted amino acid may... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090214592 - Adjuvant composition comprising aluminium phosphate and 3d-mpl: An immunogenic composition comprising: (i) an antigen; (ii) an aluminum phosphate adjuvant; and (iii) a 3-O-deacylated monophosphoryl lipid A adjuvant. Components (ii) and (iii) can also be used as a separate adjuvant system. Various features of the compositions are disclosed, including that at least 50% of the 3-O-deacylated monophosphoryl lipid... Agent: Novartis Vaccines And Diagnostics Inc.

20090214593 - Immunogen platform: Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including,... Agent: Knobbe Martens Olson & Bear LLP

20090214594 - Prevention and treatment of otitis media with non-pathogenic bacterial strains: This invention relates to a composition comprising a bacterial strain capable of boosting the systemic immune response, a bacterial strain capable of exerting bacteriostatic effects on pathogens associated with development of otitis media such as Streptococcus pneumoniae, untypeable Haemophilus influenzae and Moraxella catarrhalis and a bacterial strain capable of exerting... Agent: K&l Gates LLP

20090214595 - Means for obtaining avirulent leishmania promastigotes, promastigotes obtained, and the applications thereof: The invention relates to an expression vector of a gene coding for an antigenic protein of Leishmania promastigote, characterised in that it comprises a PSA gene insert in opposite orientation. The invention can be applied to the development of mutants under-expressing, or no longer expressing, genes coding for an antigenic... Agent: Nixon & Vanderhye, Pc

20090214596 - Nasal vaccine: e

20090214597 - Non-injection immunotherapy: Methods and compositions are disclosed for the reduction of immune responses to an exogenous allergen. The reduction is obtained by pre-treatment or pre-conditioning, without injection, of a subject with the allergen so as to reduce immune responses in the subject upon additional exposure to the allergen. The invention is advantageously... Agent: Townsend And Townsend And Crew, LLP

20090214598 - Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease: The present invention provides a pro-inflammatory synthetic polysaccharide antigen (SPA), or a pharmaceutically acceptable salt thereof, comprising a TLR2-targeting synthetic peptidoglycan (PGN) moiety onto which a first epitope and a second epitope are each covalently attached. The first epitope comprises one or more than one generic T helper peptide sequence,... Agent: Bio Technology Law Group C/o Portfolioip

20090214600 - Methods and compositions for gastric resistant oral formulations for intestinal delivery: An oral formulation for mammalian administration and treatment utilizing bioactive pharmaceuticals in need of gastric resistance to promote intestinal absorption. The oral formulation utilizes lower dosages to achieve higher plasma levels and delivers permeable solubilized bioactive pharmaceuticals directly to intestinal mucosa, avoiding premature gastric disintegration. Further, it delivers water and... Agent: Nyemaster, Goode, West, Hansell & O'brien, P.c.

20090214602 - Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor: The present disclosure provides oral dosage forms comprising an antiplatelet agent and an enterically coated acid inhibitor, as well as methods of treating subjects with an antiplatelet agent and an enterically coated acid inhibitor.... Agent: Jones Day

20090214601 - Porous drug delivery devices and related methods: The invention relates to porous drug delivery devices and related methods. In an embodiment, the invention includes an active agent delivery system including a reservoir body defining a plurality of interconnected pores, an active agent disposed within the interconnected pores, and a first polymeric layer disposed over the reservoir body.... Agent: Pauly, Devries Smith & Deffner, L.l.c.

20090214599 - Proton pump inhibitor formulations, and methods of preparing and using such formulations: Pharmaceutical formulation comprising at least one proton pump inhibitor structured and arranged to provide an initial pH-dependent delayed release, and a pH-dependent extended release of the at least one proton pump inhibitor.... Agent: Greenblum & Bernstein, P.L.C

20090214603 - Synthetic peptides: The present invention provides streptococcal SspB Adherence Region (BAR) peptides, nucleic acids encoding the BAR peptides, and methods of using the BAR peptides, and methods of screening BAR peptide mimetics.... Agent: Viksnins Harris & Padys Pllp

20090214606 - Antimicrobial porous silicon oxide particles: The present invention relates to antimicrobial, porous particles, especially porous, non-platelet-like SiO2 particles, comprising an organic, or inorganic antimicrobial compound, or composition, with the proviso that the porous particles are not porous SiOz flakes, wherein 0.70<z<2.0, especially 0.95<z<2.0, which provide enhanced (long term) antimicrobial efficacy.... Agent: Joann Villamizar Ciba Corporation/patent Department

20090214605 - Hydrophilic core polymeric micelles for the delivery of water-soluble compounds: The present invention describes the preparation of reverse polymeric micelles (RPM) through hydrophobically-modified star-shaped polyols. More specifically, RPM are obtained from polymeric structures where the polyol constitutes the hydrophilic domain while the hydrophobic shell is obtained either through the modification of existing chemical functions (e.g. esterification) or through copolymerization with... Agent: Klauber & Jackson

20090214604 - Method of obtaining hydrogels of cyclodextrins with glycidyl ethers, compositions thus obtained and applications thereof: The invention relates to a method of obtaining hydrogels based on (i) cyclodextrins, (ii) cyclodextrins and cellulose ethers or (iii) cyclodextrins and guar gum or the derivatives of same, using molecules containing two or more glycidyl ether groups in the structure thereof as a cross-linking agent. The invention also relates... Agent: Merchant & Gould Pc

20090214609 - Oral polyphosphate compositions: e

20090214608 - Polysaccharide-based products with improved easiness of use, process to make the same, and applications of the same: This invention relates to water-soluble polysaccharide-based products that require less time and effort to incorporate into aqueous formulations, compared to existing polysaccharide products. This invention can be applied more particularly to cationic guar products to be used in cosmetic compositions. The product is in the form of granules and comprises... Agent: Hunton & Williams LLP Intellectual Property Department

20090214607 - Topical use of teprenone: Topical use of teprenone in a cosmetic or dermopharmaceutical composition as an active preventing and/or limiting the skin cells sénescence and/or protecting the general state of the skin.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090214610 - Benzoic acid containing composition for maintaining hydantoinylated polymers in a biocidally active state: A tablet includes benzoic acid and trichloroisocyanuric acid. The tablet provides free available chlorine in water to maintain an N-halamine-containing polymer biocidal, without rendering the water undrinkable from high chlorine content. The tablet may be used in a water purification device having a cartridge containing an N-halamine polymer to provide... Agent: Christensen, O'connor, Johnson, Kindness, Pllc

20090214612 - Extracellular tnf inhibitors for treating cns disorders: Methods and devices to attenuate tumor necrosis factor (TNF) and other pro-inflammatory mediators in the CNS to treat neurological, neurodegenerative, neuropsychiatric disorders, and brain injury are described. More particularly, TNF blocking agents that target TNF-receptor interactions and the effects of downstream secreted cytokines associated with an inflammatory cascade are described.... Agent: K&l Gates LLP

20090214611 - Implant filling material and method: Compositions of cross-linked polyvinylpyrrolidone (PVP) are disclosed that are generally in the form of an elastic, hydrophilic, water-insoluble viscous cohesive mass of material that has many important medical uses including uses as a filler for implants. The present invention also involves a process for producing such compositions.... Agent: Nikolai & Mersereau, P.a.

20090214616 - Biomaterials having nanoscale layers and coatings: The invention generally relates to substrates and surfaces having substrates. Generally speaking, the substrates may be thinly layered substrates, and the surfaces may comprise thinly layered substrates. Additionally, the substrates may comprise a multifunctional water soluble polymer and a lipoprotein and the surfaces may comprise a multifunctional water soluble polymer... Agent: Polsinelli Shughart Pc

20090214613 - Endothelized artificial matrix comprising a fibrin gel, which is a superproducer of proangiogenic factors: The invention relates to an endothelized artificial matrix comprising a fibrin gel, which is a superproducer of proantiogenic factors. The inventive matrix comprises a fibrin gel containing embedded endothelial cells which have been transfected in vitro with at least one adenoviral vector containing the sequence encoding at least one proangiogenic... Agent: Ladas & Parry LLP

20090214617 - Immobilisation and stabilisation of virus: The present invention relates to a method for immobilization and optional stabilization of viruses whilst retaining the viral biological activity and the use of immobilized virus in therapy. In particular, the immobilized virus relates to immobilized bacteriophage and their use as an antibiotic or bacteriostatic agent and in the treatment... Agent: Alston & Bird LLP

20090214615 - Layer - by - layer stereocomplexed polymers as drug depot carriers or coatings in medical devices: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed... Agent: Philip S. Johnson Johnson & Johnson

20090214614 - Method for cell implantation: The present invention provides for a method for tissue engineering by cell implantation that involves the use of a scaffold in situ at the site of a defect, where the therapeutic cells are fixed in place into the scaffold only once the scaffold is inserted at the site of the... Agent: Jacobson Holman Pllc

20090214618 - Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications: The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.... Agent: Alston & Bird LLP

20090214619 - Implant for intraocular drug delivery: An implant for intraocular drug delivery for the treatment of inflammatory or degenerative diseases. In one embodiment, the implant includes a body portion having a first end portion and a second, opposite end portion and defining a cavity with a first opening at the first end portion, and a second,... Agent: Wilson Sonsini Goodrich & Rosati

20090214620 - Agent for use in the case of disorders of blood sugar metabolism, including diabetes: An agent for use in the case of disorders of blood sugar metabolism, including diabetes, is described, which reduces the glucose content of food and other substances with the help of 5-D-fructose dehydrogenase and glucose isomerase.... Agent: Heslin Rothenberg Farley & Mesiti Pc

20090214621 - Electrostatic patch for allergen screening and applicator for same: A dermal patch comprises a support having electrostatic properties, which is covered with or can be covered with a substance that is intended to be applied to the skin. The surface of the support that is in contact with the substance is provided with microreliefs.... Agent: Heslin Rothenberg Farley & Mesiti Pc

20090214622 - Nanoporous membrane and method of preparation thereof: A nanoporous membrane structure characterised in that it has a hexagonal array of tubes with a substantially uniform inter-pore distance between the tubes wherein the distance is within the range from 10-500 nm and wherein the tubes may have a depth of up to 500 μm.... Agent: Robins & Pasternak

20090214623 - Anisotropic hydrogels: The invention relates to an anisotropic hydrogel and a method of producing the anisotropic hydrogel. The hydrogel exhibiting anisotropic properties is poly(vinyl alcohol) produced by preparing a solution of poly(vinyl alcohol) with a pre-selected concentration, thermally cycling the solution by freezing and thawing, stretching the hydrogel and thermally cycling the... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20090214625 - Drug delivery patch: e

20090214624 - Topical nitric oxide donor devices and methods for their therapeutic use: The present invention is related to topical nitric oxide delivery systems, and to using the same for mitigating or remediating various disease states The present invention is also related to using topical nitric oxide delivery systems for enhancing blood flow.... Agent: Roetzel And Andress

20090214634 - Compositions and methods for the treatment of bladder cancer: Compositions and methods for the treatment of bladder cancer include intravesical dosage forms of a neoplastic agent and a permeation enhancer. The neoplastic agent may be valrubicin. Pharmaceutical compositions include intravesical dosage forms of a neoplastic agent complexed liposomes. Tight junction openers may be used for the effective delivery of... Agent: Foley And Lardner LLP Suite 500

20090214630 - Compositions and methods for the treatment of inflammatory bowel disease utilizing nf-kappab decoy polynucleotides: Provided herein is a method of treating or preventing inflammatory bowel disease (IBD) in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising an NF-κB decoy polynucleotide.... Agent: National Institute Of Health C/o Ballard Spahr Andrews & Ingersoll, LLP

20090214629 - Gene transfer method: A method for efficiently transferring a gene to a target cell is provided. A method of transferring a gene to a target cell, including adding or administering a positively charged complex (A) composed of the gene and a cationic substance and gas-filled microparticles (B) to a target cell-containing composition or... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090214635 - Identification of a conserved region of plasmodium falciparum msp3 targeted by biologically active antibodies: Antigenic and immunogenic determinants of Merozoite surface protein 3 (MSP3). Antigenicity and functional assays identified a 68-amino acid conserved domain of MSP3 as a target of biologically active antibodies. A peptide comprising amino acid residues 184-251 of SEQ ID NO: 2, may also be employed as may peptides consisting of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090214636 - Imaging and therapeutic method using monocytes: wherein the group Ab comprises a ligand that binds to monocytes, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering monocyte function, and when the conjugate is being used for diagnosing the... Agent: Barnes & Thornburg LLP

20090214632 - Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090214638 - Liposome encapsulated poly-iclc method to prophylactically treat an avian influenza viral infection: A method of treating an avian influenza viral infection using a poly ICLC formulation with improved therapeutic efficacy is disclosed. The poly ICLC is encapsulated within liposomes which provides a drug delivery system with slow sustained release characteristic and which has the ability to target the drug to sites of... Agent: Cermak Kenealy Vaidya & Nakajima LLP

20090214628 - Methods and compositions for treatment of skin: The present invention relates to compositions and their use for the treatment of human skin, particularly facial skin, to alleviate the symptoms of cosmetic or determatologic skin conditions. The invention relates to compositions for treating and ameliorating skin conditions including acne, rosacea and wrinkling caused by photodamage or conditions related... Agent: Frost Brown Todd, Llc

20090214627 - Methods of modifying insulin signaling using biliverdin reductase: The present invention relates to a method of modulating insulin signaling in a cell. This method involves modifying the nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof, in a cell, whereby a change in nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof,... Agent: Nixon Peabody LLP - Patent Group

20090214633 - Nanoparticles with lipid core and polymer shell structures for protein drug delivery prepared by nanoencapsulation: The present invention relates to an application of stabilized nanoparticles with a lipid core and shell structures as protein drug carriers, wherein the nanoparticles are prepared by producing nano-sized particles from lecithin obtained from natural soybean, and then adsorbing polaxamer thereon. Here, lecithin is used as an ingredient of core... Agent: Nixon Peabody, LLP

20090214637 - Novel gene therapy approach for treating the metabolic disorder obesity: The present application relates to novel methods and compositions for treating metabolic disorders. Some aspects pertain to the use of gene therapy to treat diseases related to metabolic disorders, such as diabetes, obesity, high blood pressure, wasting syndrome, cachexia and atherogenic dyslipidemia. The present application also pertains to the use... Agent: Nutter Mcclennen & Fish LLP

20090214639 - Omp p6 vaccine for treating and preventing chlamydia infection: The present invention provides a vaccine for immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The vaccine contains a polypeptide comprising an omp P6 precursor sequence of a strain of C. pneumoniae and variants of the sequence. Modifications are... Agent: Smart & Biggar P.o. Box 2999, Station D

20090214626 - Platinum complexes for targeted drug delivery: The subject invention concerns biotin-conjugated platinum complexes that exhibit direct and indirect (immunological) antitumor cell activity. The subject invention also concerns the biotin-platinum complexes of the invention that have another molecule, such as an antibody, a ligand, a receptor, etc., bound to the biotin moiety. The subject invention also concerns... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090214631 - Process for the preparation of strontium ranelate: A process for the preparation of strontium ranelate or a hydrate thereof is provided comprising (a) reacting a tetraester compound of Formula II: wherein R, R1, R2, and R3 are independently a linear or branched C1-C6 alkyl group or a substituted or unsubstituted C3-C12 cyclic group, in the presence of... Agent: M. Carmen & Associates, Pllc

20090214640 - Delayed release pharmaceutical oral dosage form and method of making same: The present invention relates to a delayed release pharmaceutical oral dosage form and method of making same. The delayed release dosage form comprises one or more active ingredients within a granulated composition, which further comprises one or more excipients selected from the group of solid aliphatic alcohols, fatty acid esters,... Agent: Fulbright & Jaworski L.l.p.

20090214641 - Sweetened capsules for administration: In an aspect of the present invention, a sweetened gelatin capsule comprises a dose and a gelatin capsule encapsulating the dose. The gelatin capsule comprises a gelatin substance, a gelatin softener, water, and a sweetener. The concentration by weight of the water in the gelatin capsule is from about 6%... Agent: Jones Day (for Nordic Naturals)

20090214642 - Coated formulations for tolterodine: A sustained release pharmaceutical composition comprising coating comprising at least one water-insoluble permeable polymer and at least one water soluble polymer and homogenous cores containing only tolterodine or a salt thereof and microcrystalline cellulose is described.... Agent: Arent Fox LLP

20090214643 - Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases: Methods for administering beta-adrenergic inverse agonists with improved pharmacokinetic profiles for the treatment of pulmonary airway diseases are disclosed. The beta adrenergic inverse agonists are formulated in a controlled-release formulation comprising: (1) a beta-adrenergic inverse agonist in a therapeutically effective quantity; and (2) at least one agent that controls release... Agent: Catalyst Law Group, Apc

20090214644 - Tranexamic acid formulations with reduced adverse effects: Disclosed are delayed release oral tranexamic acid formulations and methods of treatment therewith.... Agent: Davidson, Davidson & Kappel, Llc

20090214645 - Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent: The present invention concerns pharmaceutical compositions comprising a pH-dependent drug compound and a pH modifier.... Agent: Novartis Corporate Intellectual Property

20090214646 - Pharmaceutical formulations containing clopidogrel: The present invention relates to a composition comprising a pharmaceutically acceptable salt of Clopidogel and isomalt as a diluent, to the use of said composition in the elaboration of an oral pharmaceutical formulation, as well as to an oral pharmaceutical formulation comprising said composition.... Agent: Moore & Van Allen Pllc

20090214647 - Compositions for enternal application of microorganisms: The present invention describes a process for the manufacture of a solid composition comprising a microorganism, which process comprises a first step of blending and/or compacting the microorganism with a salt of a medium or long-chain fatty acid to prepare a powderous mixture or compacted granulate, and a second step... Agent: Nixon & Vanderhye, Pc

20090214648 - Pharmaceutical formulations comprising ibuprofen and diphenhydramine: A pharmaceutical dosage form comprising diphenhydramine, or a pharmaceutically acceptable salt thereof, and ibuprofen, wherein the dosage form provides both diphenhydramine and ibuprofen in a single monolayer tablet, and processes for preparation of dosage forms.... Agent: Dr. Reddy''s Laboratories, Inc.

20090214649 - Scaffolds with oxygen carriers, and their use in tissue regeneration: Provided are fibrin or silk matrices comprising an oxygen carrier, and matrices, which comprise an oxygen carrier and mesenchymal stem cells. Also provided are methods of generating and using same for ex vivo or in vivo tissue regeneration and/or repair such as for treating a non-union bone fracture and a... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090214650 - Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers: The current invention provides methods of treating alcohol related disorders by providing a sustained release oral drug dosage form comprising a plurality of solid state drugs i.e., baclofen and naltrexone, dispersed in a solid state unitary matrix formed from a combination of swellable polymers. The combination of swellable polymers in... Agent: Elmore Patent Law Group, Pc

20090214651 - Production of polyurethane foams: The invention relates to a process for producing polyurethane foams, by frothing and drying specific polyurethane dispersions.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, Pc

20090214652 - Soft tissue implants and anti-scarring agents: Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.... Agent: Seed Intellectual Property Law Group Pllc

20090214653 - Bone morphogenetic protein 4 and osteogenic devices and pharmaceutical products containing thereof: The present invention relates to reindeer bone formation inducing protein called bone morphogenetic protein 4 (BMP-4) and nucleotide molecules encoding the proteins and host cells expressing the proteins. The present invention relates also to the use of the BMP-4 for treating disorders related to bone and cartilage formation. Osteogenic devices... Agent: Young & Thompson

20090214654 - Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle: Delivery vehicles for controlled release of connective tissue stabilization agent for the treatment of vascular aneurysms are described. The delivery vehicle generally is combined with a connective tissue stabilization agent to form a therapeutic composition. The treatment of an aneurysm can be achieved through release of connective tissue stabilization agent... Agent: Dardi & Associates, Pllc

20090214658 - Inorganic sorbent copolymer: A medicinal preparation useful for treating viral diseases and for prophylaxis of various diseases—including zoonotic diseases—along with methods of using the same, is described. The preparation comprises a fine crystalline antimony silicate-based sorbent of the compositional formula xA2O.ySb2O5.zSiO2, wherein x is between 0.5 and 3, y is between 0.5 and... Agent: Chester G. Moore Baker, Donelson, Bearman, Caldwell & Berkowitz, Pc

20090214656 - Itraconazole compositions with improved bioavailability: A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>ΔHtr (1) (wherein ΔHtr represents the endotherm (J/g) accompanying a transition at about 240° C). The solid dispersion product shows an improved bioavailability.... Agent: Edwards Angell Palmer & Dodge LLP

20090214655 - Method and device for obtaining micro and nanometric size particles: The invention relates to a method and device for obtaining micro and nanometric particles in a controlled, reproducible manner. The aforementioned particles have a spherical shape and a very narrow, uniform size distribution. More specifically, the invention relates to a novel method of forming emulsions and to the application thereof... Agent: Ladas & Parry LLP

20090214659 - Mineral composition: The invention relates to a mineral composition for improving well-being and fitness of living beings in general as well as in the presence of equipment emitting non-ionising electromagnetic radiation, comprising a layered phyllosilicate comprising paramagnetic ions and having a conductivity, measured in non-conductive water at a concentration of 1 wt.... Agent: Lucas & Mercanti, LLP

20090214657 - Orally absorbed pharmaceutical formulation and method of administration: A pharmaceutical formulation for absorption through oral mucosae comprising an effective amount of (a) a pharmaceutical agent in mixed micellar form, (b) at least one micelle-forming compound selected from the group comprising an alkali metal alkyl sulfate and a polyoxyethylene sorbitan monooleate, (c) a block copolymer of polyoxyethylene and polyoxypropylene,... Agent: Clark & Brody

20090214660 - Encapsulation system: The present invention is directed to a composition comprising high mannuronic acid-containing alginate and a polycation having a polydispersity index of less than 1.5. The composition is particularly useful for making biocompatible microcapsules containing living cells for allo- or xeno-transplantation. Such microcapsules have enhanced durability and can maintain their structural... Agent: Greenlee Winner And Sullivan P C

20090214661 - Process for the production of beadlets: A process for the production of cross-linked beadlets containing one or more active ingredients selected from the group of a fat-soluble vitamin active material, a carotenoid and a polyunsaturated fatty acid is provided. The process comprises treating a dry particulate form at a temperature in the range of from 90°... Agent: Nixon & Vanderhye, Pc

20090214662 - Surface-layer protein coated microspheres and uses thereof: The invention provides surface-layer protein coated microspheres for delivery of a therapeutic agent to the intestine. These surface-layer protein coated microspheres generally include a core encapsulated by a microsphere which is coated by surface layer protein. The core includes a therapeutic agent, such as a defensin. The invention also includes... Agent: Moore & Van Allen Pllc

20090214663 - Virus coated nanoparticles and uses thereof: The present invention discloses method to coat nanoparticles with viral envelope containing specific proteins. The present invention also discloses that such viral envelope coated nanoparticles can be targeted to specific cells and cellular entry pathway, thereby permitting their use as vaccines, in targeted delivery of therapeutic products and in the... Agent: Benjamin Aaron Adler Adler & Associates

20090214665 - Controlled release muscarinic receptor antagonist formulation: An oral controlled release pharmaceutical composition for muscarinic receptor antagonist, preferably tolterodine, that employs a drug core, a rapidly disintegrating or rapidly dissolving coating applied to the drug core and a controlled release coating.... Agent: Martin Endres, Esq. Hedman & Costigan, P.c.

20090214664 - Pharmaceutical dosage forms comprising an active ingredient combination of nifedipine and/or nisoldipine and an angiotensini ii antagonist: The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine and/or nisoldipine and at least one angiotensin II antagonist, characterized in that the active ingredient combination undergoes controlled (modified) release in the body, and to processes for the production thereof, to the use thereof... Agent: Barbara A. Shimei Director, Patents & Licensing

20090214666 - Chitin microparticles and their medical uses: The present invention relates to chitin microparticles and their medical uses, in particular in the treatment of allergy, or the treatment of conditions that would benefit from an upregulation of the cell mediated immune system, or an up-regulation of natural killer (NK) cell activity and/or the secretion of interferon-γ (IFN-γ).... Agent: Frommer Lawrence & Haug

20090214667 - Medical technical product, method for producing the same and providing the same for surgery: A medicotechnical product for adhesion prophylaxis for the post-operative prevention of accretions in the body comprises at least one PVA (polyvinyl alcohol) selected from the group comprising uncrosslinked PVA with a molecular weight of 15,000 to 400,000, crosslinked PVA and mixtures thereof. The molecular weight of the PVA or the... Agent: The Nath Law Group

20090214668 - Preservative compositions for wood products: Preservative compositions for wood products are described. The compositions include at least one boron-containing material, such as but not limited to boric anhydride, and at least one silane-containing material, such as but not limited to methyltrichlorosilane. Optionally, at least one solvent, such as tetrahydrofuran, pentane, or water, may also be... Agent: Bliss Mcglynn, P.c.

20090214670 - rhcc peptide and uses thereof: The present invention relates to different uses of an RHCC peptide and/or a fragment thereof. Said RHCC peptide and/or fragment thereof enables an uptake and association of a drug and/or a substance into a cavity of said peptide and/or fragment, for the delivery and release of such a substance and/or... Agent: Bacon & Thomas, Pllc

20090214669 - Combination anticancer therapy and pharmaceutical compositions therefore: e

20090214671 - Personalizing cancer chemotherapy based on methylation and germ-line mutational analysis of brca-1: The present invention relates to a method for personalized diagnosing, prognosing, and treating of diseases, such as cancer, and in particular to a method for the personalized treatment of breast and/or ovarian cancer, based on a methylation and germ-line mutational analysis of the gene BRCA-1.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090214672 - Antimicrobial composition: An antimicrobial composition prepared by mixing a polymer-ammonium salt formulation comprising one or more polymers and one or more ammonium salts with alkali and a chlorine source in a molar ratio of chlorine (as Cl2) to ammonium ion of about 1:10 to about 10:1 and methods of using the composition... Agent: Nalco Company

20090214673 - Use of hydrogen sulfide in the treatment of eye diseases: Topical administration of a generator of H2S in biological tissues for the treatment of eye disorders, such as glaucoma. NaHS caused a time-dependent decrease in intrancular pressure in nomotensive, conscious albino rabbits indicating a similar role for H2S in the regulation of aqueous humor dynamics in animals and humans. H2S... Agent: Jackson Walker LLP

20090214674 - Methods and compositions for regulating biofilm development: The present invention relates to methods for promoting dispersal of, or preventing formation of microbial biofilms, comprising: exposing a biofilm to an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent; treating a surface or medium susceptible to biofilm formation with an effective amount... Agent: Morrison & Foerster LLP

20090214675 - 4-chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof: The present application relates to novel 4-chromenonyl-1,4-dihydropyridinecarbonitriles, processes for their preparation, pharmaceutical compositions containing them, and their use for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090214678 - Herbal formulation for the prevention and management of diabetes mellitus and diabetic micro-vascular complications: A novel herbal formulation for the prevention and management of diabetes mellitus and its significance in the prevention of diabetic micro-vascular complications. A novel herbal formulation for the prevention of endothelial dysfunction Diabetes Mellitus and Diabetic Micro-Vascular complications comprising: Salacia chinensis and at least one other active constituent selected from... Agent: The Webb Law Firm, P.c.

20090214676 - Method for treating ocular demodex: The present invention relates to a method for treating a disorder chosen from ocular Demodex, Demodex-induced blepharitis, rosacea, acne, and meibomian gland dysfunction in a patient in need thereof, comprising administering to the patient a composition comprising a therapeutically effective amount of a substance chosen from at least one of... Agent: Wilson Sonsini Goodrich & Rosati

20090214677 - Pharmaceutical composition containing an extract of a solidago species: An extract of a part of a Solidago species, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient is used for the regeneration of the organism of a mammal after long-lasting immobilization,... Agent: K.f. Ross P.c.

20090214679 - Pest-combating compositions comprising soy methyl ester: A pest-combating composition including soy methyl ester, and methods of combating pests utilizing same. Such composition in a preferred formulation may also include 2-undecanone. The composition may be constituted as a spray composition, lotion, paste, or other compositional form. Pests that may be usefully combated with such composition include mosquitoes,... Agent: Hunton & Williams LLP Intellectual Property Department

20090214680 - Weight loss composition: The present invention comprises a purposefully formulated weight loss composition and a method for causing a meaningful weight loss in a living human subject. The formulated weight loss composition, in its most preferred embodiments comprises: at least one amino acid that is a pharmacologically active precursor in the catecholamine biosynthesis... Agent: Robert Plotkin, Pc

20090214681 - Use of black soybean for treating ophthalmic diseases: A method for treating a disease or disorder associated with retinal pigment epithelium (RPE) disturbance, comprising administering to a human in need thereof an effective amount of a black soybean (Glycine max (L.) Merr) product is provided, wherein the black soybean product is the seed coats of black soybean or... Agent: Occhiuti Rohlicek & Tsao, LLP

20090214682 - Composition and methods for weight loss in a subject: The present invention relates generally to weight loss compositions and more particularly to orally administrable weight loss compositions for supporting weight loss in a subject in need thereof. Specifically, the present invention relates to compositions and methods comprising various combinations of orlistat and substances selected from methylxanthines, extracts of Morus... Agent: Iovate Health Science Research Inc.

20090214683 - Extracts of sacred water lotus for the treatment of cancer: The present invention provides Nelumbo extract and a method thereof. The present invention further provides a composition comprising said extract and a method for treating subject suffering from breast cancer with the composition.... Agent: Wpat, Pc Intellectual Property Attorneys

20090214684 - Method for reducing body weight and improving control of body lipids: Methods using plants from the Irvingiaceae plant genus to reduce weight in a mammal and provide numerous other health related benefits. In one embodiment, a method for reducing weight is provided. The method includes administering a composition containing an effective amount of ground up seeds of Irvingia gabonensis to a... Agent: Greenberg Traurig LLP (la)

20090214685 - Sustained release poloxamer containing pharmaceutical compositions: A thermo-reversible thermoplastic pharmaceutical composition, comprising a botulinum toxin and a biocompatible poloxamer which provides thermoreversibility to the composition and additionally stabilizes the botulinum toxin, is described. The pharmaceutical composition can be administered to a patient as a liquid, and gels after administration into a sustained release drug delivery system... Agent: Allergan, Inc.

20090208408 - Use of vcam-1 ligands for detecting and/or treating cardiovascular diseases: The invention concerns the use of VCAM-1 ligands in medical imagery, in particular for characterizing and/or therapeutic monitoring of cardiovascular diseases and more particularly for detecting vulnerable coronary atheroma. The invention also concerns the use of VCAM-1 ligands for making a medicine for treating a cardiovascular disease.... Agent: Stites & Harbison PLLC

20090208409 - Encapsulated nanoparticles for computed tomography imaging: A detection agent, including a polymerized liposome, a lectin, and an imaging agent, can be administered to an animal for the detection of polyps in the lower gastrointestinal tract.... Agent: National Institutes Of Health C/o Venable LLP

20090208411 - Cytotoxicity mediation of cells evidencing surface expression of cd44: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB) or derivatives thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the... Agent: Mchale & Slavin, P.A.

20090208410 - Ed-b fibronectin as stratification marker for anti-tumor drugs: The present invention relates to a method for stratifying tumor cells comprising the steps: (a) providing a sample comprising tumor cells to be analysed, (b) contacting said sample with an ED-B fibronectin-specific molecule and assessing the binding thereof to tumor cells in said sample, and (c) stratifying said tumor cells... Agent: Millen, White, Zelano & Branigan, P.C.

20090208412 - Contrast agents: A contrast agent of the general formula (I): Z1-L-V-Z2 (I) wherein at least one of Z1 and Z2 is present and are equal or different reporter moieties detectable in in vivo imaging of the human or animal body, V is a targeting moiety with binding affinity for areas of collagen... Agent: Ge Healthcare, Inc.

20090208414 - Method for the use of [11c] carbon monoxide in labeling synthesis of 11c-labelled ketones by photo-induced free radical carbonylation: Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using alkyl/aryl iodides with carbanion precursors pretreated by a base are provided. The resultant carbon-isotope labeled ketones, and pharmaceutical acceptable salts and solvates are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits and method... Agent: Ge Healthcare, Inc.

20090208413 - Registry method and control system for dea schedule ii-v medicines: The present invention provides compositions and methods for synthesizing labeled drugs. The present invention further provides methods for preventing or stopping prescription drug abuse for all agents registered as a Drug Enforcement Agency (DEA) schedule II through schedule V medications. According to the present invention, methods are provided for monitoring... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090208415 - Tropane compounds: The present invention provides novel tropane compounds and methods for their use.... Agent: Edwards Angell Palmer & Dodge LLP

20090208416 - Monoclonal antibodies against nkg2a: The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090208420 - Iron oxide-binding peptides: The invention relates to diagnostic compositions comprising metal oxide particles, especially iron oxide particles, which are coated with binding peptides. The binding peptides bind with high affinity to the metal oxide particles so that the peptide-coated metal oxide particles are suitable for medical applications, for example as contrast media for... Agent: Millen, White, Zelano & Branigan, P.C.

20090208421 - Process for preparing a pharmaceutical formulation of contrast agents: e

20090208422 - Composition for improving efficiency of drug delivery: Method and composition suitable for administering by direct convective interstitial infusion are disclosed. The method comprises: placing at least one direct convective interstitial infusion catheter in contact with the tissue, and pressuring the composition through the catheter. The composition is in a liquefied form having a viscosity above a predetermined... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090208417 - Detection and localized imaging of cancer using x-ray fluorescent nanoparticle/preferential locator conjugates: A method for detecting gold or other nanoparticles conjugated to preferential locators commences by contacting tissue suspected of being neoplastic with gold nanoparticle/preferential locator conjugates for a time adequate for the conjugates to bind with the tissue. A beam of gamma photons (such as from, 99mTc) is directed at the... Agent: Mueller And Smith, Lpa Mueller-smith Building

20090208419 - Multimodality imaging of reporter gene expression using a novel fusion vector in living cells and animals: Novel double and triple fusion reporter gene constructs harboring distinct imagable reporter genes are provided, as well as applications for the use of such double and triple fusion constructs in living cells and in living animals using distinct imaging technologies.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20090208418 - Superantibody synthesis and use in detection, prevention and treatment of disease: Superantibodies having enhanced autophilic, catalytic, and/or membrane-penetrating properties are prepared by affinity-based conjugation of a photoactivatable organic molecule to a target immunoglobulin. The photoactivatable organic molecule bears a chromophoric aromatic hydrocarbon moiety, which has affinity for the immunoglobulin. Upon photolysis, the organic molecule is covalently linked to the immunoglobulin. A... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090208423 - Synergistic insecticidal composition containing chloronicotynyle and pyrethroids compounds: A synergistic insecticidal composition is formed containing a Chloronicotynyle compound and a Pyrethroids compound. The Chloronicotynyle compound is provided in an amount preferably ranging from 0.1 to 5.0% by weight of the synergistic insecticidal composition. The Pyrethroids compound is provided in an amount preferably ranging from 1 to 60% by... Agent: Jones, Tullar & Cooper, P.C.

20090208424 - Compositions and methods for delivery of solution to the skin: Compositions and methods for delivery of medicaments to human or animal skin, for example, the scalp, comprising the steps of transporting the medicaments in a volatile carrier solution to a position adjacent to the skin, and atomizing the preparation at said position onto the skin to thereby uniformly distribute the... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090208425 - Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone: Use of idebenone for the preparation of a medicament for transmucosal administration.... Agent: Kilyk & Bowersox, P.l.l.c.

20090208426 - Use of diacetyl trimer as an aromatic and flavouring substance: in the form of one of its stereoisomers or in the form of a mixture consisting of or containing two or more of the stereoisomers (i) as an odoriferous or aromatic substance, (ii) for imparting, intensifying and/or modifying a creamy and/or fatty sensation in the mouth, (iii) for imparting, intensifying... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20090208427 - Vanillin acetals and sensory stimulant composition containing the same: The invention relates to a sensory stimulant composition containing one or more of vanillin acetals represented by the general formula (1), and a flavor and fragrance composition, a beverage or food product, a fragrance or cosmetic product, a daily utensil product, an oral composition, or a pharmaceutical product containing the... Agent: Mcdermott Will & Emery LLP

20090208428 - Bioactive glass: The present invention relates to a bioactive glass comprising strontium and silicon dioxide, processes for the production of the bioactive glass and the use of the bioactive glass in medicine.... Agent: Pepper Hamilton LLP

20090208434 - 3-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-1-propanone and its use in cosmetic and pharmaceutical preparations: e

20090208432 - Ah receptor antagonists: The invention relates to the field of aryl hydrocarbon receptor (Ah receptor; AhR) antagonists and their uses.... Agent: Connolly Bove Lodge & Hutz LLP

20090208433 - Ah receptor antagonists: The invention relates to the field of aryl hydrocarbon receptor (Ah receptor; AhR) antagonists and their uses.... Agent: Connolly Bove Lodge & Hutz LLP

20090208430 - Glow and sunless tanning color enhancement by cationic copolymers: A cosmetic composition for sunless tanning or imparting glow to skin is herein described. The composition includes from about 0.1 to about 20% by weight of a tanning agent and from 0.1 to 20% by weight of a crosslinked cationic copolymer having a monomer unit which is a methacryloylethyl or... Agent: Unilever Patent Group

20090208429 - Glow and sunless tanning via a heated flowable cosmetic transferred onto skin: A product and method for tanning or imparting glow to skin is herein described. The product is a package with associated instructions for applying a tanning cosmetic composition to skin dispensed from a heating device. The heated cosmetic composition imparts a more rapid development of color than an identical composition... Agent: Unilever Patent Group

20090208431 - Topical turmeric skin care products: A topical skin care product is provided that contains therapeutic concentrations of turmeric and other constituents which is colorless upon application to the skin. The product can be used for cosmetic, protective, and healing purposes without staining skin or clothing yellow.... Agent: Honigman Miller Schwartz & Cohn LLP

20090208435 - Method of quenching electronic excitation of chromophore-containing organic molecules in photoactive compositions: wherein A and B are the same or different and are selected from the group consisting of oxygen, amino and sulfur; R1 and R3 are the same or different and are selected from the group consisting of C1-C30 alkyl, C2-C30 alkylene, C2-C30 alkyne, C3-C8 cycloalkyl, C1-C30 substituted alkylene, C2-C30 substituted... Agent: Marshall, Gerstein & Borun LLP

20090208436 - Orange pearlescent pigments: An orange pearlescent pigment comprising a substrate and a first layer containing FeOOH, and a second layer containing Fe2O3 located between the substrate and the first layer. The color of the pigment is such that a homogeneous coating of the pigment, measured over a white background, has a CIELAB hue... Agent: Frost Brown Todd, LLC

20090208437 - Glycopyrrolate in cosmetic preparations: Glycopyrronium bromide, derivatives and/or isomers thereof in combination with one or more active substances selected from a list of substances as recited in the claims and/or in the form of a W/Si emulsion, an O/W gel, a soap gel stick, and/or a surfactant-containing cleansing formula, and corresponding cosmetic preparations, in... Agent: Greenblum & Bernstein, P.L.C

20090208438 - Topical deodorant composition, and method of its manufacture and use: A topical deodorant composition comprising unrefined Shea butter, sodium bicarbonate, cornstarch, cocoa butter, coconut oil, lavender oil, Clary sage oil, benzoin gum tincture and vitamin E. The topical deodorant composition controls body odor and improves the moisture, texture and appearance of the skin. To prepare the topical deodorant composition, unrefined... Agent: Williamson Intellectual Property Law, LLC

20090208440 - Biological entities and the use thereof: The present invention provides engineered enzymes generated from protein scaffolds combined with Specificity Determining Regions, the production thereof and the use of said engineered enzymes for research, nutritional care, personal care and industrial purposes.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090208439 - Agent for permanent hair waving containing heterocyclic mercapto compound: wherein R1 and R2 each independently represent a hydrogen atom or an optionally substituted alkyl group having 1 to 5 carbon atoms; X represents —O—, —S—, —NH—, or —NR3—; R3 represents an alkyl group having 1 to 5 carbon atoms; n is an integer of 0 to 2; and, when... Agent: Sughrue Mion, PLLC

20090208443 - Cationic copolymer and starches formulated cosmetic compositions exhibiting radiance with soft focus: A cosmetic composition is provided which includes a starch, a cationic copolymer having a monomer unit which is acryloylethyl tri(C1-C3 alkyl)ammonium salt, and a cosmetically acceptable carrier. The compositions are used to impart radiance with soft focus effect onto skin. Most preferred as the cationic copolymer is acrylamide/acryloylethyl trimethylammonium chloride/tris(hydroxymethyl)acrylamidomethane... Agent: Unilever Patent Group

20090208442 - Cationic copolymers formulated with pigmented cosmetic compositions exhibiting radiance with soft focus: A cosmetic composition is provided which includes a silicone elastomer, a cationic copolymer with monomeric units selected from at least an acryloylethyl tri(C1-C3 alkyl) ammonium salt, and light reflecting platelet shaped particles. The compositions are particularly useful to impart radiance as well as soft focus effects onto the skin. A... Agent: Unilever Patent Group

20090208441 - Process for the controlled radical polymerization or copolymerization of one or more monomers in the presence of an initiator of alkoxyamine type: The invention relates to a process for the polymerization of one or more monomers comprising a stage in which the said monomer or monomers is/are brought into contact, in a medium comprising water, with at least one specific initiator of the alkoxyamine type corresponding, for example, to the following formula:... Agent: Millen, White, Zelano & Branigan, P.C.

20090208444 - Novel formulation: e

20090208445 - Compositions comprising eucalyptol and/or ocimene and/or farnesol for use as bumblebee pheromones: Compositions comprising eucalyptol and/or ocimene and/or farnesol are provided for use as bumblebee pheromones. The compositions are useful in agriculture to assist in the pollination of angiosperm plant species. Such compositions can attract insects of the genus Bombus (bumblebee) to angiosperm plants where the composition is applied to the plant,... Agent: Pepper Hamilton LLP

20090208446 - Dub3 as a cancer therapy target: Described is a method of modulating the activation of a Rho, Arf, Rab, Ran or Rap family protein, said method comprising administering to said sample a USP-17 modulator, for example an inhibitor of expression or activity of DUB-3. The invention enables the use of USP-17 modulators in the treatment of... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090208449 - Heterocyclic antiviral compounds: Compounds having the formula I wherein R1, R2, R3, R4, R5 and X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090208448 - Inhibition of angiogenesis: Cholesterol-uptake-blocking drugs inhibit angiogenesis and are useful to inhibit diseases perpetuated by angiogenesis. Cholesterol reduction with the use of the drugs increases the intratumoral level of thrombospondin-1, an angiogenesis inhibitor. Ezetimibe (Zetia®), a specific cholesterol-uptake blocking drug, also retards the growth of human tumors, most preferably in combination with low-cholesterol... Agent: Cynthia Soumoff Porzio, Bromberg & Newman, P.C.

20090208450 - Method for enhancing the efficacy of antigen specific tumor immunotherapy: The invention provides a method for the improved processing efficiency of T cell tumor antigen epitopes using bioinformatic means. The proteolytic sites in the generation of 47 experimentally identified HLA-A2.1-restricted immunodominant tumor antigen epitopes was compared to those of 52 documented HLA-A2.1-restricted immunodominant viral antigen epitopes. The amino acid frequencies... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090208447 - Polypeptides: The present invention provides polypeptides having the property of binding to a given Class I pMHC CHARACTERISED IN THAT said polypeptide has a KD for the said given Class I pMHC of less than or equal to 1 μM and/or has an off-rate (koff) for the said given Class I... Agent: Banner & Witcoff, Ltd.

20090208451 - Halogen phosphonate monoesters: The present invention relates to detection, immobilization, and production of proteolytic antibodies using halogen phosphonate monoester probes, immobilizing reagents, and antigen conjugates.... Agent: Townsend And Townsend And Crew, LLP

20090208453 - High pressure treatment of aggregated interferons: High pressure to treat aggregated interferons, particularly recombinant human interferon-β, to reduce the aggregate content of interferon material. Highly pure, soluble monomeric recombinant interferon-β is prepared in representative embodiments. Multiple strategies may be used in combination that make nonglycosylated IFN-β more amenable to high pressure treatment. It has been found... Agent: Kagan Binder, PLLC

20090208452 - Inhibitor of endogenous human interferon-gamma: The invention relates to an inhibitor of endogenous human interferon-gamma (hIFN-&gammad;) in autoimmune diseases, especially in multiple sclerosis. More precisely, the invention relates to inactivated protein derivatives of the hIFN-&gammad; with preserved affinity to the hIFN-&gammad; receptor. The derivatives represent genetically modified variants of hIFN-&gammad; where the C-terminal part of... Agent: Jacobson Holman PLLC

20090208455 - method for treating polyglutamine expansion neurodegenerative diseases: The present invention relates to use of an inducer of Promyelocytic Leukemia protein (PML) expression, and especially PML IV for the manufacture of a medicament intended for the treatment of polyglutamine expansion neurodegenerative diseases. More specifically, the present invention relates to the use of an interferon polypeptide for the manufacture... Agent: Occhiuti Rohlicek & Tsao, LLP

20090208454 - Modified interferon beta polypeptides and their uses: Modified interferon beta polypeptides and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20090208456 - Imidazo[4,5-d]pyrimidines, their uses and methods of preparation: The present invention relates to pharmaceutical compositions for the treatment of prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyrimidine having the general formula (A), wherein the substituents are described in the specification. The invention also relates to processes for the preparation of compounds according to... Agent: Gilead Sciences Inc

20090208457 - Tricyclic-nucleoside prodrugs for treating viral infections: Disclosed are compounds, compositions and methods for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus.... Agent: Dority & Manning, P.A.

20090208459 - Methods of treating anemia using recombinant adeno-associated virus virions: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the... Agent: Robins & Pasternak

20090208460 - Mutant herpes simplex viruses comprising nucleic acid encoding a nitroreductase: An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a nitroreductase (NTR) is disclosed. Disclosed herpes simplex viruses are indicated to be useful in the treatment of cancer which may involve gene directed enzyme prodrug therapy.... Agent: Swanson & Bratschun, L.L.C.

20090208461 - Recombinant bacteria with e.coli hemolysin secretion system and increased expression and/or secretion of hlya, process of manufacturing and uses thereof: The invention relates to a recombinant bacterium with E. coli hemolysin secretion system and increased expression and/or increased secretion of full length or partial HlyA.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090208458 - Transcriptional inhibitor for human k-ras gene: A transcriptional inhibitor for human K-ras gene which comprises one or more proteins selected from the group consisting of a protein having the amino acid sequence represented by SEQ ID NO:1, a protein having an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 by... Agent: Edwards Angell Palmer & Dodge LLP

20090208469 - Use of lactobacillus for treatment of autoimmune diseases: The present technology relates to the use of at least one strain of probiotic bacteria selected from Lactobacillus for the manufacture of a medicament for the treatment and/or prevention of an autoimmune disease.... Agent: Buchanan, Ingersoll & Rooney PC

20090208470 - Microorganisms having bad smell removal activity of organic waste and use thereof: The present invention relates to novel microorganisms having the efficiency of removing an offensive odor from organic waste and the use thereof. More particularly, the novel microorganisms have the effects of preventing or removing the offensive odor from organic waste, killing insects and fungi, preventing decomposition, and promoting digestion and... Agent: Edwards Angell Palmer & Dodge LLP

20090208466 - Ink-jet printing of tissues: A method of forming an array of viable cells is carried out by ink-jet printing a cellular composition containing said cells on a substrate. At least two different types of viable mammalian cells are printed on the substrate, the at least two different types of viable mammalian cells selected to... Agent: Myers Bigel Sibley & Sajovec

20090208464 - Mesenchymal stem cell isolation and transplantation method and system to be used in a clinical setting: A system and method for the percutaneous, autologous transplantation of mesenchymal stem cells and progenitor helper cells (PHC) from bone marrow to degenerated intervertebral discs or joints. This method is designed to be used by operating room staff in a clinical setting to isolate a mesenchymal stem cell population and... Agent: Swanson & Bratschun, L.L.C.

20090208463 - Mesenchymal stem cells and uses therefor: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting wound healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.... Agent: Mcandrews Held & Malloy, Ltd

20090208465 - Method of treating neural defects: The present invention provides a therapeutic agent for a nerve injury and a method for treating a nerve injury. One aspect of the invention is the method for treating a nerve injury by administering to a patient with a nerve injury a therapeutic agent for a nerve injury containing a... Agent: Clark & Elbing LLP

20090208462 - Methods of treatment: The invention concerns the use of a nucleic acid encoding a photoactivator in the manufacture of a medicament for inducing photosensitivity in neuronal cells. In particular, the invention concerns the induction of photosensitivity in retinal ganglion cells (RGCs) for restoring sight and/or alleviating blindness in an individual. The invention further... Agent: Marshall, Gerstein & Borun LLP

20090208467 - P27 and p21 in gene therapies: The expansion of a population of stem cells or progenitor cells, or precursors thereof, may be accomplished by disrupting or inhibiting p21cip1/waf1 and/or p27, cyclin dependent kinase inhibitors. In the absence of p27 activity, progenitor cells move into the cell cycle and proliferate; whereas in the absence of p21 activity,... Agent: C. Hunter Baker, M.d., Ph.d. Choate, Hall & Stewart, Exchange Place

20090208468 - Suppressors of cpg oligonucleotides and methods of use: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in... Agent: Klarquist Sparkman, LLP

20090208471 - Isolation and use of human regulatory t cells: The present invention provides a new method for isolating and enriching human regulatory T cells. The enriched cells are useful in the treatment of autoimmune disease.... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090208473 - Compositions and methods to modulate cell membrane resealing: Disclosed herein are compositions and methods for repairing cell membranes. In addition, the invention relates to therapeutic compositions comprising nucleotides and/or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the repair of cell membranes. Moreover, the invention relates to the treatment and/or prevention... Agent: Mccarter & English, LLP Hartford Cityplace I

20090208472 - Oil-in-water emulsion composition containing licorice-derived polyphenol: The present invention provides a licorice polyphenol-containing oil-in-water emulsion composition comprising medium-chain triglyceride, a licorice hydrophobic extract comprising, as a main component, licorice polyphenol in a weight ratio relative to the medium-chain triglyceride of 1-50%, and a polyglycerol fatty acid ester comprised of a fatty acid residue having a carbon... Agent: Sughrue Mion, PLLC

20090208474 - Biological entities and the use thereof: The present invention provides engineered enzymes generated from protein scaffolds combined with Specificity Determining Regions, the production thereof and the use of said engineered enzymes for research, nutritional care, personal care and industrial purposes.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090208476 - Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins: The present invention relates to compositions and methods to administer compositions comprising cupredoxin and/or cytochrome and/or variants, derivatives, truncations and structural equivalents of cupredoxin and cytochrome to treat and/or prevent two or more conditions in a mammalian cell. The invention also relates to compositions and methods to administer compositions comprising... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090208475 - Mina53 assays: The present invention comprises a method for assaying oxygenase activity the method comprising monitoring oxygenase activity of Mina53.... Agent: Brooks Kushman P.C.

20090208477 - Production of high mannose proteins in plant culture: A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090208478 - Transducible polypeptides for modifying metabolism: Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains.... Agent: Pabst Patent Group LLP

20090208479 - Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol: Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a... Agent: Fox Rothschild LLP Sanofi-aventis

20090208480 - Long half-life recombinant butyrylcholinesterase: The present invention provides for butyrylcholinesterase (BChE) attached to polyethylene glycol (PEG) to form a complex having greatly increased mean residence time (MRT) in the system of an animal following injection thereinto. Also disclosed are compositions of such complexes, methods of preparing these complexes and method for using these complexes... Agent: Alan J Grant Carella Byrne Brain Giffillan Cecchi Stwartolstein

20090208481 - Proteomic analysis of active multiple sclerosis lesions: The invention provides methods for treating demyelinating inflammatory diseases by administering to the subject an effective amount of an agent that provides activated protein C activity, where the dose is effective to reduce the adverse clinical indicia of the disease. In some embodiments, the patient being treating is of the... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090208485 - 3-aminocyclopentanecarboxamides as modulators of chemokine receptors: e

20090208483 - Antibody selective for dr4 and uses thereof: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of DR5 and DR4 antibodies have been elucidated and vectors and cells containing... Agent: Fish & Richardson P.C.

20090208482 - Human obesity susceptibility gene encoding a member of the neurexin family and uses thereof: The present invention more particularly discloses the identification of a human obesity susceptibility gene, which can be used for the diagnosis, prevention and treatment of obesity and associated disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses certain alleles of the contactin associated... Agent: Occhiuti Rohlicek & Tsao, LLP

20090208484 - R-spondin compositions and methods of use thereof: The invention provides for a method for screening compounds that bind to and modulate a regulator of Wnt signaling, R-spondin 4. The invention further provides for methods for diagnosing a keratin-related abnormality, such as anonychia congenital, in a subject. The invention also provides for isolated RSPO4 mutant molecules.... Agent: Wilmerhale/columbia University

20090208486 - Pharmaceutical composition comprising cxcr3 inhibitor: A pharmaceutical composition for the treatment of cancer of which survival and/or metastasis is under the influence of signal transduction mediated by a chemokine receptor CXCR3, which comprises an agent to inhibit CXCR3, and a method of treatment and diagnosis of such cancer.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090208495 - Anti-tumor effective paramyxovirus: Paramyxovirus from the group APMV3, APMV4, APMV5, APMV6, APMV7, APMV8, APMV9, Mapueravirus and Fer-de-Lance virus are described, which can be used for the production of a medicament for the treatment of tumors. The virus has a selectivity to kill human tumor cells but not human normal differentiated and human normal... Agent: Millen, White, Zelano & Branigan, P.C.

20090208489 - Antibodies that bind ov064 and methods of use therefor: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding... Agent: Millennium Pharmaceuticals, Inc.

20090208491 - Compositions and methods for diagnosing and treating cancer: Humanized antibodies that specifically binds to a non-ligand binding region of human Notch1 are described. Also described are methods of treating cancer, the methods comprising administering a therapeutically effective amount of a humanized anti-Notch1 antibody.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090208493 - Compounds and methods for the selective inhibition of abcb1, abcc1 and abcg2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors: Compounds disclosed which inhibit ABCB1 transporter protein are useful for treating diseases in which ABCB1 transporter protein mediates the disease state, including numerous cancers, including hematopoietic cancers, including various leukemias, especially T-lineage acute lymphoblastic leukemia, as well as cancerous tumors, especially forms which exhibit multiple drug resistance. Pharmaceutical compositions which... Agent: Coleman Sudol Sapone, P.C.

20090208498 - Genetic products differentially expressed in tumors and the use thereof: The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with... Agent: Mcandrews Held & Malloy, Ltd

20090208496 - Humanized anti-cd4 antibody with immunosuppressive properties: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.... Agent: Cermak Kenealy Vaidya & Nakajima LLP

20090208497 - Humanized anti-cd4 antibody with immunosuppressive properties: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.... Agent: Cermak Kenealy Vaidya & Nakajima LLP

20090208494 - Humanized antibody molecules specific for il-31: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.... Agent: Zymogenetics, Inc. Intellectual Property Department

20090208492 - Lyophilized immunoglobulin formulations and methods of preparation: The present invention relates generally to the field of pharmaceutical formulation of immunoglobulins. Specifically, the present invention relates to stable, lyophilized, high concentration immunoglobulin formulations. This invention is exemplified by a stabilized lyophilized formulation of the recombinant humanized anti-alpha-4 integrin antibody natalizumab.... Agent: Crowell & Moring LLP Intellectual Property Group

20090208490 - Molecules that are able to inhibit the binding between ngf and the trka receptor as analgesics with prolonged effect: Use of an anti-NGF antibody capable of inhibiting the binding between NGF and TrkA, capable of blocking the biological activity of TrkA for the preparation of a medicament for treating and/or preventing chronic pain.... Agent: Hoffmann & Baron, LLP

20090208499 - N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use: The present invention relates to an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof, the N-(phosphonoalkyl)-amino acid, related compound or derivative thereof being in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, other than N-(phosphonomethyl)-glycine or N,N-bis(phosphonomethyl)-glycine. Also... Agent: Panitch Schwarze Belisario & Nadel LLP

20090208487 - Prevention and treatment of synucleinopathic and amyloidogenic disease: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic... Agent: Townsend And Townsend And Crew, LLP

20090208488 - Regulation of dendritic cell functions by the dcal-2 receptor: This invention provides antibodies that specifically bind to DCAL-2 and other DCAL-2 reagents that modulate dendritic cell function. Modulators of the receptor, including modulators that alter DCAL-2 associated signals to and from DCs, can be used to alter dendritic cell function and to enhance or inhibit immune responses to cancer... Agent: Townsend And Townsend And Crew, LLP

20090208501 - Anti-pathogen immunoadhesins: Chimeric molecules that include a pathogen recognition module derived from a pathogen binding domain of a pathogen recognition protein, e.g., a toll-like receptor (TLR), CD14, BPI, MD-2, scavenger receptors (SRs), surfactant proteins (SP), C-reactive protein (CRP), Mannan-binding lectin (MBL), or complement Clq globular binding domain, an optional linker, and an... Agent: Fish & Richardson PC

20090208502 - Apoptosis-inducing protein complexes and therapeutic use thereof: The invention relates to the fields of immunology and molecular medicine. In particular, it relates to protein complexes that can be applied as therapeutic agent to induce apoptotic cell death in a target cell population, for example tumour cells or virally infected cells. Provided is a multivalent monospecific protein complex... Agent: Hoffmann & Baron, LLP

20090208500 - Method of producing antibodies with improved function: The invention provides methods for controlling fucosylation levels and improving ADCC activity in antibodies.... Agent: Genentech, Inc.

20090208503 - Immunotherapeutic treatment: The use of immunotherapy against oxidised LDL to induce regression of pre-existing atherosclerotic lesions in an individual. The immunotherapy can be passive immunotherapy utilising antibodies that bind to epitopes present on oxidised LDL, or active immunotherapy utilising a vaccine composition for induction of an immune response against epitopes present on... Agent: Fish & Richardson P.C.

20090208504 - Polypeptides involved in immune response: Novel polypeptides which comprise a receptor-ligand pair involved in T-cell, activation are disclosed. Nucleic acid molecules encoding said polypeptides, and vectors and host cells for expressing same are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders.... Agent: Amgen Inc.

20090208506 - Antibodies against flagellin and uses thereof: The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090208505 - Mutations of the pik3ca gene in human cancers: Phosphatidylinositol 3-kinases (PI3Ks) are known to be important regulators of signaling pathways. To determine whether PI3Ks are genetically altered in cancers, we analyzed the sequences of the P13K gene family and discovered that one family member, PIK3CA, is frequently mutated in cancers of the colon and other organs. The majority... Agent: Banner & Witcoff, Ltd.

20090208507 - Protein isoforms and uses thereof: (b) correlating the results of said assay(s) to the presence or absence of MCI and AD in the subject, to a therapeutic regimen to be used in the subject, or to the prognostic risk of one or more clinical outcomes for the subject suffering from MCI.... Agent: Klauber & Jackson

20090208508 - Novel use of ubiquitin c-terminal hydrolase-l1: )

20090208509 - Pharmaceutical formulation of an antibody against il-1r: Pharmaceutical formulation of an antibody against IL-1R (interleukin-1 receptor), a process for the preparation and uses of the formulation.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090208510 - Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins: A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090208512 - Catalytic anti-factor viii allo-antibodies: The present invention relates to a method of determining the presence of catalytic anti-Factor VIII allo-antibodies capable of degrading Factor VIII in a mammal, and of characterising the cleavage sites in said Factor VIII molecule by said catalytic anti-Factor VIII allo-antibodies. It also relates to an anti-Factor VIII allo-antibody-catalysed Factor... Agent: Clark & Brody

20090208511 - Novel method for identifying diabetic patients at increased risk for pathological complications: The present invention provides methods for detecting and measuring, in a sample from a subject, the plasma levels of endothelial cell antibodies to diagnose an increased risk of pathological complications, such as visual impairment, associated with diabetes.... Agent: Mandel & Adriano

20090208513 - Diagnostic and therapeutic uses of augmenter of liver regeneration in inflammatory conditions: The present invention provides for methods and kits for detecting sepsis, trauma/hemorrhage or inflammation in a subject. It is based, at least in part, on the discovery that Augmenter of Liver Regeneration (“ALR”) is an early marker of these conditions. Accordingly, in other embodiments, the present invention provides for a... Agent: Baker Botts L.L.P.

20090208514 - Method of diagnosing esophageal cancer: In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection.... Agent: Townsend And Townsend And Crew, LLP

20090208517 - Preparation of antigen-presenting human gamma-delta t cells and use in immunotherapy: The invention relates to a method for the preparation of efficient antigen-presenting human γδ T cells, to the γδ T cells prepared by such a method, and to their use in immunotherapy, vaccination, vaccine development and diagnostics. Similar to dendritic cells (DCs) in potency and efficacy, these human γδ T... Agent: King & Schickli, PLLC

20090208516 - Promoter for introducing a gene into a lymphocyte or blood cell and application thereof: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression... Agent: King & Spalding LLP

20090208515 - Vaccine composition: The present invention relates to virus vectors comprising oligonucleotides encoding HIV polypeptides, more particularly wherein the virus vector is an adenovirus. In particular, such adenoviruses are non-human primate adenoviruses such as simian adenoviruses, more particularly chimpanzee adenoviruses. In particular the invention relates to adenovirus vectors which comprise HIV polynucleotide sequences... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090208518 - Immunogenic peptides for the treatment of prostate and breast cancer: Immunogenic T-cell receptor gamma Alternate Reading Frame Protein (TARP) polypeptides are disclosed herein. These immunogenic TARP polypeptides include nine consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 9 and do not comprise amino acids 1-26 or amino acids 38-58 of SEQ ID NO: 1.... Agent: Klarquist Sparkman, LLP

20090208519 - Novel neospora caninum vaccine: Neospora caninum is the causal agent of bovine neosporosis which results in high levels of abortion. The present study determined the protective efficacy of two Neospora antigens—Neospora cyclophilin (NcCyP) and NcSRS2. The ability of native NcCyP to upregulate mouse IFNγ was also confirmed in this study. Recombinant NcCyP or NcSRS2... Agent: Usda, Ars, Ott

20090208520 - Prrsv gp5 based compositions and methods: The disclosure includes compositions and methods for the production of an immune response against porcine reproductive and respiratory syndrome (PRRS) virus, or PRRSV. The disclosure is based in part on the use of two or more peptide domains, each with a different sequence, from the PRRSV GP5 protein ectodomain. Compositions... Agent: Patentique PLLC

20090208521 - Pharmaceutical compositions containing protein nma0939: The present invention is related to field of medicine, particularly to the development of pharmaceutical formulations containing NMA0939 protein. Formulations described in this invention are able to confer protection against different diseases caused or not by pathogenic agents. NMA0939 protein was identified as a Neisseria meningitidis outer membrane vesicle component,... Agent: Hoffmann & Baron, LLP

20090208522 - Neutralizing epitope-based growth enhancing vaccine: The invention provides a fusion protein comprising a plant virus coat protein and a GDF8 peptide domain, or antigenic fragment of the GDF8 peptide domain. Plant virus vectors expressing the fusion protein and methods of using these vectors are also provided.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090208523 - Adjuvant for vaccines: Vaccine containing a first vaccine, adjuvated with an oil-in-water emulsion comprising 5% squalene, 0.5% polysorbate 80 and 0.5% sorbitan trioleate in aqueous citrate buffer pH 6.5, and a nonadjuvated second vaccine as combination partners for the simultaneous, separate or phased application for immunization against viral, bacterial or parasitic infectious diseases.... Agent: Novartis Vaccines And Diagnostics Inc.

20090208524 - Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an α2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment... Agent: Jones Day

20090208525 - Antiaging method for skin using pleurotus abalonus: The present invention provides an antioxidant and a whitening agent having high safety, and a external preparation for skin using the same. The antioxidant and whitening agent comprise, as an effective component, one or more extracts from Basidiomycetes selected from the group consisting of Pleurotus abalonus, Pholiota squarrosa, Onnia orientalis,... Agent: Rankin, Hill & Clark LLP

20090208526 - Combination vaccines with low dose of hib conjugate: Provided herein are combination vaccines comprising antigens for protecting a subject against at least diphtheria, tetanus, pertussis and Hib, wherein: (a) the antigen for protecting against Hib is a conjugate of a Hib capsular saccharide; (b) the concentration of the Hib conjugate in the vaccine is <15 μg/ml; and (c)... Agent: Novartis Vaccines And Diagnostics Inc.

20090208527 - Multi plasmid system for the production of influenza virus: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken... Agent: Medimmune, LLC Jonathan Klein-evans

20090208528 - Empty capsids (vlps(-vp4)) of the infectious bursal disease virus (ibdv), obtainment process and applications: The empty capsids of the infectious bursal disease virus (IBDV), VLP(−VP4), are characterized in that they are constituted only by assembly of IBDV pVP2 proteins and IBDV VP3 proteins. Said capsids have immunogenic activity and can be used in the manufacture of vaccines for protecting animals from the infection caused... Agent: Klarquist Sparkman, LLP

20090208529 - Recombinant novirhabdoviruses and uses thereof: The invention relates to recombinant novirhabdoviruses having at least one sequence encoding a polypeptide of interest added to their genome. Said recombinant novirhabdoviruses are useful as gene vectors, for producing recombinant proteins, or for producing vaccines for fish or for higher vertebrates.... Agent: Morgan Lewis & Bockius LLP

20090208530 - Hiv polynucleotides and polypeptides derived from botswana mj4: The present disclosure relates to novel polynucleotides that encode HIV Env polypeptides. In particular, the disclosure relates to sequences derived from HIV strain Botswana MJ4 encoding Env polypeptides. Compositions comprising these polynucleotides and methods of using polynucleotides are also disclosed.... Agent: Novartis Vaccines And Diagnostics Inc.

20090208531 - Antiviral agents and vaccines against influenza: These vaccines target H5N1, H1, H3 and other subtypes of influenza and are designed to elicit neutralizing antibodies, as well as cellular immunity. The DNA vaccines express hemagglutinin (HA) or nucleoprotein (NP) proteins from influenza which are codon optimized and/or contain modifications to protease cleavage sites of HA which affect... Agent: Knobbe, Martens, Olson & Bear, LLP

20090208532 - Methods of producing influenza vaccine compositions: Methods and compositions for the optimization and production of influenza viruses, e.g., ca influenza B strains, in eggs and host cells suitable as influenza vaccines are provided.... Agent: Medimmune, LLC Jonathan Klein-evans

20090208533 - Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions: Provided are methods for recombinant production of an O-acetyltransferase and methods for acetylating capsular polysaccharides, especially those of a Serogroup A Neisseria meningitidis using the recombinant O-acetyltransferase, and immunogenic compositions comprising the acetylated capsular polysaccharide.... Agent: Greenlee Winner And Sullivan P C

20090208534 - Attenuated salmonella as a delivery system for sirna-based tumor therapy: The invention relates to an attenuated Salmonella sp. that is capable of targeting a solid tumor when administered in vivo comprising a short hairpin (sh) RNA construct, and methods of inhibiting the growth or reducing the volume of a solid tumor cancer comprising administering an effective amount of an attenuated... Agent: Knobbe, Martens, Olson & Bear, LLP

20090208535 - Novel methods of diagnosis of treatment of p. aeruginosa infection and reagents therefor: The present invention relates to novel diagnostic, prognostic and therapeutic reagents for infection of an animal subject such as a human by Pseudomonas aeruginosa, and conditions associated with such infections, such as, for example, an acute clinical exacerbation in a cystic fibrosis (CF) subject. In particular, the present invention relates... Agent: Fenwick & West LLP

20090208536 - Composition comprising fractions or sub-fraction of leishmania promastigotes or leishmania amastigotes called fucose mannose ligand (fml) and saponin, composition for preparation of leishmaniasis transmission blocking vaccines in humans and animals compri: The invention relates to a composition comprising Leishmania promastigotes or Leishmania amastigotes fractions or sub-fractions called “Fucose Mannose Ligand” (FML) and saponin. The invention also comprises the use of the composition for preparation of a blocking vaccine impeding Leishmaniasis transmission in humans or animals.... Agent: Pearl Cohen Zedek Latzer, LLP

20090208537 - Anti-neovasculature preparations for cancer: Disclosed herein are immunogenic compositions, methods of designing immunogenic compositions, methods of treatment using immunogenic compositions, methods of evaluating cell-mediated immunity resulting from immunogenic compositions, research models, and methods of making research models, all of which relate to targeting tumor vasculature.... Agent: Davis Wright Tremaine LLP/mankind Corporation

20090208538 - Methods and compositions for tumor vaccination and therapy: The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090208540 - Implantable device for the delivery of naltrexone and methods of use thereof: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver naltrexone and formulations thereof at a constant rate for an extended period of time. The devices and methods of use thereof are biocompatible and biostable, and useful for the delivery of naltrexone in... Agent: Foley And Lardner LLP Suite 500

20090208539 - Stable atorvastatin formulations: A simple yet efficient formulation for providing excellent bioefficacy, wherein the formulation includes atorvastatin or a salt thereof, in crystalline or amorphous form, with at least one pharmaceutical excipient selected to a form of atorvastatin that has beneficial properties, such as enhanced stability. These formulations do not need to include... Agent: Winston & Strawn LLP Patent Department

20090208543 - Method and apparatus for applying a protective oral care composition: Compositions and methods for whitening human teeth containing peroxide and a hydroperoxidase inhibitor. The compositions exhibit superior teeth whitening effects while also retaining a greater amount of peroxide compared to compositions not containing the hydroperoxidase inhibitors. The compositions may be formulated in a hydrocarbon humectant free vehicle comprising a peroxide... Agent: Townsend And Townsend And Crew, LLP

20090208544 - Method of obtaining phytoalexins: Topical composition containing (a) from 0.1% to 5% of encapsulated UV-elicited dedifferentiated plant cells comprising vacuoles rich in stilbenes, and (b) cosmetically acceptable excipients.... Agent: Hovey Williams LLP

20090208541 - Oil-in-water nanoemulsion, a cosmetic composition and a cosmetic product comprising it, a process for preparing said nanoemulsion: The present invention relates to an oil-in-water emulsion for cosmetic use, wherein the oil particles have an average diameter ranging from 50 to 200 nm (nanometers). The nanoemulsion comprises an emulsifying system having components such as ceteareth-20, ceteareth-12, glyceryl stearate, cetearyl alcohol and cetyl palmitate. This composition imparts to the... Agent: Alston & Bird LLP

20090208542 - Product and method for transferring heated flowable cosmetic onto skin: A product and method for treating skin with a heated lotion is herein described. The product is a packaged cosmetic composition with associated instructions for applying to skin a heated form of the cosmetic composition dispensed from a heating device. The cosmetic composition includes porous particles which function to retain... Agent: Unilever Patent Group

20090208545 - System and method for providing medicinal treatment: A medicinal delivery device, system and method for providing medicinal treatment to an area skin. The medicinal delivery device may be configured to be a size and shape suitable to conform to the contours of the body (e.g., the perineum region) and configured to retain the medicant, while allowing transfer... Agent: Snell & Wilmer L.L.P. (main)

20090208546 - Aqueous coating compositions: A pesticidal coating composition is provided which comprises an aqueous dispersion of at least one film-forming binder and at least one microencapsulated pesticide; wherein a coating prepared from such composition is substantially water-impermeable upon curing. The present invention further provides methods of coating substrates with the pesticidal coating composition, as... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090208548 - Copolymer-stabilized emulsions: An emulsion includes a substantially continuous liquid medium, and a plurality of droplet structures dispersed within the substantially continuous liquid medium. Each droplet structure of the plurality of droplet structures includes an outer droplet of a first liquid having an outer surface; an inner droplet of a second liquid having... Agent: Venable LLP

20090208547 - Oxidizing composition including a gel layer: A composition that generates and releases a biocidal solution comprising at least chlorine dioxide and hypobromous acid is presented. The composition comprises reactants capable of in-situ generation of chlorine dioxide and hypobromous acid, and a gelling agent that slows the rate of dissolution of the reactants, thereby increasing yield and... Agent: Roy W. Martin

20090208549 - Devices and methods for reverse lipid transport: The present disclosure relates to devices methods for the reverse transport of lipids such as cholesterols for the treatment diseases and conditions caused by vulnerable plaques. The devices can reduce or eliminate vulnerable plaques by transporting the plaques away from their location.... Agent: Medtronic Vascular, Inc.IPLegal Department

20090208550 - Methods and compositions for treating hepatic diseases: The invention provides methods and compositions for treating a hepatic disease, for reducing fat deposition in the liver and for inhibiting fibrosis of the liver by administering a compound or agent that modulates an adenosine receptor, in particular, an inhibitor or antagonist of an adenosine receptor, especially an A1 or... Agent: Klauber & Jackson

20090208554 - Baclofen formulation in a polyorthoester carrier: Effective treatments of pain for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of baclofen formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused... Agent: Medtronic, Inc.

20090208551 - Biological implantation material and method for preparing same: f

20090208552 - Cross-linked fatty acid-based biomaterials: Fatty acid-based, pre-cure-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents. Methods of forming... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090208553 - Monomers and polymers with covalently - attached active ingredients: Methods to form an active agent modified monomer comprising a ring opening cyclic monomer linked to an active agent via a degradable covalent linkage. Methods to form a polymer or copolymer comprising an active agent modified monomer. Methods to form an active agent modified monomer comprising combining a ring opening... Agent: Howrey LLP-hn

20090208555 - Control of the degradation of biodegradable implants using a coating: The invention relates to an endovascular implant, which is at least largely biodegradable and whose in vivo degradation can be controlled. To achieve this, the implant comprises a tubular base body, open on its end faces and consisting of at least one biodegradable material, said base body having an in... Agent: Bryan Cave Powell Goldstein

20090208556 - Porous photonic crystals for drug delivery to the eye: A minimally invasive controlled drug delivery system for delivering a particular drug or drugs to a particular location of the eye, the system including a porous film template having pores configured and dimensioned to at least partially receive at least one drug therein, and wherein the template is dimensioned to... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20090208557 - Kinase inhibitors: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the... Agent: David B. Buttars

20090208558 - Use of combination preparations comprising antifungal agents: The invention relates to the use of an antimycotic agent and an epithelial cell or endothelial cell adhesion inhibitor for producing a combination drug for the topical treatment of Candida mycoses selected from vulvovaginal candidiasis, oropharyngeal candidiasis (oral thrush), diaper dermatitis (diaper thrush) and intertriginous (Candida) eczema.... Agent: Fulbright & Jaworski L.L.P.

20090208560 - Cover material and plaster with cover material: A cover material adapted to cover the entirety of a patch is provided. The cover material has a support layer and, superimposed on a surface thereof, a pressure sensitive adhesive layer. The patch has a support film with a thickness of 12- to 30 μm and, superimposed thereon, a drug... Agent: The Nath Law Group

20090208559 - Device for delivering active ingredients to humans, animals and plants: A device for controlled delivery of an active ingredient to a receiving site (1) such as a plant, human or animal. The device comprises a filmic substrate including a water soluble carrier layer (2) disposed between first and second water soluble control layers (3, 4). The second control layer (4)... Agent: Amin Talati, LLC

20090208561 - Transdermal therapeutic system: The present invention relates to a transdermal therapeutic system for the controllable release of an active ingredient, particularly a substance promoting wound healing, to a chronic wound or for chemotherapy, with at least one waveguide, wherein the active ingredient is deposited on the waveguide via a bond that is cleavable... Agent: Rader, Fishman & Grauer PLLC

20090208564 - Compositions of asymmetric interfering rna and uses thereof: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the... Agent: Hiscock & Barclay, LLP

20090208563 - Method for delivering genes: Methods of delivering transgenes to target cells using plasmids comprising viral inverted terminal repeat (ITR) sequences are described. Such plasmids are capable of directing sustained transgene expression in target cells in rats provided that at least one adeno-associated virus (AAV) ITR sequence is present in the plasmid, regardless of whether... Agent: Robins & Pasternak LLP

20090208565 - Stabilized exendin-4 compounds: The present invention discloses compositions comprising a stabilized Exendin-4 (1-39) and related compounds. The invention describes stabilized Exendin-4 agonists that include at least one modified amino acid residue particularly at positions Gln13, Met14, Trp25, or Asn28 of the Exendin-4 (1-39) molecule. Disclosed are preferred modifications of deaminated, hydrolyzed, oxidized, or... Agent: Clark & Elbing LLP

20090208562 - Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide: The present invention relates to a composition comprising at least one fibronectin binding protein, and/or at least one a truncated fibronectin binding protein and/or at least one fibronectin binding peptide, all comprising at least one fibronectin binding domain; and at least one Iscom matrixcomplex and/or liposome and/or at least one... Agent: Schwegman, Lundberg & Woessner, P.A.

20090208566 - Capsules containing seminal material for artificial insemination: Capsules or microcapsules comprising: a) a nucleus containing seminal material or the spermatozoa of animal species chosen from the group consisting of equids, buffalo, ovicaprids, canids, felids, lagomorphs, laboratory animal species chosen from mice and rats, and possibly man, b) a membrane of a bivalent or trivalent metal alginate.... Agent: Abelman, Frayne & Schwab

20090208567 - Substance-containing carbon nanohorn composite having polyamine plug and process for producing the same: The present invention provides: a carbon nanohorn composite including a carbon nanohorn, a substance encapsulated in the carbon nanohorn, and a polyamine adsorbed by chemical reaction firmly to a surface functional group present on the opening part on the surface of the carbon nanohorn, wherein the release amount and release... Agent: Dickstein Shapiro LLP

20090208568 - Gellan seamless breakable capsule and process for manufacturing thereof: The invention relates to a process for manufacturing a seamless breakable capsule, comprising—co-extruding an external and hydrophilic liquid phase, and an internal and lipophilic liquid phase, in order to form a capsule constituted of a core comprising the internal and lipophilic phase, and a shell comprising the external and hydrophilic... Agent: Young & Thompson

20090208569 - Homogeneous, thermoreversible alginate films and soft capsules made therefrom: The present invention is directed to a homogeneous, thermoreversible gel film comprising a film forming amount of a water soluble, thermoreversible alginate, and optionally at least one of a plasticizer, a second film former, a bulking agent, and a pH controlling agent; and processes for the preparation thereof. The present... Agent: Patent Administrator Fmc Corporation

20090208570 - Extended release dosage forms of metoprolol: The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms.... Agent: Bio Intellectual Property Services (bio Ips) LLC

20090208571 - Dosage form containing pantoprazole as active ingredient: Dosage forms for the oral administration of the magnesium salt of pantoprazole are described.... Agent: Nath & Associates PLLC

20090208572 - Oral controlled release tablet: a coating surrounding the said core, the coating comprising a polymer insoluble in an aqueous medium comprising from 0% v/v to 40% v/v of alcohol, whereby upon contact with aqueous gastrointestinal fluids, the upper compressed layer swells to cause removal of the coating from the upper surface of the upper... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090208574 - Dip coated compositions containing a starch having a high amylose content: The present invention features a method of making a coated tablet by dipping a core comprising an active agent into a coating liquid and drying said dipped core to form a outer-coating on the core, wherein the coating liquid contains at least one a starch having an amylose content of... Agent: Philip S. Johnson Johnson & Johnson

20090208573 - Novel polymorph form of irbesartan: New form of irbesartan having favourable chargeability is prepared from the alcoholic/etheric or ketonic solution of irbesartan after slow cooling with sporadic or light agitation and alternatively new crystalline form of an acid addition salt of irbesartan is prepared from the aqueous solution of a sodium salt of irbesartan after... Agent: Arent Fox LLP

20090208575 - Pharmaceutical composition of acid labile substances: A pharmaceutical composition for oral use comprising a) a core comprising an effective amount of benzimidazole and an organic stabilizing agent which is present in an amount effective to stabilize the composition, b) an intermediate layer comprising of a water insoluble polymer and an organic stabilizer, and c) an outer... Agent: Merchant & Gould PC

20090208576 - Orally disintegrating tablets: The present invention describes a directly compressible composite prepared by co-processing a water-soluble excipient and calcium silicate. The present invention further describes the incorporation of the co-processed composite into a tablet formulation. The orally disintegrating tablets are of optimal mechanical strength and disintegrate within 60 seconds in the oral cavity.... Agent: Mallinckrodt Inc.

20090208577 - Inkjet printing of tissues and cells: Provided herein is an apparatus for printing cells which includes an electrospinning device and an inkjet printing device operatively associated therewith. Methods of making a biodegradable scaffold having cells seeded therein are also provided. Methods of forming microparticles containing one or more cells encapsulated by a substrate are also provided,... Agent: Myers Bigel Sibley & Sajovec

20090208578 - Method of tissue repair using a multi-layered matrix: A multi-layered matrix, a method of tissue repair using the same, and multi-layered implant prepared thereof are provided. The multi-layered matrix comprises a first element and a second element connected thereto, and the second element comprises a hollow cavity. The first and the second elements are composed of a composite... Agent: Birch Stewart Kolasch & Birch

20090208579 - Matrix type sustained-release preparation containing basic drug or salt thereof, and method for manufacturing the same: A matrix type sustained-release preparation and a manufacturing method therefor are provided wherein dissolution with low pH dependence of a basic drug or a salt thereof at the early stage of dissolution can be ensured in a dissolution test, and wherein as the dissolution test proceeds, a ratio of a... Agent: Venable LLP

20090208581 - Formulations limiting spread of pulmonary infections: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as... Agent: Pabst Patent Group LLP

20090208580 - Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles: The present invention relates to compositions comprising functionalized dendrimer-stabilized nanoparticles (DSNPs), functionalized dendrimer-encapsulated nanoparticles (DENPs) (e.g., metal DENPs), and methods of generating and using the same.... Agent: Casimir Jones, S.c.

20090208582 - Templated open flocs of anisotropic particles for enhanced pulmonary delivery: The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is... Agent: Chalker Flores, LLP

20090208583 - Tablets comprising candesartan cilexetil: Composition in the form of a tablet, comprising candesartan cilexetil and optionally further active agents and usual adjuncts, wherein the surface of at least the active agent candesartan cilexetil in this composition is provided with a coating, made from a compound or a mixture of compounds selected from tri-(C1-C6)alkyl citrate,... Agent: Hoffmann & Baron, LLP

20090208584 - Solid preparation: The solid preparation of the present invention aims at providing a solid preparation superior in the stability during production and preservation even when a poorly water-soluble substance having a low melting point is contained in a large amount, and also superior in the disintegration property and release property of a... Agent: Foley And Lardner LLP Suite 500

20090208585 - Stabilisation of biological materials: Biological materials such as vaccines can be stabilised in certain glassy materials, soluble in water. It has been proposed to form these glassy materials as a powder suspended in a non-aqueous liquid for injection into a patient. There is a problem in maintaining the suspension because the particles tend to... Agent: Kolisch Hartwell, P.C.

20090208586 - Porous bioabsorbable material and method of producing the same: [Means for Solving Problems] A porous bioabsorbable material characterized by being formed of a porosified bioabsorbable polymer which is obtained in a manner that a bioabsorbable polymer is gelled with a good solvent and a poor solvent, compatible with each other, for the bioabsorbable polymer and the gelled bioabsorbable polymer... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090208587 - Dairy based foodstuff containing central nervous system lipids: The central nervous system (CNS), i.e. the spinal cord and the brain, contains a large amount of various lipids, collectively called CNS lipids. These lipids are essential for embryonic induction but are also active in the adult body in keeping our cells in healthy normal function. By actively incorporating these... Agent: Ladas & Parry LLP

20090208588 - Gerd carbohydrate compositions: In accordance with the present invention, there is to provide a dietary supplement of essential sugars that provides humans and animals with the essential carbohydrates needed to maintain proper health and to provide a healthier alternative to PPI medications for the treatment of GERD using a mixture of honey and... Agent: Roger W. Brown, Ph.d.

20090208589 - Novel hydrophilic polymers as medical lubricants and gels: The present invention provides new biopolymers which mimic the properties of natural polysaccharides found in vivo. The inventive polysaccharides can be used as viscosupplements, viscoelastics, tissue space fillers, and/or anti-adhesive agents. Also provided are pharmaceutical compositions comprising the inventive polymers and methods of using them including, for example, in the... Agent: Choate, Hall & Stewart LLP

20090208590 - Analogs of benzoquinone-containing ansamycins and methods of use thereof: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase... Agent: Foley Hoag, LLP (w/ipx)

20090208591 - Gallium compositions for the treatment of liver cancer and methods of use: Provided are compositions and methods to treat liver cancer and related disorders in human or veterinary individuals. Primary liver cancers, including those metastatic to other parts of the body, as well as cancers metastatic to the liver cancer, can be treated and/or prevented with the compositions and methods of the... Agent: Lawrence R. Bernstein

20090208592 - Thickened product and method for transferring heated flowable cosmetic onto skin: A product and method for treating skin with a heated lotion is herein described. The product is a package with associated instructions for applying a heated cosmetic composition to skin dispensed from a heating device. The cosmetic composition includes an inorganic structurant material such as a clay which functions to... Agent: Unilever Patent Group

20090208594 - Cosmetic and dermatological composition for psoriatic skin treatment: Cosmetic and dermatological composition for the treatment of psoriatic skin, comprising 5%-15% quince seeds; 10%-40% natural base cream; and 55%-75% mixture of anti-oxidants, skin softening agents, absorption aids, tissue regenerating and protecting agents, preservatives and thickening agents.... Agent: Brux Software Solutions Ltd.

20090208595 - Extract of plant dendrobii caulis and preparing process thereof: An extract of plant Dendrobii Caulis and preparing process thereof are provided. A physiologically active extract of a plant Dendrobii Caulis and the method thereof are provided in the present invention. The extract is obtained by an extraction of the plant or parts thereof with a water miscible organic solvent... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20090208593 - Phyto aroma micro-nutritherapeutic compositions in orodietology: The invention concerns a composition comprising at least a nutrient and at least a phytotherapeutic compound. The composition according to the invention is characterized in that it also comprises at least an essential oil and/or essence and it is in the form of a granule. The invention is used as... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090208596 - Medical herb composition for the alleviation of cardiopulmonary ailments or the improvement of cardiopulmonary function in a mammal: A medical herb composition for the alleviation of cardiopulmonary ailments or the improvement of cardiopulmonary function in a mammal is disclosed. The medical herb composition comprises: Schisandra extract; Ginseng extract; Radix ophiopogonis extract; and Saliva miltiorrhiza extract. The medical herb composition comprising the extracts above is proved to be efficient... Agent: Bacon & Thomas, PLLC

20090208597 - Heat processed vegetabilic fiber preparation and its use as inhibitor of the effects of carcinogenic substances in humans or animals: The present inventions relates to a vegetabilic, preferably potato, fiber preparation and fractions thereof for use as a supplement, a functional food, a functional mix, a pro health product and a pharmaceutical composition; it further relates to a food additive, and a food product, a feed additive and a feed... Agent: Morrison & Foerster LLP

20090208598 - Use of a combination of ethanolic rosa sp., urtica dioica and tanacetum vulgare extracts, further compromising selenium and urea and having been exposed to a pulsed electromagnetic field, for the preparation of a medicament for immunostimulation and/or tr: The present invention refers to a method for preparing a herbal extract from Rosa sp., Urtica dioica and/or Tanacetum vulgare, preferably comprising a treatment by pulsed electromagnetic field of high frequency. The herbal extract, optionally comprising selenium and/or urea, is useful in the treatment of conditions associated with impaired immune... Agent: Patent Central LLC Stephan A. Pendorf

20090202430 - Composition for cytocompatible, injectable, self-gelling polysaccharide solutions for encapsulating and delivering live cells or biologically active factors: The present invention provides compositions and methods for tissue repair using a cytocompatible self-gelling cross-linked hydrogel. The composition comprises a biocompatible mixture of chitosan, bifunctional dialdehyde, and hydroxylated polymer, which can be used to immobilize or encapsulate viable cells, or bioactive substances. The method includes the process of mixing bioactive... Agent: David S. Resnick

20090202429 - Methods for testing anti-thrombotic agents: The invention provides a transgenic non-human animal expressing von Willebrand Factor A1 protein containing at least one mutation selected from the group consisting of: 1263P>S, 1269N>D, 1274K>R, 1287M>R, 1302G>D, 1308H>R, 1313R>W, 1314I>V, 1326R>H, 1329L>I, 1330E>G, 1333A>D, 1344T>A, 1347I>V, 1350T>A, 1370G>S, 1379H>R, 1381T>A, 1385T>M 1391P>Q, 1394A>S, 1397L>F, 1421S>N, 1439L>V, 1442G>S, 1449R>Q,... Agent: Wilmerhale/columbia University

20090202428 - Use of dtbz for imaging endocrine pancreas and beta cell mass in type 1 diabetes: The present invention provides non-invasive methods for determining the beta cell mass in the pancreas of a subject by administering to the subject an effective amount of a vesicular monoamine transporter type 2 (VMAT2)-specific radioligand; obtaining at least one computerized image of at least a portion of the pancreas of... Agent: Bryan Cave LLP

20090202433 - Methods and compositions for generating bioactive assemblies of increased complexity and uses: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD)... Agent: Immunomedics, Inc.

20090202431 - Stem-like cells in bone sarcomas: Isolation and purification of stem cells from within a bulk sarcoma tumor. These cells express the marker genes of pluripotent embryonic stem cells, Stat 3, Oct 3/4, and Nanog. A subset of these cells show the surface marker of mesenchymal stem cells Stro-1, as well as express attributes of mesodermal,... Agent: Akerman Senterfitt

20090202432 - Treatment and prophylaxis of amyloidosis: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils.... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20090202434 - Pharmaceutical composition and dressing for treating skin lesion, as well as the use of cerium salt associated with a collagen matrix: The present invention refers to a pharmaceutical composition for treating skin lesion, comprising a cerium salt on a collagen matrix and a dermatologically acceptable carrier. The present invention also refers to a wound dressing for treating skin lesion, comprising the pharmaceutical composition of the present invention. The present invention further... Agent: Alston & Bird LLP

20090202436 - Bupivacaine formulation in a polyorthoester carrier: Effective treatments of pain, such as chronic pelvic pain, for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of bupivacaine formulated within a polyorthoester. By administration of one or more drug depots,... Agent: Medtronic, Inc.

20090202435 - Diagnostic compounds for targeting a chemokine receptors: The present invention relates to a compound comprising, firstly a component for targeting at least one chemokine receptor and, secondly, a detection component capable of being identified by a medical imaging method.... Agent: Birch Stewart Kolasch & Birch

20090202438 - Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto: The present invention is concerned with epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto.... Agent: Merchant & Gould PC

20090202437 - Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases: The invention relates to nucleic acid molecules encoding (poly)peptides having LPI (Lectin Pathway Inhibitor) activity, to recombinant vectors harboring such molecules, and the host cells carrying the vectors. The invention further relates to methods for preparing recombinant (poly)peptides having LPI activity and to the use of such recombinant (poly)peptides having... Agent: Bozicevic, Field & Francis LLP

20090202439 - Methods for treatment of angiogenesis: The present invention includes methods for treatment and prophylaxis of diseases, post-surgical disorders and bacterial infections associated with lactosylceramide. The methods generally provide for administration to a subject one or more compounds that alter the activity of VEGF pathway members, including LacCer synthase (GalT-V/VI), PECAM1, VEGFR, VEGF or related pathway... Agent: Edwards Angell Palmer & Dodge LLP

20090202440 - Model animal of dendritic cell immunoreceptor gene knockout disease: It is intended to disclose the function of dendritic cell immunoreceptor (DCIR) and clarify its role in the onset of autoimmune arthritis. It is also intended to provide a method of screening a substance which is useful in treating/preventing an autoimmune disease or osteoporosis. A nonhuman disease model animal characterized... Agent: Bozicevic, Field & Francis LLP

20090202441 - Compositions and methods to prevent cancer with cupredoxins: The present invention discloses methods and materials for killing and/or inhibiting the growth of a cancer cell via preferential entry of a cytotoxic compound. Preferential entry of the cytotoxic compound is accomplished by the use of protein transduction domains derived from cupredoxins, including the p18 and p28 truncations of azurin.... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090202442 - Enerceutical activation of the alternative cellular energy (ace) pathway in therapy of diseases: Alternative cellular energy pigments (ACE-pigments) provide a source of cellular energy other than that provided through the oxidative metabolism of foods, or in the case of plants and certain bacteria, through the process of photosynthesis. In some patients, ACE pigments exist in a form that can be further energized or... Agent: William John Martin

20090202443 - Methods of improving skin quality: Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs.... Agent: 3m Innovative Properties Company

20090202445 - Composition of a liquid dietary supplement to treat symptoms of autism spectrum disorders in children.: The object of the present invention is to provide an all-natural dietary supplement formulation that may be beneficial to the management of behavioral and neurological symptoms associated with autism spectrum disorders; symptoms that may not be effectively improved by conventional drug treatment and behavioral therapy alone.... Agent: Bart Nieuwenhuijsen

20090202444 - Treatment and prevention of systemic xylella fastidiosa infections of plants using antimicrobial metal compositions: An embodiment of the invention is a treatment for the mitigation and prevention of systemic infection of plants by Xylella fastidiosa using materials derived from bactericidal metals wherein one metal is silver. The candidate bactericidal metal is preferably introduced in metallic, nanocrystalline, salt form, chelated form, or otherwise coupled form.... Agent: Karel Newman

20090202447 - Inhalant aerosol formulations containing ethanol: The invention relates to inhalant, propellant-free aerosol formulations containing ethanol, said formulations having defined particle size distribution sizes.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090202446 - Microemulsion composition for air freshener: The present invention relates to air freshener devices of water-based liquid compositions, preferably clear liquids, that provide an improved diffusion of the composition and allow the use of fragrance materials with a wide range of characteristics, namely a wide range of clogP values. The compositions are clear microemulsions particularly adapted... Agent: Winston & Strawn LLP Patent Department

20090202448 - Metal lactate powder and method for preparation: The present invention relates to a method for the preparation of a new metal lactate powdery product and to the resulting product itself with new properties. The metal lactate powder of the present invention is made via spray-drying and has a higher flowability, is less sticky and dusty, has an... Agent: Oliff & Berridge, PLC

20090202449 - Use of osteopontin in dental formulations: Use of osteopontin for reducing plaque bacterial growth on tooth enamel and dental formulations containing osteopontin.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090202450 - Oral care product and methods of use and manufacture thereof: This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form, together with an anionic surfactant, and to methods of using and of making such compositions.... Agent: Colgate-palmolive Company

20090202451 - Oral care product and methods of use and manufacture thereof: This invention relates to oral care compositions comprising a basic amino acid or salt thereof, and a small particle fraction: and to methods of using and of making these compositions.... Agent: Colgate-palmolive Company

20090202452 - Oral care regimen: The invention includes methods of cleaning an oral surface, maintaining oral health and/or increasing oral health. Such methods encompass contacting an oral surface with a primary oral care composition at least once daily, contacting the oral surface with a periodic oral care maintenance composition at least once monthly, wherein the... Agent: Colgate-palmolive Company

20090202454 - Oral care product and methods of use and manufacture thereof: This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form, together with an antibacterial agent, and to methods of using and of making such compositions.... Agent: Colgate-palmolive Company

20090202455 - Oral care product and methods of use and manufacture thereof: This invention relates to oral care compositions comprising an effective amount of a salt of a basic amino acid the salt having a pH in an unbuffered solution of less than about 7.5; an effective amount of a soluble fluoride salt; and a particulate material which has a pH in... Agent: Colgate-palmolive Company

20090202453 - Oral composition: An opaque toothpaste composition and method for making such, the toothpaste comprising water, a zinc salt, a chelating agent for the zinc salt, the chelating agent having a log Ks1 as herein defined of from 3.0 to 7.0, and an abrasive present at from 10% to 70% by weight of... Agent: Unilever Patent Group

20090202456 - Novel salts and their uses: The invention relates to novel arginine salts, compositions comprising them, and their uses.... Agent: Colgate-palmolive Company

20090202457 - Method for exfoliating skin: The present invention relates to an exfoliating composition. The composition comprises a mixture. The mixture comprises phenolsulfonic acid, guaiacolsulfonic acid, and optionally sulfosalicylic acid and citric acid.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20090202460 - Composition of a water-soluble sunscreen preparation for acne rosacea: The object of the invention is to provide a topical preparation for (acne) rosacea and other sensitive skin types that protects the face from harmful UV rays without the use of chemical sunscreen ingredients. It has long been found that chemical sunscreen ingredients (most popular are oxybenzone and avobenzone) can... Agent: Bart Nieuwenhuijsen

20090202459 - Photoprotective compositions with glycol and styrene/acrylate copolymer: A photoprotective composition includes one or more photoactive agents (such as a UV filter compound), one or more optimizing agents, and a copolymer booster. Such a composition provides an unexpected synergistic combination of the one or more optimizing agents and the copolymer booster for increasing at least one of SPF,... Agent: Michaud-duffy Group LLP

20090202458 - Si-rna-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation: The present invention describes compositions and methods for treating, preventing and improving hyperpigmentation, or other unwanted pigmentation of the skin, or other unwanted skin condition, such as age spots, aged skin, skin discoloration, etc., wherein the compositions include siRNA-gene silencing oligomers specific for tyrosinase. The compositions are used to treat... Agent: Avon Products, Inc.

20090202461 - Anhydrous cosmetic composition comprising a crosslinked polyrotaxane and an oil: The invention relates to an anhydrous cosmetic composition intended to be applied to keratinous substances, in particular the skin, the lips or the eyelashes. This composition comprises at least one crosslinked polyrotaxane polymer and at least one oil. This composition makes it possible in particular to form, on keratinous substances,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090202462 - Solid cosmetic compostion comprising a polyester: e

20090202463 - Antimicrobial compositions, products and methods employing same: Antimicrobial compositions that provide enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, coronovirus, respiratory syncytial virus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, antimicrobial compositions comprising an organic acid or organic acid mixture and a short-chain anionic surfactant having at least one of a large... Agent: Brinks Hofer Gilson & Lione

20090202464 - Fragrance compounds: A method of providing a fragrant odour to an application, comprising the addition thereto of at least one compound of the formula (I) wherein X and Y are independently selected from the group consisting of —CR1R2R3, —NR4R5 and —OR6, wherein R1 to R5 are selected from H and essentially hydrocarbon... Agent: Curatolo Sidoti Co., Lpa

20090202465 - Neutralised cationic polymer, composition containing said polymer and a cosmetic treatment method: The invention relates to an ethylene cationic polymer comprising at least one primary, secondary or tertiary protonable amine function which is at least partially neutralised by a polymer organic acid neutralising agent which contains at least one carboxylic, sulphonic and/or phosphonic acid function. Said invention also relates to a cosmetic... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090202466 - Oligomeric amidoamides or amidoquats for fabric or hair treatment compositions: Provided are oligomeric amidoamines, an oligomeric amidoamine salt of the oligomeric amidoamine, and/or an oligomeric amidoquat of the oligomeric amidoamine. These materials can be used as fabric softeners in fabric softener compositions or as a hair treatment in hair treatment compositions.... Agent: Colgate-palmolive Company

20090202467 - Sclerotherapy for varicose veins: This invention is directed to pharmaceutical compositions and methods of treating varicose veins, including telangiectasias and reticular veins, and related symptoms and diseases. Embodiments comprise injection into a varicose vein of an amphiphilic block copolymer which has properties of conversion from liquid to gel state, surfactant properties, or combinations thereof.... Agent: James Remenick Novak Druce & Quigg, LLP

20090202468 - Attractant compounds for yellow jacket wasps: The use of individual chemical compounds as attractants in traps for yellow jacket wasps Vespula germanica, and more specifically, the use of certain alcohols of more than 7 carbon atoms, aldehydes more than 4 carbon atoms, and cetones more than 6 carbon atoms as attractants for specific yellow jacket wasps... Agent: Stratton Ballew

20090202469 - Detection of inflammatory disease and composition for preventing or treatment of inflammatory disease: A novel method for detection of an inflammatory disease and a novel composition for prevention or treatment of an inflammatory disease are provided. The method for detection of an inflammatory disease comprises using RANKL and/or OPG as a marker in a biological sample. The composition for prevention or treatment of... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090202473 - Combination of an anti-edb fibronectin antibody-il-2 fusion protein, and a molecule binding to b cells, b cell progenitors and/or their cancerous counterpart: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.... Agent: Millen, White, Zelano & Branigan, P.C.

20090202481 - Composition for sustained release delivery of proteins or peptides: The present invention provides a novel liquid composition suitable for in-situ formation of a depot system to deliver a protein or peptide in a controlled manner. The composition of the present invention comprises: (a) a hydrophobic non-polymeric carrier material; (b) a water miscible biocompatible organic solvent that dissolves the hydrophobic... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20090202475 - Compositions and methods for treatment of microbial disorders: The present invention relates to compositions and methods for treatment of microbial disorder by modulation of the host immune response. More particularly, the present invention relates to compositions that mediate an anti-microbial immune response, and methods of treating a microbial infection using such compositions.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090202476 - Crystalline forms of n-(tert-butoxycarbonyl)-3-methyl-l-valyl-(4r)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-n-((1r,2s)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-l-prolinamide: The present disclosure generally relates to crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well of methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such... Agent: Louis J. Wille Bristol-myers Squibb Company

20090202474 - Expression of orphan gpr64 in inflammatory diseases: Methods of screening for agents for treating inflammatory diseases are provided. The methods involve screening for agents that modulate the activity or expression of GPR64, which has been discovered herein to play a role in inflammatory diseases. Methods for treating an inflammatory disease, as well as methods of modulating the... Agent: Wilmerhale/wyeth

20090202478 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090202480 - Macrocyclic serine protease inhibitors: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.... Agent: Jones Day

20090202479 - Method for modulating immune responses using stem cells and cytokines: The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20090202477 - Methods of treating infections using il-21: Methods for treating mammals with infections, particularly viral infections using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be... Agent: Zymogenetics, Inc. Intellectual Property Department

20090202472 - Molecules and chimeric molecules thereof: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the IL-2 protein family such as IL-2, IL-2Ra, IL-2Rb, IL-2Rg or chimeric molecules thereof, such as IL-2-Fc, IL-2Ra-Fc, IL-2Rb-Fc and IL2Rg-Fc, comprising... Agent: Seed Intellectual Property Law Group PLLC

20090202471 - Molecules with effects on cellular development and function: This invention relates to methods to stabilize and/or improve the function of parenchymal cells. Also provided are systems of co-cultures of hepatocyte-stabilizing non-parenchymal cells used in bioreactor microenvironments to identify hepatic stabilizing factors by gene-expression profiling.... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20090202470 - Phosphonate analogs of hiv inhibitor compounds: The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences Inc

20090202483 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090202482 - Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes: Conformational epitopes of the envelope proteins E1 and E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conserved conformational and linear epitopes of the HCV protein E1 or E2 have been determined to be... Agent: Choate, Hall & Stewart LLP

20090202486 - Difluorinated tripeptides as hcv serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090202485 - Heteroaryl-containing tripeptide hcv serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090202484 - Modulators of toll-like receptor 7: The present application provides for a compound of Formula (I) or (II): or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional active... Agent: Gilead Sciences Inc

20090202487 - Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers... Agent: Immunomedics, Inc.

20090202492 - Adenovirus vaccine utilizing ikk as adjuvant: The invention provides an adenovirus that expresses a constitutively activated form of human NF-κB activating kinase (IKK). Co-administration of the adenovirus expressing the constitutively activated form of IKK (Ad-IKKβ) and an antigen confers an enhanced immune response against the antigen relative to co-administration of the antigen and adenovirus that do... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090202491 - Method for modulating, regulating and/or stabilizing angiogenesis: A method of modulating, regulating and/or stabilizing angiogenesis in a mammal in need thereof, in which the PDGF-D level or activity or both in the mammal are modulated or increased. In preferred embodiments, an active PDGF-D polypeptide, or a polynucleotide encoding an active PDGF-D is administered to the mammal, preferably... Agent: Fulbright & Jaworski, LLP

20090202493 - Mir-150 for the treatment of blood disorders: The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.... Agent: David S. Resnick

20090202490 - Mutant adeno-associated virus virions and methods of use thereof: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene.... Agent: Uc Berkeley - Otl Bozicevic, Field & Francis LLP

20090202488 - Use of the foamy virus bet protein for inactivating apobec: Described is the foamy virus Bet-mediated inactivation of the mutagenic, genome-modifying and vector-inactivating cellular enzyme ABOBEC. Such inactivation is useful for the treatment or prevention of various diseases, e.g., cancer, or for enhancing the production and genetic stability of gene therapy vectors, preferably retroviral vectors.... Agent: Howrey LLP-ca

20090202502 - Hepatic stellate cell specific promoter and uses thereof: Methods and reagents for effecting transgene expression in Hepatic Stellate Cells (HSC) comprising a 2.2 kb fragment of the promoter region of the Glial Fibrillary Acidic Protein (GFAP) gene, said construct being up-regulated by pro-fÊbronetic cytokines such as TGF-beta 1 in a dose and time dependent manner, and uses thereof.... Agent: Klarquist Sparkman, LLP

20090202504 - Methods for the detection and prognosis of breast tumors: This invention relates to the production of specific antibodies for the detection of human tumor associated urokinase-type plasminogen activator receptor (uPAR) deletion variants in biological samples as well as to their diagnostic and therapeutic application.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090202505 - Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein: The invention provides methods for treating ocular diseases using a recombinant vehicle to express a protein useful in the treatment of ocular disease, with particular preference for use of neurotrophin-4 (NT4) for targeting subpopulations of cells in the retina. A genetically engineered gene transfer vector containing sequences encoding a growth... Agent: Dla Piper LLP (us)

20090202503 - Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof: This invention relates to a compound that induces or activates telomerase activity based on the nucleotide sequence of the GSE 24.2 fragment of dyskerin or the protein or peptide sequence encoded by said nucleotide sequence. Another part of the invention relates to vectors that comprise said sequence and cells transformed... Agent: Darby & Darby P.C.

20090202501 - Chimeric nk receptor and methods for treating cancer: The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are... Agent: Licata & Tyrrell P.C.

20090202494 - Combined use of glp-1 agonists and gastrin for regulating blood glucose levels: The invention relates generally to novel compositions and methods comprising a gastrin compound. The compositions and methods provide beneficial effects, in particular sustained beneficial effects, in particular sustained beneficial effects, in particular sustained beneficial effects, in the treatment of diabetes.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090202498 - Direct differentiation of cardiomyocytes from human embryonic stem cells: The present invention relates to the induction of differentiation in stem cells to cardiomyocytes and factors such as prostaglandin alone or in combination with other factors including essential minerals selected from the group including transferrin and selenium, small molecules selected from the group including a p38 MAPK inhibitor such as... Agent: Scully Scott Murphy & Presser, PC

20090202499 - Human telomerase reverse transcriptase peptides: Tumor antigens can be categorized as tumor type specific or common. Telomerase reverse transcriptase (TRT) is the first bona fide common tumor antigen. While several 9mer peptides of the human TRT (hTRT) have been identified for HLA-A2, the most prevalent (˜50%) HLA type in humans, little information exists on peptides... Agent: Morrison & Foerster LLP

20090202495 - Hyaluronic acid derivative and neural stem cells for sci and pnt regeneration: A biomaterial for the treatment of spinal cord or of peripheral nerve injury injury, obtainable by: a) treating a hyaluronic acid derivative with a coating solution promoting Neuronal Stem Cells adhesion, branching and differentiation; b) contacting isolated Neuronal Stem Cells with the hyaluronic acid derivative obtained from step a) and... Agent: Ladas & Parry LLP

20090202496 - Method for regenerating an immune system: An isolated and purified cell line of hematopoeitic stem cells (HSC) that are incapable of expressing the CCR5 receptor on the cell surface (“the CCR5Δ32 cells” are used to regenerate the immune system in a subject in need thereof and especially to treat a subject infected with human immunodeficiency virus... Agent: Ratnerprestia

20090202500 - Pharmaceuticals that promote functional regeneration of damaged tissues:

20090202497 - Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes: The present invention relates to the use of GLP-I, GLP-I derivatives or GLP-I fragments for skin regeneration or hair growth in mammals. As used for skin regeneration, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to dermal wounds including burns, lacerations, cuts and scrapes. As used for hair growth,... Agent: David S. Resnick

20090202506 - Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen... Agent: Philip S. Johnson Johnson & Johnson

20090202507 - Intelligent nanomedicine integrating diagnosis and therapy: A method of controlling the activity of a biologically active compound. The method concerns an oligonucleotide-based compound, comprising a hairpin-forming oligonucleotide, an effector moiety physically associated with the oligonucleotide, where the effector moiety possesses a biological activity, and a regulating moiety physically associated with the oligonucleotide, where the regulating moiety... Agent: Berliner & Associates

20090202508 - Negative regulation of hypoxia inducible factor 1 by os-9: The present invention discloses that OS-9 interacts with both HIF-1α and HIF-1α prolyl hydroxylases. Overexpression of OS-9 promotes the hydroxylation of HIF-1α, HIF-1α binding to VHL, proteasomal degradation of HIF-1α, and loss of HIF-1-mediated transcription. OS-9 loss-of-function increases HIF-1α protein levels and HIF-1-mediated transcription under non-hypoxic conditions. These data indicate... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20090202509 - Methods and agents for reducing oxidative stress: The present invention relates to novel methods for enhancing endogenous protection mechanisms against oxidative stress, and agents for use in such methods. In particular, the present invention provides a pharmaceutical composition which provides an oxidative signal upon administration to a subject, the signal triggering a therapeutic or prophylactic effect by... Agent: Mcandrews Held & Malloy, Ltd

20090202510 - Altered sumoylation of lamin a protein associated with dilated cardiomyopathy: This invention relates to methods of diagnosing dilated cardiomyopathy using analysis of the lamin A protein and sumylation of same, as well as methods for treating dilated cardiomyopathy, comprising enhancing the sumoylation of the lamin A protein in a subject in need thereof.... Agent: Crowell & Moring LLP Intellectual Property Group

20090202512 - Proteins for use in human and animal staphylococcus infections: The present invention relates to a polypeptide termed ply_pitti26 comprising the sequence as depicted in SEQ ID NO:1 as well as variants of this polypeptide. Furthermore, the present invention relates to nucleic acids and vectors encoding for said polypeptide and variants thereof as well as host cells comprising these nucleic... Agent: Fulbright & Jaworski L.L.P.

20090202513 - Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer: The present invention relates to methods and kits for the treatment of cancer. A novel drug combination comprising a ribonuclease compound and a thiazolidinedione compound has been identified as producing a synergistic cytotoxicity effect in cancer cells. Methods and kits pertaining to the co-administration of these compounds are discussed herein.... Agent: Wolf Greenfield & Sacks, P.C.

20090202511 - Targeted protein replacement for the treatment of lysosomal storage disorders: The present invention relates to compositions and methods for delivering lysosomal proteins. The compositions and methods described herein permit the targeted delivery of exogenous lysosomal proteins to cell surface proteins that allow their internalization via non-clathrin pathways. The present invention further relates to the use 10 of the compositions and... Agent: Jones Day

20090202514 - Agents for improving chronic obstructive pulmonary diseases: The present invention relates to agents for suppressing pulmonary emphysematous lesions and agents for suppressing emphysematous lesions which are suitable for treating and/or preventing COPD, which comprise as an active ingredient a substance having an activity of promoting CSPG degradation, inhibiting CSPG synthesis, or inhibiting CSPG sulfation (examples of such... Agent: Bozicevic, Field & Francis LLP

20090202515 - Agents for suppressing neural fibrotic degeneration: The present invention examined the accumulation of chondroitin sulfate proteoglycans (CSPGs). The present invention relates to neurodegeneration-suppressing agents that are suitable for gene therapy or prevention of neural fibrotic degenerative diseases which induce neural cell death due to an accumulation of abnormal proteins, where the therapies are based on siRNAs... Agent: Bozicevic, Field & Francis LLP

20090202516 - Inhibition and treatment of gastrointestinal biofilms: Orally administered physiologically acceptable anti-biofilm compositions comprising enzymes and if desired additional components such as antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful... Agent: Graybeal Jackson LLP

20090202517 - Agents for improving inflammatory bowel disease: The present inventors discovered for the first time that intestinal inflammation could be efficiently suppressed by suppressing the production or accumulation of chondroitin sulfate proteoglycans. Specifically, inflammation in the large intestine can be suppressed by using siRNA to suppress the expression of versican, which is one of the chondroitin sulfate... Agent: Bozicevic, Field & Francis LLP

20090202489 - Adenoviruses mutated in the va genes for cancer treatment: This invention refers to the use of an adenovirus for cancer treatment, being this adenovirus defective in its virus-associated (VA) RNAs. Said adenovirus has a mutation in the VAI or VAII gene sequence or both. This adenovirus may also have mutations in the sequences controlling expression of the VA RNAs.... Agent: Fish & Richardson P.C.

20090202523 - Antibodies against a peptide epitope of apoliporotein b: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent: Gauthier & Connors, LLP

20090202521 - Bifunctional polyazamacrocyclic chelating agents: A bifunctional polyazamacrocyclic chelating agent of the formula (I): wherein: and the variables A, L, Q, Q1, X, Y, Z, Z1, m, n and r are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a... Agent: Morgan Lewis & Bockius LLP

20090202519 - Compositions and methods for treating gram positive bacterial infection in a mammalian subject: Compositions and methods are provided for treating Gram positive bacterial infection in a mammalian subject. Compositions and methods are further provided for treating Gram positive bacterial skin infection in the mammalian subject. Compositions and method are provided that comprise administering to the mammalian subject an effective amount of a compound... Agent: The Scripps Research Institute

20090202525 - Dihydroisoindolones as allosteric modulators of glucokinase: m

20090202524 - Pai-1 expression and activity inhibitors for the treatment of ocular disorders: The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 expression or PAI-1 activity. Another embodiment of the present invention is a method of treating a... Agent: Alcon

20090202520 - Treatment and diagnostic methods for fibrosis related disorders: Compositions and methods are provided for the treatment of fibrosis related disorders utilizing the ratio of the concentration of serum amyloid P(SAP) to C-reactive protein (CRP) in a patient. The methods may further comprise determining the R131/H131 polymorphism of FcγRIIA. Diagnostic methods are also provided.... Agent: Ropes & Gray LLP

20090202518 - Treatment of sepsis and inflammation with alpha2a adrenergic antagonists: Provided are methods for treating a mammal undergoing sepsis, or at risk for sepsis. Also provided are methods of preventing or treating a physiological effect of sepsis in a mammal. Additionally provided are methods of inhibiting an inflammatory response in a mammal. Further provided is the use of an α2A-adrenergic... Agent: Amster, Rothstein & Ebenstein LLP

20090202522 - Use of goat serum for veterinary treatment: Methods for veterinary treatment of mammals are described, for treatment of conditions having an inflammatory component. The methods are particularly suited to treatment of cats, dogs, or horses.... Agent: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

20090202526 - Agonist anti-trkc antibodies and methods using same: The invention concerns agonist anti-trkC antibodies, polypeptides, and polynucleotides encoding the same. The invention further concerns use of such antibodies, polypeptides and/or polynucleotides in the treatment and/or prevention of neuropathies, such as sensory neuropathies, including taxol-induced sensory neuropathy, cisplatin-induced sensory neuropathy, and pyridoxine-induced sensory neuropathy.... Agent: Foley & Lardner LLP

20090202536 - Antibody-drug conjugates and methods: where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other... Agent: Genentech, Inc.

20090202541 - Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent: A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) a chemotherapeutic agent selected from antineoplastic agents, especially as defined herein, and agents effective in treating acute... Agent: Novartis Corporate Intellectual Property

20090202534 - Compositions and methods for modulating immune responses: Disclosed is a newly identified CD28 family member that functions as lymphocyte inhibitory receptor termed pG6b, which is expressed on T cells. Methods and compositions for modulating pG6b-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic, and research purposes are also disclosed.... Agent: Zymogenetics, Inc. Intellectual Property Department

20090202538 - F11 receptor (f11r) antagonists as therapeutic agents: The present invention provides a cell adhesion molecule (CAM), designated F11 receptor (F11R) and its use to inhibit platelet aggregation and platelet adhesion for the treatment and prevention of cardiovascular disorders. Cloned F11R cDNA and full length F11R cDNA and amino acid sequences are provided. F11R-antagonists and methods for the... Agent: Scully Scott Murphy & Presser, PC

20090202537 - Fcgammariib specific antibodies and methods of use thereof: The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc... Agent: Edell, Shapiro & Finnan, LLC

20090202532 - High functional bispecific antibody: The present invention is therefore related to a humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of... Agent: Birch Stewart Kolasch & Birch

20090202530 - Identification of tumor-associated antigens for diagnosis and therapy: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.... Agent: Mcandrews Held & Malloy, Ltd

20090202535 - Method for neutralizing effects of spla2: e

20090202539 - Method for treating cancer using anti-wnt2 monoclonal antibodies and sirna: This invention relates to methods of inhibiting the growth of cells, in particular cancer cells, that overexpress Wnt2. The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein, interferes with Wnt2 signaling or inhibits binding of the Wnt2 protein to another protein, such... Agent: Bozicevic, Field & Francis LLP

20090202540 - Substituted oxazaphosphorines: The present invention relates to new oxazaphosphorine alkylating agents and/or immuno-suppressive agents, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20090202528 - Surface-located streptococcus pneumoniae polypeptides: The present invention relates to cell-surface-located polypeptides of Streptococcus pneumoniae and their use in immunisation against Streptococcal infection, in diagnosis of Streptococcus and in identification of compounds with anti-Streptococcus activity. In a further aspect, the invention relates to antibodies capable of recognising cell surface-located polypeptides of Streptococcus pneumoniae and uses... Agent: Davis Wright Tremaine LLP - San Francisco

20090202533 - Treatment and prophylaxis of th2 mediated disorders: The present invention provides a method for the treatment or prophylaxis of T-helper type 2 (Th2)-mediated disorders using antagonists of IL-11.... Agent: Scully Scott Murphy & Presser, PC

20090202527 - Treatment for multiple sclerosis: Methods of treating multiple sclerosis and other disorders are disclosed.... Agent: Lando & Anastasi, LLP B2047

20090202529 - Use of egfr inhibitors to prevent or treat obesity: Methods of treating or preventing obesity or obesity related disorders in a subject are provided, comprising administering to the subject a treatment effective in reducing one or more activities of an epidermal growth factor receptor (EGFR) in the subject. Methods of screening for compositions that can modulate one or more... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090202531 - Uses of anti-cd40 antibodies: Methods for treating a human patient for an inflammatory or autoimmune disease that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who... Agent: Alston & Bird LLP

20090202542 - Rage protein derivatives: The present invention is drawn to fusion proteins comprising a Receptor for Advanced Glycation Endproducts (RAGE) and an immunoglobulin element. The invention also encompasses methods of treating a condition characterized by activation of an inflammatory cytokine cascade comprising administering such fusion proteins. The invention is also drawn to nucleic acids... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090202548 - Antibodies and related molecules that bind to psca proteins: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The... Agent: Agensys C/o Morrison & Foerster LLP

20090202547 - Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof: Molecules comprising the antigen-binding portion of antibodies that block constitutive and/or ligand-dependent activation of a receptor protein tyrosine kinase, such as fibroblast growth factor receptor 3 (FGFR3), are found through screening methods, where a soluble dimeric form of a receptor protein tyrosine kinase is used as target for screening a... Agent: Winston & Strawn LLP Patent Department

20090202546 - Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.... Agent: Genentech, Inc.

20090202543 - Gene and polypeptide relating to breast cancer: The present application provides novel human gene B7330N whose expression is markedly elevated in breast cancers. The gene and polypeptide encoded by the gene can be used, for example, in the diagnosis of breast cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of... Agent: Townsend And Townsend And Crew, LLP

20090202545 - Melanoma biomarker and methods of uses: The present invention relates to the use of TROY, also called tumor necrosis factor receptor superfamily, member 19 (TNFRSF 19) also called toxicity and JNK inducer (TAJ), in diagnosis and therapy of non-epithelial cancers, such as melanoma. Accordingly, the invention provides in vitro and in vivo diagnostic and/or prognostic methods... Agent: Ronald I. Eisenstein

20090202544 - Methods of treating diseases by targeting silt3: This invention provides a method of treating a subject afflicted with a disease, comprising withdrawing blood from the subject, treating the withdrawn blood so as to remove sILT3 from the blood, and returning the treated blood to the subject, thereby treating the subject afflicted with the disease. This invention also... Agent: Ropes & Gray LLP

20090202549 - Anti-il-12 antibodies, epitopes, compositions, methods and uses: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids... Agent: Philip S. Johnson Johnson & Johnson

20090202555 - Antibodies against a peptide epitope of apoliporotein b: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent: Gauthier & Connors, LLP

20090202553 - Antibodies against anthrax protective antigen: A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090202552 - Gene expressed in prostate cancer and methods of use: A new polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Novel Gene Expressed in Prostate (NGEP). Polynucleotides encoding NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies are disclosed that specifically bind NGEP.... Agent: Klarquist Sparkman, LLP

20090202551 - Immunomodulation by altering sphingosine 1-phosphate lyase (spl) activity: Compositions and methods for modulating immune function are provided based on the unexpected discovery that inhibition of sphingosine-1-phosphate lyase (SPL) activity confers useful immunosuppressive effects, for example to modulate immune function in treatment or prevention of inflammation, transplant graft rejection, autoimmune disease, allergy, or other conditions, including therapeutic alteration of... Agent: Seed Intellectual Property Law Group PLLC

20090202554 - Method of modulation of interaction between receptor and ligand: The present invention relates to a method for modulating the interaction between at least two proteins, wherein at least one of the two proteins is a functional cell-surface receptor and the other protein is the receptor ligand. The invention features a binding site of said functional cell-surface receptor on the... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090202550 - Monoclonal antibodies and immunodetection assay specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor: The present invention describes monoclonal antibodies specific for the chemotactic epitope of the uPAR. In particular, the invention comprises monoclonal antibodies against uPAR fragments specifically recognizing in whole or in part the chemotactic sequence of uPAR connecting domain 1 to domain 2.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090202556 - Anti-claudin-4 antibody: An object of the present invention is to provide a monoclonal antibody which is useful as a diagnostic agent or a therapeutic agent for a disease relating to a polypeptide encoded by Claudin-4 (hereinafter referred to as “CLDN4”) gene or a polypeptide encoded by a Claudin-3 (hereinafter referred to as... Agent: Sughrue-265550

20090202557 - Compositions and methods for crystallizing antibody fragments: The invention provides methods of crystallizing antibodies and fragments thereof as well as crystals produced thereby. More particularly, the invention provides methods of crystallizing human and non-human Fab fragments of antibodies, either alone or as co-crystals with their target ligand. For example, a crystal comprising a murine Fab fragment of... Agent: Abbott Bioresearch

20090202558 - Tnfalpha-neutralizing antibodies: The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of... Agent: Bozicevic, Field & Francis LLP

20090202560 - Method for diagnosing efficacy of xenotypic antibody therapy: The invention concerns methods and compositions for intiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen.... Agent: Ropes & Gray LLP

20090202559 - Anti-mesothelin antibodies: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well... Agent: Woodcock Washburn LLP

20090202561 - Novel raag10 cell surface target and a family of antibodies recognizing that target: The invention provides the identification and characterization of disease and cancer-associated antigen, RAAG10. The invention also provides a family of monoclonal antibodies that bind to antigen RAAG10, methods of diagnosing and treating various human cancers and diseases that express RAAG10.... Agent: Morrison & Foerster LLP

20090202562 - Anti-gfralpha3 antibodies: Antibodies and antibody fragments that bind to the receptor GFRalpha3 and inhibit formation of a Neublastin-GFRalpha3-Ret ternary complex are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit phosphorylation of Ret in a cell and treat disorders and in a subject.... Agent: Fish & Richardson P.C.

20090202563 - C20orf23 as modifier of the igfr pathway and methods of use: Human C20ORF23 genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of C20ORF23 are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090202564 - Methods of isolating stem cells: The present inventors discovered for the first time that labeling cell nuclei makes it possible to efficiently isolate stem cells. Namely, it was elucidated that stem cells with labeled nuclei remained labeled even after cell division, and showed self-renewing and long-living abilities characteristic of stem cells. Efficient isolation of stem... Agent: Bozicevic, Field & Francis LLP

20090202565 - Torc polynucleotides and polypeptides and method of use: The present invention relates to a broad range of methods that utilize a transducer of regulated CREB (TORC)-related polynucleotide, polypeptide, or TORC-specific antibody. In addition the invention relates to TORC-related polynucleotide, polypeptide, or TORC-specific antibody compositions, including variants of TORC wild-type sequences. Exemplary methods include a method of stimulating a... Agent: Novartis Corporate Intellectual Property

20090202566 - Use of the endo-180 gene and polypeptide for diagnosis and treatment: This application is directed to a process of identifying a compound capable of modulating activity of a human ENDO180 receptor that comprises the steps of measuring the binding of the ENDO180 receptor to an interactor with which the ENDO180 receptor interacts specifically in vivo, in the absence or presence of... Agent: Cooper & Dunham, LLP

20090202568 - Binding members for interleukin-4 receptor alpha (il-4ra)-173: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4Rα), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4Rα, IL-4 and/or IL-13, examples of which are asthma and COPD.... Agent: Astrazeneca R&d Boston

20090202567 - Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating b cell neoplasm: The invention provides nine oligonucleotides with sequences of SEQ ID NO: 1-9 or their functional homologues or a composition comprising the same and a method for treating B cell neoplasm by using the oligonucleotides or their functional homologues or the composition comprising the oligonucleotides. The oligonucleotides induce the apoptosis of... Agent: Morgan, Lewis & Bockius LLP (sf)

20090202570 - Pm-2 antibodies, functional fragments and methods for treating metastasis: The invention provides PM-2 antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions. Antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions are useful in treatment and diagnostic methods. One method includes treating metastasis of a neoplasia, tumor or cancer in a subject in... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090202569 - Prophylactic/therapeutic agent for cancer: The present invention provides a preventative/therapeutic agent for cancer capable of selectively and effectively killing cancer cells. A medicament of the present invention prepared by combining at least one selected from a substance that inhibits the activity of an enzyme belonging to the acyl-CoA synthase family and a substance that... Agent: Foley And Lardner LLP Suite 500

20090202571 - Bioreductively-activated prodrugs: A compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: —Ar is a substituted heteroaryl group bearing at least one nitro or azido group or is a benzoquinone, naphthoquinone or fused heterocyloquinone; -R1 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090202572 - Compositions and methods for modulating bone mass: The instant invention relates to compositions and methods for treating or preventing bone diseases. In certain aspects, the invention provides compositions comprising a β-adrenergic antagonist or agonist associated to a bone-targeted molecule, as well as methods of modulating bone mass and/or growth in a mammal by administering a composition of... Agent: Dla Piper LLP (us)

20090202573 - Polymeric conjugates containing positively-charged moieties: The present invention provides polymeric conjugates containing positively charged moieties. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed.... Agent: Lucas & Mercanti, LLP

20090202575 - Immunostimulatory nucleic acid molecules: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20090202574 - Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer: The present invention relates to administration of metal ion-saturated lactoferrin, preferably bovine lactoferrin, preferably iron-saturated bovine lactoferrin, or a metal ion-saturated functional variant or fragment thereof to inhibit tumour formation or growth, maintain or improve one or both of the white blood cell count and red blood cell count, stimulate... Agent: Knobbe Martens Olson & Bear LLP

20090202577 - Casb618 polynucleotides and polypeptides and their use: CASB618 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB618 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly ovarian and colon cancers, autoimmune diseases, and related conditions.... Agent: Glaxosmithkline Corporate Intellectual Property

20090202576 - Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides: The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 8, 67, 89, as well as peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, and having cytotoxic T cell inducibility. The present invention also... Agent: Townsend And Townsend And Crew, LLP

20090202578 - Surface proteins from coagulase-negative staphylococci and staphylococcus aureus that generate cross-reactive monoclonal and polyclonal antibodies: Surface proteins are provided which generate polyclonal and monoclonal antibodies which are cross-reactive to both coagulase-positive staphylococcus bacteria, such as S. aureus and to coagulase-negative bacteria, such as S. epidermidis and S. hemolyticus. The antibodies may be generated from surface proteins that have been isolated on the basis of characteristics... Agent: Stites & Harbison PLLC

20090202579 - Methods and compositions for treating and preventing malaria (2): The present invention provides compositions and methods useful in the treatment or prevention of a condition caused by or associated with infection by Plasmodium falciparum, such as malaria. The compositions include various antigens of Plasmodium falciparum, both alone and in combination. The invention further includes fragments of the antigens.... Agent: Birch Stewart Kolasch & Birch

20090202580 - Method for the preparation of specific antibodies against saccharidic antigens: The present invention relates to new compounds useful for the stimulation of the production of antibodies. Said compounds comprises a saccharidic tumor antigen and a polymeric scaffold. The present invention also encompasses conjugated compounds useful in ELISA assay for the selection of antibodies against saccharidic antigens.... Agent: Bracco Research Usa Inc.

20090202581 - Cosmetic formulation: The present invention provides an improved skin care formulation for enhancing the overall quality of the skin and treating aging skin comprising cassia angustilfolia seed polysaccharide, dipeptide-4, glutamylamidoethyl indole, and kluyveromyces extract, in a cosmetically/dermatologically acceptable medium. The formulation improves skin quality by moisturizing and softening the skin, while protecting... Agent: Cislo & Thomas LLP

20090202582 - Water-disposable or water-soluble polymer film as a vehicle for dermatologic and cosmetic active agents: Described are water-dispersible or water-soluble polymer films incorporating at least one cosmetic or dermatologic active agent and a method for the production thereof. The active agents involved are particularly anti-cellulite agents, moisturizers, anti-wrinkle agents and skin smoothing agents.... Agent: Maginot, Moore & Beck, LLP Chase Tower

20090202583 - Rhinovirus vaccines: The present invention relates generally to peptide vaccines. More specifically, the present invention relates to vaccines against rhinoviruses and other related and non-related pathogenic animal viruses. In addition, the present invention relates generally to methods of designing and producing vaccines against viruses and, in certain embodiments, against rhinoviruses and other... Agent: Bryan Cave LLP

20090202585 - Tat-based tolerogen compositions and methods for making and using same: A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune... Agent: K&l Gates LLP

20090202584 - Treatment of epstein-barr virus-associated diseases: The present invention relates to a vaccine for the treatment or prevention of an EBV-associated disease in a subject, wherein said vaccine comprises a synthetic polypeptide comprising a plurality of different segments of at least one parent EBV polypeptide, and wherein the segments are linked together in a different relationship... Agent: Knobbe Martens Olson & Bear LLP

20090202586 - Attenuated vaccine for tularemia: A scan of F. tularensis genome for homology to a regulatory protein that controls virulence identified gene FTL0552. A knock out mutation in FTL0552 was created using reverse transcriptase PCR and the construct inserted into F. tularensis. This mutant was defective for survival in macrophages and found avirulent in in... Agent: Smith Hopen, Pa

20090202587 - Compositions comprising hmw-maa and fragments thereof, and methods of use thereof: This invention provides recombinant polypeptides comprising a fragment of a High Molecular Weight Melanoma-Associated Antigen (HMW-MAA), recombinant Listeria strains comprising same, and methods of inducing an anti-HMW-MAA and anti HER-2/neu immune response thus treating and impeding the growth of tumors, comprising administering same.... Agent: Pearl Cohen Zedek Latzer, LLP

20090202588 - Nucleic acids encoding tgev and prrsv sequences for improved expression of prrsv sequences: i

20090202589 - Fermenter system for biotechnical processes: A fermenter for use in biotechnical processes in particular for culturing cells is disclosed. The object, to provide a fermenter vessel (1) the inner volume of which can be optically monitored and which fermenter vessel can also be efficiently sterilized, is achieved by a fermenter vessel (1) having an outside... Agent: Novartis Vaccines And Diagnostics Inc.

20090202590 - Influenza vaccines extemporaneously adsorbed to aluminium adjuvants: Antigen and adjuvant components of an adjuvanted influenza vaccine are not mixed during manufacture, but are provided as separate components for extemporaneous mixing at the time of use, for example as a kit comprising (i) an antigen component, comprising an influenza virus antigen; and (ii) an adjuvant component, comprising an... Agent: Novartis Vaccines And Diagnostics Inc.

20090202591 - Leucine-based motif and clostridial neurotoxins: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques.... Agent: Allergan, Inc.

20090202592 - Cytolethal distending toxin, inhibition and use thereof: This invention relates to immunotoxins and their use. Specifically, the invention relates to compositions comprising Cdt toxins or their inhibitors and their use in methods for treating infectious and proliferative diseases.... Agent: Pearl Cohen Zedek Latzer, LLP

20090202593 - Novel immunogenic compositions for the prevention and treatment of meningococcal disease: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of... Agent: Wyeth Patent Law Group

20090202594 - Anti-bacterial vaccine compositions: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.... Agent: Pharmacia & Upjohn

20090202595 - Anti-pdef antibodies and uses thereof: The present invention relates to an isolated antibody or antigen-binding fragment thereof that specifically binds with high affinity to at least a portion of a segment of human prostate-derived Ets transcription factor (PDEF). The anti-PDEF antibody of the present invention is effective in prognostic and diagnostic assays for detecting PDEF... Agent: Heslin Rothenberg Farley & Mesiti PC

20090202597 - Ache-nmda combination wafer: Sheet-like pharmaceutical preparations based on hydrophilic polymers, which rapidly disintegrate upon contact with moisture and which are used to treat dementia-related illnesses The dosage form contains an active agent combination of at least two active agents which are suitable for the treatment of dementia (antidementia agents). The antidementia agents should... Agent: D Peter Hochberg D Peter Hochberg Co

20090202596 - Pharmaceutical compositions with biological barriers permeation enhancing properties: Pharmaceutical compositions comprising a water/oil/water (W1/O2/W3) or an oil/water/oil (O1/W2/O3) double microemulsion, with droplets size below one micron, with the drug included in the internal water phase W1 or internal oil phase 01, whereas the external oil 02 and second water phase W3 or the external water phase W2 and... Agent: Young & Thompson

20090202598 - Invert emulsion comprising an aqueous solution of hydrogen peroxide and an inert phase with water solubility of less than 1%: The invention relates to an invert emulsion for bleaching keratin fibres and, in particular, human keratin fibres, such as hair. According to the invention, the emulsion consists of an inert phase comprising at least one non-oxygenated, non-perfluorinated liquid compound having a water solubility at 25° C. of less than 1%... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090202600 - Oil-in-water emulsified milky skin cosmetic preparation: The present invention provides an oil-in-water emulsified milky skin cosmetic preparation, which is able to impart a refreshing feeling, an astringent effect, a moisturizing effect, and a softening effect to skin, when it is singly used, and which is excellent in terms of emulsion stability although it has a high... Agent: Rankin, Hill & Clark LLP

20090202599 - Solid antiperspirant composition and method for making same: Solid emulsion antiperspirant products are described. The antiperspirant products contain a continuous phase including a water-immiscible liquid and a structurant and a disperse phase including an antiperspirant active dissolved in a polar solvent. The disperse phase has a conductivity of less than or equal to about 75 mS/cm at 25°... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090202601 - Method for inhibiting onset of or treating pollen allergy: The intermolecular mutual recognition between a disease-state inducing substance (e.g., allergen group, pathogen et cetera) and a living body which functions at the time when such a disease-state inducing substance reaches the living body is inhibited by making use of pectins and nucleic acids.... Agent: Young & Thompson

20090202602 - Pharmaceutical composition for application to nail: Since treatment effects of conventional external preparations were not satisfactory, it is aimed to provide a novel external preparation that is excellent in drug permeability to nail, capable of fully exhibiting effects of an antifungal drug, and effective for treatments of diseases such as nail mycosis and nail candidiasis, particularly,... Agent: Sughrue Mion, PLLC

20090202603 - Compacted 2,2-dibromo-3-nitrilopropionamide: The present invention provides an essentially pure compacted 2,2-Dibromo-3-nitrilopropionamide (DBNPA) in a granular and/or tablet and/or briquette and/or pellet form. The present invention further provides a process for preparing the same essentially pure compacted DBNPA.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090202604 - Benzodiazepine formulation in a polyorthoester carrier: Effective treatments of pain for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of a benzodiazepine, such as midazolam, formulated within a polyorthoester. By administration of one or more drug depots, one... Agent: Medtronic, Inc.

20090202607 - Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions: Heparin-like compounds inhibit collagen-induced platelet aggregation in flowing whole blood. The compounds share properties displayed by native mast-cell derived heparin proteoglycans (HEP-PG) and/or heparin glycosaminoglycan (HEP-GAG) molecules. The compounds are useful in prevention and treatment of severe vascular disorders including arterial thrombosis.... Agent: Buchanan, Ingersoll & Rooney PC

20090202605 - High aspect ratio template and method for producing same for central and peripheral nerve repair: Millimeter to nano-scale structures manufactured using a multi-component polymer fiber matrix are disclosed. The use of dissimilar polymers allows the selective dissolution of the polymers at various stages of the manufacturing process. In one application, biocompatible matrixes may be formed with long pore length and small pore size. The manufacturing... Agent: Davis Wright Tremaine LLP/los Angeles

20090202606 - Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor: The present invention relates to methods for treating or preventing cardiac conditions in a subject comprising administering to the subject two or more isoforms of hepatocyte growth factor (HGF). The present invention further relates to methods for promoting endothelial cell growth in a blood vessel comprising administering to the blood... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090202608 - Devices, formulations, and methods for delivery of multiple beneficial agents: The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations... Agent: Intarcia Therapeutics, Inc. Attn: Barbara G. Mcclung

20090202611 - Composite self-cohered web materials: The present invention is directed to implantable bioabsorbable non-woven self-cohered web materials having a high degree of porosity. The web materials are very supple and soft, while exhibiting proportionally increased mechanical strength in one or more directions. The web materials often possess a high degree of loft. The web materials... Agent: Gore Enterprise Holdings, Inc.

20090202609 - Medical device with coating composition: Coating compositions containing bioactive agents, and medical devices coated with compositions containing bioactive agents are described. In certain embodiments the coating compositions comprise a first layer, said first layer containing a bioactive agent and a polymeric material derived from poly[vinylpyrrolidone]; and a second layer outside said first layer, said second... Agent: Pauly, Devries Smith & Deffner, L.L.C.

20090202610 - Medical implants with polysaccharide drug eluting coatings: A medical implant can include a bioerodible metal portion and a coating overlying the bioerodible metal portion. The coating can include a therapeutic agent and a polysaccharide matrix reversibly cross-linked with polyvalent metal cations. Upon implantation of the implant within a body, the therapeutic agent is released and the bioerodible... Agent: Fish & Richardson P.C.

20090202612 - Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090202613 - Nutritionally enhanced therapeutic preventative food supplement and method of making same: The present invention is directed to a nutritionally enhanced therapeutic preventative food supplement which includes one or more food ingredients, a mineral and vitamin mix component, a base coating component, and an immune system potentiate, wherein the immune system potentiate is not denatured. The present invention includes a process to... Agent: Blank Rome LLP

20090202614 - Methods for stepwise deposition of silk fibroin coatings: The invention provides a method for the controlled assembly of layered silk fibroin coatings using aqueous silk fibroin material. The methods described herein can be used to coat substrates of any material, shape, or size. Importantly, the described methods enable control of the biomaterial surface chemistry, thickness, morphology and structure... Agent: David S. Resnick

20090202615 - Compositions for treating biofilms and methods for using same: Compositions containing a surface active agent and a sub-lethal amount of an antimicrobial agent and methods for using such compositions are provided herein.... Agent: Pepper Hamilton LLP

20090202616 - Composite, method of producing the composite and uses of the same: The invention relates to a composite comprising a semi-permeable barrier layer that is permeable to oxygen and impermeable to moisture; and a scaffold fiber layer formed by electrospinning fibers on one side of the barrier layer.... Agent: Quarles & Brady LLP

20090202617 - Gas based wound and tissue therapeutics: This invention provides articles of manufacture and bandages comprising compartments and layers comprising oxygen and other therapeutic gas storage forms and perfluorocarbons. This invention also provides for methods of delivering oxygen and other therapeutic gases to a tissue in a subject comprising a administering to the tissue a composition comprising... Agent: Cooper & Dunham, LLP

20090202621 - Cell-surface decoration with active agents: A lipid vesicle comprising a functionalized lipid comprising a tether moiety having binding affinity for a ligand portion of an active agent and the active agent are provided. Methods of decorating endothelial cells, tissues, and organs with active agents utilizing the disclosed lipid vesicles are also provided.... Agent: Stites & Harbison, PLLC

20090202618 - Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases: The present invention is related to recombinant constructs encoding active fragments of HSP60 which are effective in treating T cell-mediated inflammatory autoimmune diseases by DNA vaccines. The HSP60 fragments of the present invention are identified by their ability to react with T cells isolated from an animal vaccinated with DNA... Agent: Winston & Strawn LLP Patent Department

20090202623 - Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent: The present invention relates to a small interfering RNA (siRNA) suppressing the expression of adenine nucleotide trnaslocator 2 (ANT2) gene and an anticancer agent containing the same. Particularly, the invention relates to ANT2 siRNA comprising a sense sequence selected from the nucleotide sequences of ANT2 mRNA, a hairpin loop sequence... Agent: Klarquist Sparkman, LLP

20090202624 - Method for detecting carcinoma and agent for suppressing carcinoma: An object of the present invention is to identify genes exhibiting characteristic behavior in the cases of carcinoma such as oral squamous-cell carcinoma using a change of expression level of micro RNA in oral squamous-cell carcinoma as an indicator, so as to provide a method for detecting carcinoma and an... Agent: Birch Stewart Kolasch & Birch

20090202627 - Methods and compositions for diseases associated with amyloidosis: The present invention generally relates to the detection, treatment or prevention of disease states. Specifically, the present invention relates to the detection, treatment or prevention of amyloidosis or amyloid-associated diseases. The present invention further comprises methods and compositions comprising therapeutic vaccines, antisera and molecular constructs, comprising expression vectors and fusion... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090202620 - Polymer-stabilized liposomal compositions and methods of use: The invention provides liposomal particle compositions, which incorporate a lipophilic biodegradable polymer, such as amino acid-containing polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU), throughout the particles to stabilize the composition for in vivo delivery in of an incorporated biologic agent. For oral delivery, a biologic, such as... Agent: Dla Piper LLP (us)

20090202619 - Polyoxyalkylene chain-containing lipid derivative and lipid film structure containing such derivative: e

20090202626 - Treatment of bladder diseases with a tlr7 activator: The invention provides a method for the treatment of superficial bladder cancer and inflammatory diseases of the bladder which employs certain Toll-like Receptor (TLR)-agonists.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090202625 - Trypanosome microsome system and uses thereof: The present invention provides cell free preparations of protozoan microsomes, wherein the cell free preparation of protozoan microsomes demonstrate the ability to translocate a protozoan polypeptide into the microsome, methods of preparing cell free preparations of protozoan microsomes, and methods of using cell free preparations of protozoan microsomes.... Agent: Mueting, Raasch & Gebhardt, P.A.

20090202622 - Virosome-like vesicles comprising gp41-derived antigens: The present invention relates to a virosome-like vesicle comprising at least a gp41-derived antigen or an analogue thereof, said gp41-derived antigen being located to the external surface of and/or encapsulated inside said vesicle and being in a convenient configuration for conferring said virosome-like vesicle with an ability to induce an... Agent: Oliff & Berridge, PLC

20090202628 - Nanoparticles for protein drug delivery: The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery.... Agent: Hosheng Tu

20090202629 - Controlled release hydrocodone formulations: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.... Agent: Davidson, Davidson & Kappel, LLC

20090202631 - Methods and dosage forms for controlled delivery of paliperidone and risperidone: Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or... Agent: Philip S. Johnson Johnson & Johnson

20090202630 - Orally disintegrating tablet compositions of ranitidine and methods of manufacture: The present invention is directed to pharmaceutical compositions comprising taste-masked microcapsules comprising ranitidine, orally disintegrating tablets comprising such compositions, and methods of making the pharmaceutical compositions and dosage forms of the present invention. The present invention is also directed to methods of administering the pharmaceutical compositions and orally disintegrating tablets... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090202632 - Sublingual buccal effervescent: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of additional pH... Agent: Ross J. Oehler Cephalon, Inc.

20090202635 - Delivery system, application, and method: A sequenced biologically compatible delivery system, application, and method is provided, which increases therapeutic care of animals by conveniently and effectively supplying meticulous administration plans requiring sequential administration of varying biologically active agents.... Agent: Stephen M. Scott

20090202633 - Extended release formulations of guaifenesin: The present invention relates to extended release formulations comprising expectorant. More particularly, the present invention relates to extended release formulations comprising guaifenesin. The present invention also relates to a process for the preparation of extended release formulations comprising guaifenesin.... Agent: Jay R. Akhave

20090202634 - Pharmaceutical dosage form: The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a breaking... Agent: Norris, Mclaughlin & Marcus, Pa

20090202636 - Pharmaceutical composition: A stable formulation of telmisartan and hydrochlorothiazide having both substances in separate units is prepared, exhibiting exceptional stability when subjecting to stress conditions.... Agent: Arent Fox LLP

20090202637 - Oral pharmaceutical coated composition for pulsatile release: A pharmaceutical composition comprising a pharmaceutically active agent, a core, a coating comprising an inner film comprising cellulose acetate and hydroxypropylmethylcellulose in a ratio of cellulose acetate:hydroxypropylmethylcellulose of 80% to 99.5%:0.5% to 20% and an outer film comprising ethylcellulose and hydroxypropylcellulose in a ratio of ethylcellulose:hydroxypropylcellulose of 50% to 80%:20%... Agent: Novartis Corporate Intellectual Property

20090202638 - Bmp gene and fusion protein: This invention relates to BMP fusion genes, BMP fusion proteins, and methods for making BMP fusion genes and BMP fusion proteins. The invention further relates to methods for treatment using BMP fusion genes and BMP fusion proteins. Additionally, the invention relates to BMP fusion gene and BMP fusion protein pharmaceutical... Agent: Darby & Darby P.C.

20090202639 - Biomaterials consisting of sulphated hyaluronic acid and gellan to be used in the prevention of spinal adhesions: New biomaterials consisting of a combination of sulphated hyaluronic acid and gellan (as well as gellan that has not been associated with other polymers), to be used as a highly effective barrier to prevent post-surgical adhesions in abdominal, pelvic and, above all, spine surgery.... Agent: Ladas & Parry LLP

20090202642 - Drug delivery system comprising microparticles and gelation system: Disclosed are drug delivery compositions comprising a continuous aqueous phase comprising a reverse thermal gelation system comprising a blend of a cellulose derivative and polyethylene glycol; a discontinuous particulate phase comprising microparticles; and an agent to be delivered contained in at least said discontinuous particulate phase. Also disclosed are sustained... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090202641 - Hollow fibrous organic nanotube and production method thereof: Disclosed is a method of synthesizing a water-free nanotube capable of efficiently encapsulating a functional substance therein, in large quantities. The method comprises: dissolving, in an organic solvent heated up to a temperature equal to or less than a boiling point thereof, an N-glycoside type glycolipid represented by the following... Agent: Sughrue Mion, PLLC

20090202640 - Hydrogels of polysaccharide mixtures for tissue engineering and as carriers of active compounds: The present invention describes the preparation of hydrogels (or 3D matrices) obtainable from aqueous solutions of mixtures of acid polysaccharides and derivatives of basic polysaccharides, such as oligosaccharide derivatives of chitosan. Said solutions are suitably gelled with either chemical or physical gelling agents with the aim of encapsulating either cells,... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090202648 - Agricultural compositions: Compositions have been discovered that are suitable for forming a stable dispersion. The compositions comprise an agriculturally active compound and a multivalent metal oligomeric or polymeric compound having a molecular weight of from about 150 to about 15,000 Daltons.... Agent: Dow Agrosciences LLC

20090202644 - Functional nanoparticle filled carbon nanotubes and methods of their production: Carbon nanotubes filled with a suspension or colloidal solution of functional nanoparticles and methods for production of carbon nanotubes loaded with functional nanoparticles are provided.... Agent: Woodcock Washburn LLP

20090202645 - Intrasynovial formulations of stanozolol: Disclosed are intrasynovial formulations comprising stanozolol and a suitable carrier.... Agent: Young & Thompson

20090202646 - Method for preparing nano-scale particle of active material: Disclosed herein is a method for preparing nanoscale particles of active material with using a gas of a supercritical fluid, by dissolving an active material into a solvent which is in solid phase at room temperature, to produce nanoscale particles of the active materials which can be advantageously used in... Agent: Sughrue Mion, PLLC

20090202643 - Oil-in-water emulsions containing lignan-class compounds and compositions containing the same: Provided is an oil-in-water emulsion which comprises a water phase and an oil phase comprising at least one kind of lignan-class compounds dissolved therein and being emulsified in the water phase, wherein the oil droplets which serve as a dispersion phase in the emulsion are made finer by high-speed agitation... Agent: Drinker Biddle & Reath (dc)

20090202647 - Solid form of racemic rotigotine: Disclosed herein are solid state forms, amorphous and crystalline forms, of racemic rotigotine having high purity, adequate stability, good flowability and good dissolution properties, a process for preparation, and pharmaceutical compositions comprising amorphous racemic rotigotine.... Agent: Cantor Colburn, LLP

20090202649 - Fenofibrate formulations: The present invention relates to pharmaceutical formulations comprising fenofibrate. The invention also relates to stable and bioavailable pharmaceutical formulations comprising fenofibrate. Further the invention also relates to processes for preparing the compositions and/or formulations of fenofibrate and their methods of use, treatment and administration.... Agent: Dr. Reddy''s Laboratories, Inc.

20090202651 - Antigen specific fluorescent nanoparticles: The present invention relates, in general, to nanoparticles and, in particular, to nanoparticles coated with, for example, peptides, proteins, and/or carbohydrates, and to methods of producing and using same. The invention further relates to kits comprising the coated nanoparticles.... Agent: Nixon & Vanderhye, PC

20090202650 - Methods of treating cancers: A method of treating cancer. The method includes introducing an effective amount of an oxidative catalyzing agent including titanium oxide, zinc oxide, zirconium oxide, tungsten oxide or tin oxide into a biological entity, and irradiating the biological entity with a ray. The oxidative catalyzing agent produces hydroxyl or hydrogen peroxide... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20090202652 - Photo-responsive microencapsulation materials, compositions and methods of use thereof: Photoactivatable prepolymers and methods of use thereof are disclosed for microencapsulation of a substantially water-insoluble material within a nonporous shell. As provided herein, the microencapsulated material is released with no more than a slow release rate. Upon exposure of the nonporous shell to light, the nonporous shell is converted into... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090202653 - Compositions and method for enhancing proteoglycan production: The present invention provides compositions comprising notochord enriched media and/or one or more factors derived therefrom. Such compositions are useful for enhancing the production of proteoglycan in cells or animals in need thereof, for example for treating degenerative disc disease. The notochord enriched media is preferably obtained from a nonchondrodystrophic... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20090202654 - Skin care compositions and treatments: The invention is directed compositions containing growth agents synthesized from cultured cells from skin. Skin cells such as keratinocytes and dermal fibroblasts are cultured in vitro in cell medium and in the course of culture the cultured cells synthesize and secrete agents into the cell medium. The medium containing agents... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090202656 - Antimicrobial coating: An antimicrobial coating composition consisting essentially of 70 to 80 wt. percent water; 5 to 10 wt. percent methyl alcohol; 3 to 8 wt. percent octadecyl dimethyl trimethoxyl silylpropyl-ammonium chloride; 1 to 5 wt. percent chloropropyl trimethoxysilane; 0.5 to 1.5 wt. percent aminopropyltrialkosilane; 0.5 to 1.5 wt. percent of a... Agent: Rogers Towers, P.A.

20090202655 - Titanosilicate molecular sieve supported metallic nanodots and methods of use to adsorb noble gases: A metal nanodot material is formed by ion-exchange with an ETS zeolite, followed by activation to form metallic nanodots. The nanodot may be formed from silver, nickel, copper, gold or a platinum group metal.... Agent: Edward Yoo C/o Bennett Jones

20090202657 - Methods and compositions for the prevention and treatment of inflammatory diseases: The invention provides compositions for preventing or treating inflammatory disease comprising one or more omega-3 fatty acids, one or more sulfur containing amino acids, and manganese and methods for preventing and treating inflammatory disease comprising administering such compositions to an animal susceptible to or suffering from inflammatory disease. In a... Agent: Colgate-palmolive Company

20090202658 - Versatile antimicrobial agent and uses thereof: The present disclosure relates, according to some embodiments, to antimicrobial agents comprising nitric acid, tetraethylorthosilicate, tetraethyl phosphate, zinc nitrate, and gallium nitrate. Antimicrobial agents may also include borane-tert-butylamine. Antimicrobial agents restrict and/or prevent the growth of at least one bacteria and/or at least one fungus. Bacteria may include, for example,... Agent: Baker Botts L.L.P.

20090202659 - Modulation of peripheral clocks in adipose tissue: Genes encoding the transcription factors controlling the core circadian oscillator (BMAL, Clock, NPAS, Per) and their regulatory targets (Rev-erbα, Rev-erb) have been found in adipose tissue. The circadian pattern of these genes was entrained using restricted feeding. The circadian gene expression profiles were examined in mice and in undifferentiated and... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20090202660 - Agents and methods for osteogenic oxysterols inhibition of oxidative stress on osteogenic cellular differentiation: The present invention discloses oxygenic oxygenic oxysterols. Also disclosed, agents and methods for protecting, blocking or rescuing marrow stromal cells from the inhibitory effects of oxidative stress on their osteoblastic cellular differentiation. Exemplary agents include oxysterols, rhBMP2, alone or in combination which are demonstrated to specifically combat oxidative stress caused... Agent: Venable LLP

20090202661 - Beverage manufacture, processing, packaging and dispensing using electrochemically activated water: A system using electrochemically-activated water (ECAW) for manufacturing, processing, packaging, and dispensing beverages including: (a) using ECAW to neutralize incompatible residues when transitioning from the production of one beverage to another; (b) using ECAW to rehabilitate and disinfect granular activated charcoal beds used in the feed water purification system; (c)... Agent: Fellers Snider Blankenship Bailey & Tippens

20090202663 - Pharmaceutical composition for the treatment of otomycosis: Disclosed is a composition comprising betamethasone, griseofulvin and tea tree oil, for use in the treatment of ear fungal infections, particularly otomycosis, particularly infections caused by Aspergillus niger or Candida albicans. The composition may be in the form of ointment, cream, gel or liquid, e.g. ear drops.... Agent: Kevin D. Mccarthy Roach Brown Mccarthy & Gruber, P.C.

20090202662 - Treatment of erectile dysfunction and libido enhancement: A process for the production of a substance or composition for the therapeutic or prophylactic treatment of erectile dysfunction or the enhancement of libido in a male human or animal subject comprises the step of formulating the substance or composition from at least one of plant material and an extract... Agent: Leydig Voit & Mayer, Ltd

20090202664 - Herbal cream or oil for the treatment hemorroids and wounds: p

20090202665 - Nasal irrigation device: A nasal irrigation device includes a container for storing nasal cleansing fluid, a spout having a connecting end, a nose engaging end and a spout passage, the connecting end of the spout being removably coupled to the container to allow the spout passage to receive nasal cleansing fluid from an... Agent: Dla Piper LLP (us )

20090202666 - Cosmetic use of a cassumunarin, an arylbutenoid, and/or a botanical extract containing them: The present invention relates to a cosmetic skin care method to prevent and/or treat at least one sign of skin ageing, comprising the topical application to the skin of a composition comprising at least one active ingredient selected from cassumunarin and/or an arylbutenoid and/or a botanical extract containing them, such... Agent: Young & Thompson

20090202667 - Grape seeds extracts obtainable by fractioning on a resin: e

20090202668 - Use of a polyphenol in the treatment of the metabolic syndrome and endothelial dysfunction or other vascular sequellae: The invention relates to the use of a polyphenol in the manufacture of a nutriceutical, a food, a food supplement or a medicament for the prophylactic or therapeutic treatment of endothelial dysfunction or the Metabolic Syndrome and other vascular sequellae. The invention further relates to a composition comprising at least... Agent: Miles & Stockbridge PC

20090202430 - Composition for cytocompatible, injectable, self-gelling polysaccharide solutions for encapsulating and delivering live cells or biologically active factors: The present invention provides compositions and methods for tissue repair using a cytocompatible self-gelling cross-linked hydrogel. The composition comprises a biocompatible mixture of chitosan, bifunctional dialdehyde, and hydroxylated polymer, which can be used to immobilize or encapsulate viable cells, or bioactive substances. The method includes the process of mixing bioactive... Agent: David S. Resnick

20090202429 - Methods for testing anti-thrombotic agents: The invention provides a transgenic non-human animal expressing von Willebrand Factor A1 protein containing at least one mutation selected from the group consisting of: 1263P>S, 1269N>D, 1274K>R, 1287M>R, 1302G>D, 1308H>R, 1313R>W, 1314I>V, 1326R>H, 1329L>I, 1330E>G, 1333A>D, 1344T>A, 1347I>V, 1350T>A, 1370G>S, 1379H>R, 1381T>A, 1385T>M 1391P>Q, 1394A>S, 1397L>F, 1421S>N, 1439L>V, 1442G>S, 1449R>Q,... Agent: Wilmerhale/columbia University

20090202428 - Use of dtbz for imaging endocrine pancreas and beta cell mass in type 1 diabetes: The present invention provides non-invasive methods for determining the beta cell mass in the pancreas of a subject by administering to the subject an effective amount of a vesicular monoamine transporter type 2 (VMAT2)-specific radioligand; obtaining at least one computerized image of at least a portion of the pancreas of... Agent: Bryan Cave LLP

20090202433 - Methods and compositions for generating bioactive assemblies of increased complexity and uses: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD)... Agent: Immunomedics, Inc.

20090202431 - Stem-like cells in bone sarcomas: Isolation and purification of stem cells from within a bulk sarcoma tumor. These cells express the marker genes of pluripotent embryonic stem cells, Stat 3, Oct 3/4, and Nanog. A subset of these cells show the surface marker of mesenchymal stem cells Stro-1, as well as express attributes of mesodermal,... Agent: Akerman Senterfitt

20090202432 - Treatment and prophylaxis of amyloidosis: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils.... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20090202434 - Pharmaceutical composition and dressing for treating skin lesion, as well as the use of cerium salt associated with a collagen matrix: The present invention refers to a pharmaceutical composition for treating skin lesion, comprising a cerium salt on a collagen matrix and a dermatologically acceptable carrier. The present invention also refers to a wound dressing for treating skin lesion, comprising the pharmaceutical composition of the present invention. The present invention further... Agent: Alston & Bird LLP

20090202436 - Bupivacaine formulation in a polyorthoester carrier: Effective treatments of pain, such as chronic pelvic pain, for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of bupivacaine formulated within a polyorthoester. By administration of one or more drug depots,... Agent: Medtronic, Inc.

20090202435 - Diagnostic compounds for targeting a chemokine receptors: The present invention relates to a compound comprising, firstly a component for targeting at least one chemokine receptor and, secondly, a detection component capable of being identified by a medical imaging method.... Agent: Birch Stewart Kolasch & Birch

20090202438 - Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto: The present invention is concerned with epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto.... Agent: Merchant & Gould PC

20090202437 - Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases: The invention relates to nucleic acid molecules encoding (poly)peptides having LPI (Lectin Pathway Inhibitor) activity, to recombinant vectors harboring such molecules, and the host cells carrying the vectors. The invention further relates to methods for preparing recombinant (poly)peptides having LPI activity and to the use of such recombinant (poly)peptides having... Agent: Bozicevic, Field & Francis LLP

20090202439 - Methods for treatment of angiogenesis: The present invention includes methods for treatment and prophylaxis of diseases, post-surgical disorders and bacterial infections associated with lactosylceramide. The methods generally provide for administration to a subject one or more compounds that alter the activity of VEGF pathway members, including LacCer synthase (GalT-V/VI), PECAM1, VEGFR, VEGF or related pathway... Agent: Edwards Angell Palmer & Dodge LLP

20090202440 - Model animal of dendritic cell immunoreceptor gene knockout disease: It is intended to disclose the function of dendritic cell immunoreceptor (DCIR) and clarify its role in the onset of autoimmune arthritis. It is also intended to provide a method of screening a substance which is useful in treating/preventing an autoimmune disease or osteoporosis. A nonhuman disease model animal characterized... Agent: Bozicevic, Field & Francis LLP

20090202441 - Compositions and methods to prevent cancer with cupredoxins: The present invention discloses methods and materials for killing and/or inhibiting the growth of a cancer cell via preferential entry of a cytotoxic compound. Preferential entry of the cytotoxic compound is accomplished by the use of protein transduction domains derived from cupredoxins, including the p18 and p28 truncations of azurin.... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090202442 - Enerceutical activation of the alternative cellular energy (ace) pathway in therapy of diseases: Alternative cellular energy pigments (ACE-pigments) provide a source of cellular energy other than that provided through the oxidative metabolism of foods, or in the case of plants and certain bacteria, through the process of photosynthesis. In some patients, ACE pigments exist in a form that can be further energized or... Agent: William John Martin

20090202443 - Methods of improving skin quality: Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs.... Agent: 3m Innovative Properties Company

20090202445 - Composition of a liquid dietary supplement to treat symptoms of autism spectrum disorders in children.: The object of the present invention is to provide an all-natural dietary supplement formulation that may be beneficial to the management of behavioral and neurological symptoms associated with autism spectrum disorders; symptoms that may not be effectively improved by conventional drug treatment and behavioral therapy alone.... Agent: Bart Nieuwenhuijsen

20090202444 - Treatment and prevention of systemic xylella fastidiosa infections of plants using antimicrobial metal compositions: An embodiment of the invention is a treatment for the mitigation and prevention of systemic infection of plants by Xylella fastidiosa using materials derived from bactericidal metals wherein one metal is silver. The candidate bactericidal metal is preferably introduced in metallic, nanocrystalline, salt form, chelated form, or otherwise coupled form.... Agent: Karel Newman

20090202447 - Inhalant aerosol formulations containing ethanol: The invention relates to inhalant, propellant-free aerosol formulations containing ethanol, said formulations having defined particle size distribution sizes.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090202446 - Microemulsion composition for air freshener: The present invention relates to air freshener devices of water-based liquid compositions, preferably clear liquids, that provide an improved diffusion of the composition and allow the use of fragrance materials with a wide range of characteristics, namely a wide range of clogP values. The compositions are clear microemulsions particularly adapted... Agent: Winston & Strawn LLP Patent Department

20090202448 - Metal lactate powder and method for preparation: The present invention relates to a method for the preparation of a new metal lactate powdery product and to the resulting product itself with new properties. The metal lactate powder of the present invention is made via spray-drying and has a higher flowability, is less sticky and dusty, has an... Agent: Oliff & Berridge, PLC

20090202449 - Use of osteopontin in dental formulations: Use of osteopontin for reducing plaque bacterial growth on tooth enamel and dental formulations containing osteopontin.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090202450 - Oral care product and methods of use and manufacture thereof: This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form, together with an anionic surfactant, and to methods of using and of making such compositions.... Agent: Colgate-palmolive Company

20090202451 - Oral care product and methods of use and manufacture thereof: This invention relates to oral care compositions comprising a basic amino acid or salt thereof, and a small particle fraction: and to methods of using and of making these compositions.... Agent: Colgate-palmolive Company

20090202452 - Oral care regimen: The invention includes methods of cleaning an oral surface, maintaining oral health and/or increasing oral health. Such methods encompass contacting an oral surface with a primary oral care composition at least once daily, contacting the oral surface with a periodic oral care maintenance composition at least once monthly, wherein the... Agent: Colgate-palmolive Company

20090202454 - Oral care product and methods of use and manufacture thereof: This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form, together with an antibacterial agent, and to methods of using and of making such compositions.... Agent: Colgate-palmolive Company

20090202455 - Oral care product and methods of use and manufacture thereof: This invention relates to oral care compositions comprising an effective amount of a salt of a basic amino acid the salt having a pH in an unbuffered solution of less than about 7.5; an effective amount of a soluble fluoride salt; and a particulate material which has a pH in... Agent: Colgate-palmolive Company

20090202453 - Oral composition: An opaque toothpaste composition and method for making such, the toothpaste comprising water, a zinc salt, a chelating agent for the zinc salt, the chelating agent having a log Ks1 as herein defined of from 3.0 to 7.0, and an abrasive present at from 10% to 70% by weight of... Agent: Unilever Patent Group

20090202456 - Novel salts and their uses: The invention relates to novel arginine salts, compositions comprising them, and their uses.... Agent: Colgate-palmolive Company

20090202457 - Method for exfoliating skin: The present invention relates to an exfoliating composition. The composition comprises a mixture. The mixture comprises phenolsulfonic acid, guaiacolsulfonic acid, and optionally sulfosalicylic acid and citric acid.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20090202460 - Composition of a water-soluble sunscreen preparation for acne rosacea: The object of the invention is to provide a topical preparation for (acne) rosacea and other sensitive skin types that protects the face from harmful UV rays without the use of chemical sunscreen ingredients. It has long been found that chemical sunscreen ingredients (most popular are oxybenzone and avobenzone) can... Agent: Bart Nieuwenhuijsen

20090202459 - Photoprotective compositions with glycol and styrene/acrylate copolymer: A photoprotective composition includes one or more photoactive agents (such as a UV filter compound), one or more optimizing agents, and a copolymer booster. Such a composition provides an unexpected synergistic combination of the one or more optimizing agents and the copolymer booster for increasing at least one of SPF,... Agent: Michaud-duffy Group LLP

20090202458 - Si-rna-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation: The present invention describes compositions and methods for treating, preventing and improving hyperpigmentation, or other unwanted pigmentation of the skin, or other unwanted skin condition, such as age spots, aged skin, skin discoloration, etc., wherein the compositions include siRNA-gene silencing oligomers specific for tyrosinase. The compositions are used to treat... Agent: Avon Products, Inc.

20090202461 - Anhydrous cosmetic composition comprising a crosslinked polyrotaxane and an oil: The invention relates to an anhydrous cosmetic composition intended to be applied to keratinous substances, in particular the skin, the lips or the eyelashes. This composition comprises at least one crosslinked polyrotaxane polymer and at least one oil. This composition makes it possible in particular to form, on keratinous substances,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090202462 - Solid cosmetic compostion comprising a polyester: e

20090202463 - Antimicrobial compositions, products and methods employing same: Antimicrobial compositions that provide enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, coronovirus, respiratory syncytial virus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, antimicrobial compositions comprising an organic acid or organic acid mixture and a short-chain anionic surfactant having at least one of a large... Agent: Brinks Hofer Gilson & Lione

20090202464 - Fragrance compounds: A method of providing a fragrant odour to an application, comprising the addition thereto of at least one compound of the formula (I) wherein X and Y are independently selected from the group consisting of —CR1R2R3, —NR4R5 and —OR6, wherein R1 to R5 are selected from H and essentially hydrocarbon... Agent: Curatolo Sidoti Co., Lpa

20090202465 - Neutralised cationic polymer, composition containing said polymer and a cosmetic treatment method: The invention relates to an ethylene cationic polymer comprising at least one primary, secondary or tertiary protonable amine function which is at least partially neutralised by a polymer organic acid neutralising agent which contains at least one carboxylic, sulphonic and/or phosphonic acid function. Said invention also relates to a cosmetic... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090202466 - Oligomeric amidoamides or amidoquats for fabric or hair treatment compositions: Provided are oligomeric amidoamines, an oligomeric amidoamine salt of the oligomeric amidoamine, and/or an oligomeric amidoquat of the oligomeric amidoamine. These materials can be used as fabric softeners in fabric softener compositions or as a hair treatment in hair treatment compositions.... Agent: Colgate-palmolive Company

20090202467 - Sclerotherapy for varicose veins: This invention is directed to pharmaceutical compositions and methods of treating varicose veins, including telangiectasias and reticular veins, and related symptoms and diseases. Embodiments comprise injection into a varicose vein of an amphiphilic block copolymer which has properties of conversion from liquid to gel state, surfactant properties, or combinations thereof.... Agent: James Remenick Novak Druce & Quigg, LLP

20090202468 - Attractant compounds for yellow jacket wasps: The use of individual chemical compounds as attractants in traps for yellow jacket wasps Vespula germanica, and more specifically, the use of certain alcohols of more than 7 carbon atoms, aldehydes more than 4 carbon atoms, and cetones more than 6 carbon atoms as attractants for specific yellow jacket wasps... Agent: Stratton Ballew

20090202469 - Detection of inflammatory disease and composition for preventing or treatment of inflammatory disease: A novel method for detection of an inflammatory disease and a novel composition for prevention or treatment of an inflammatory disease are provided. The method for detection of an inflammatory disease comprises using RANKL and/or OPG as a marker in a biological sample. The composition for prevention or treatment of... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090202473 - Combination of an anti-edb fibronectin antibody-il-2 fusion protein, and a molecule binding to b cells, b cell progenitors and/or their cancerous counterpart: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.... Agent: Millen, White, Zelano & Branigan, P.C.

20090202481 - Composition for sustained release delivery of proteins or peptides: The present invention provides a novel liquid composition suitable for in-situ formation of a depot system to deliver a protein or peptide in a controlled manner. The composition of the present invention comprises: (a) a hydrophobic non-polymeric carrier material; (b) a water miscible biocompatible organic solvent that dissolves the hydrophobic... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20090202475 - Compositions and methods for treatment of microbial disorders: The present invention relates to compositions and methods for treatment of microbial disorder by modulation of the host immune response. More particularly, the present invention relates to compositions that mediate an anti-microbial immune response, and methods of treating a microbial infection using such compositions.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090202476 - Crystalline forms of n-(tert-butoxycarbonyl)-3-methyl-l-valyl-(4r)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-n-((1r,2s)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-l-prolinamide: The present disclosure generally relates to crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well of methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such... Agent: Louis J. Wille Bristol-myers Squibb Company

20090202474 - Expression of orphan gpr64 in inflammatory diseases: Methods of screening for agents for treating inflammatory diseases are provided. The methods involve screening for agents that modulate the activity or expression of GPR64, which has been discovered herein to play a role in inflammatory diseases. Methods for treating an inflammatory disease, as well as methods of modulating the... Agent: Wilmerhale/wyeth

20090202478 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090202480 - Macrocyclic serine protease inhibitors: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.... Agent: Jones Day

20090202479 - Method for modulating immune responses using stem cells and cytokines: The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20090202477 - Methods of treating infections using il-21: Methods for treating mammals with infections, particularly viral infections using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be... Agent: Zymogenetics, Inc. Intellectual Property Department

20090202472 - Molecules and chimeric molecules thereof: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the IL-2 protein family such as IL-2, IL-2Ra, IL-2Rb, IL-2Rg or chimeric molecules thereof, such as IL-2-Fc, IL-2Ra-Fc, IL-2Rb-Fc and IL2Rg-Fc, comprising... Agent: Seed Intellectual Property Law Group PLLC

20090202471 - Molecules with effects on cellular development and function: This invention relates to methods to stabilize and/or improve the function of parenchymal cells. Also provided are systems of co-cultures of hepatocyte-stabilizing non-parenchymal cells used in bioreactor microenvironments to identify hepatic stabilizing factors by gene-expression profiling.... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20090202470 - Phosphonate analogs of hiv inhibitor compounds: The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences Inc

20090202483 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090202482 - Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes: Conformational epitopes of the envelope proteins E1 and E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conserved conformational and linear epitopes of the HCV protein E1 or E2 have been determined to be... Agent: Choate, Hall & Stewart LLP

20090202486 - Difluorinated tripeptides as hcv serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090202485 - Heteroaryl-containing tripeptide hcv serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090202484 - Modulators of toll-like receptor 7: The present application provides for a compound of Formula (I) or (II): or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional active... Agent: Gilead Sciences Inc

20090202487 - Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers... Agent: Immunomedics, Inc.

20090202492 - Adenovirus vaccine utilizing ikk as adjuvant: The invention provides an adenovirus that expresses a constitutively activated form of human NF-κB activating kinase (IKK). Co-administration of the adenovirus expressing the constitutively activated form of IKK (Ad-IKKβ) and an antigen confers an enhanced immune response against the antigen relative to co-administration of the antigen and adenovirus that do... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090202491 - Method for modulating, regulating and/or stabilizing angiogenesis: A method of modulating, regulating and/or stabilizing angiogenesis in a mammal in need thereof, in which the PDGF-D level or activity or both in the mammal are modulated or increased. In preferred embodiments, an active PDGF-D polypeptide, or a polynucleotide encoding an active PDGF-D is administered to the mammal, preferably... Agent: Fulbright & Jaworski, LLP

20090202493 - Mir-150 for the treatment of blood disorders: The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.... Agent: David S. Resnick

20090202490 - Mutant adeno-associated virus virions and methods of use thereof: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene.... Agent: Uc Berkeley - Otl Bozicevic, Field & Francis LLP

20090202488 - Use of the foamy virus bet protein for inactivating apobec: Described is the foamy virus Bet-mediated inactivation of the mutagenic, genome-modifying and vector-inactivating cellular enzyme ABOBEC. Such inactivation is useful for the treatment or prevention of various diseases, e.g., cancer, or for enhancing the production and genetic stability of gene therapy vectors, preferably retroviral vectors.... Agent: Howrey LLP-ca

20090202502 - Hepatic stellate cell specific promoter and uses thereof: Methods and reagents for effecting transgene expression in Hepatic Stellate Cells (HSC) comprising a 2.2 kb fragment of the promoter region of the Glial Fibrillary Acidic Protein (GFAP) gene, said construct being up-regulated by pro-fÊbronetic cytokines such as TGF-beta 1 in a dose and time dependent manner, and uses thereof.... Agent: Klarquist Sparkman, LLP

20090202504 - Methods for the detection and prognosis of breast tumors: This invention relates to the production of specific antibodies for the detection of human tumor associated urokinase-type plasminogen activator receptor (uPAR) deletion variants in biological samples as well as to their diagnostic and therapeutic application.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090202505 - Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein: The invention provides methods for treating ocular diseases using a recombinant vehicle to express a protein useful in the treatment of ocular disease, with particular preference for use of neurotrophin-4 (NT4) for targeting subpopulations of cells in the retina. A genetically engineered gene transfer vector containing sequences encoding a growth... Agent: Dla Piper LLP (us)

20090202503 - Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof: This invention relates to a compound that induces or activates telomerase activity based on the nucleotide sequence of the GSE 24.2 fragment of dyskerin or the protein or peptide sequence encoded by said nucleotide sequence. Another part of the invention relates to vectors that comprise said sequence and cells transformed... Agent: Darby & Darby P.C.

20090202501 - Chimeric nk receptor and methods for treating cancer: The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are... Agent: Licata & Tyrrell P.C.

20090202494 - Combined use of glp-1 agonists and gastrin for regulating blood glucose levels: The invention relates generally to novel compositions and methods comprising a gastrin compound. The compositions and methods provide beneficial effects, in particular sustained beneficial effects, in particular sustained beneficial effects, in particular sustained beneficial effects, in the treatment of diabetes.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090202498 - Direct differentiation of cardiomyocytes from human embryonic stem cells: The present invention relates to the induction of differentiation in stem cells to cardiomyocytes and factors such as prostaglandin alone or in combination with other factors including essential minerals selected from the group including transferrin and selenium, small molecules selected from the group including a p38 MAPK inhibitor such as... Agent: Scully Scott Murphy & Presser, PC

20090202499 - Human telomerase reverse transcriptase peptides: Tumor antigens can be categorized as tumor type specific or common. Telomerase reverse transcriptase (TRT) is the first bona fide common tumor antigen. While several 9mer peptides of the human TRT (hTRT) have been identified for HLA-A2, the most prevalent (˜50%) HLA type in humans, little information exists on peptides... Agent: Morrison & Foerster LLP

20090202495 - Hyaluronic acid derivative and neural stem cells for sci and pnt regeneration: A biomaterial for the treatment of spinal cord or of peripheral nerve injury injury, obtainable by: a) treating a hyaluronic acid derivative with a coating solution promoting Neuronal Stem Cells adhesion, branching and differentiation; b) contacting isolated Neuronal Stem Cells with the hyaluronic acid derivative obtained from step a) and... Agent: Ladas & Parry LLP

20090202496 - Method for regenerating an immune system: An isolated and purified cell line of hematopoeitic stem cells (HSC) that are incapable of expressing the CCR5 receptor on the cell surface (“the CCR5Δ32 cells” are used to regenerate the immune system in a subject in need thereof and especially to treat a subject infected with human immunodeficiency virus... Agent: Ratnerprestia

20090202500 - Pharmaceuticals that promote functional regeneration of damaged tissues:

20090202497 - Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes: The present invention relates to the use of GLP-I, GLP-I derivatives or GLP-I fragments for skin regeneration or hair growth in mammals. As used for skin regeneration, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to dermal wounds including burns, lacerations, cuts and scrapes. As used for hair growth,... Agent: David S. Resnick

20090202506 - Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen... Agent: Philip S. Johnson Johnson & Johnson

20090202507 - Intelligent nanomedicine integrating diagnosis and therapy: A method of controlling the activity of a biologically active compound. The method concerns an oligonucleotide-based compound, comprising a hairpin-forming oligonucleotide, an effector moiety physically associated with the oligonucleotide, where the effector moiety possesses a biological activity, and a regulating moiety physically associated with the oligonucleotide, where the regulating moiety... Agent: Berliner & Associates

20090202508 - Negative regulation of hypoxia inducible factor 1 by os-9: The present invention discloses that OS-9 interacts with both HIF-1α and HIF-1α prolyl hydroxylases. Overexpression of OS-9 promotes the hydroxylation of HIF-1α, HIF-1α binding to VHL, proteasomal degradation of HIF-1α, and loss of HIF-1-mediated transcription. OS-9 loss-of-function increases HIF-1α protein levels and HIF-1-mediated transcription under non-hypoxic conditions. These data indicate... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20090202509 - Methods and agents for reducing oxidative stress: The present invention relates to novel methods for enhancing endogenous protection mechanisms against oxidative stress, and agents for use in such methods. In particular, the present invention provides a pharmaceutical composition which provides an oxidative signal upon administration to a subject, the signal triggering a therapeutic or prophylactic effect by... Agent: Mcandrews Held & Malloy, Ltd

20090202510 - Altered sumoylation of lamin a protein associated with dilated cardiomyopathy: This invention relates to methods of diagnosing dilated cardiomyopathy using analysis of the lamin A protein and sumylation of same, as well as methods for treating dilated cardiomyopathy, comprising enhancing the sumoylation of the lamin A protein in a subject in need thereof.... Agent: Crowell & Moring LLP Intellectual Property Group

20090202512 - Proteins for use in human and animal staphylococcus infections: The present invention relates to a polypeptide termed ply_pitti26 comprising the sequence as depicted in SEQ ID NO:1 as well as variants of this polypeptide. Furthermore, the present invention relates to nucleic acids and vectors encoding for said polypeptide and variants thereof as well as host cells comprising these nucleic... Agent: Fulbright & Jaworski L.L.P.

20090202513 - Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer: The present invention relates to methods and kits for the treatment of cancer. A novel drug combination comprising a ribonuclease compound and a thiazolidinedione compound has been identified as producing a synergistic cytotoxicity effect in cancer cells. Methods and kits pertaining to the co-administration of these compounds are discussed herein.... Agent: Wolf Greenfield & Sacks, P.C.

20090202511 - Targeted protein replacement for the treatment of lysosomal storage disorders: The present invention relates to compositions and methods for delivering lysosomal proteins. The compositions and methods described herein permit the targeted delivery of exogenous lysosomal proteins to cell surface proteins that allow their internalization via non-clathrin pathways. The present invention further relates to the use 10 of the compositions and... Agent: Jones Day

20090202514 - Agents for improving chronic obstructive pulmonary diseases: The present invention relates to agents for suppressing pulmonary emphysematous lesions and agents for suppressing emphysematous lesions which are suitable for treating and/or preventing COPD, which comprise as an active ingredient a substance having an activity of promoting CSPG degradation, inhibiting CSPG synthesis, or inhibiting CSPG sulfation (examples of such... Agent: Bozicevic, Field & Francis LLP

20090202515 - Agents for suppressing neural fibrotic degeneration: The present invention examined the accumulation of chondroitin sulfate proteoglycans (CSPGs). The present invention relates to neurodegeneration-suppressing agents that are suitable for gene therapy or prevention of neural fibrotic degenerative diseases which induce neural cell death due to an accumulation of abnormal proteins, where the therapies are based on siRNAs... Agent: Bozicevic, Field & Francis LLP

20090202516 - Inhibition and treatment of gastrointestinal biofilms: Orally administered physiologically acceptable anti-biofilm compositions comprising enzymes and if desired additional components such as antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful... Agent: Graybeal Jackson LLP

20090202517 - Agents for improving inflammatory bowel disease: The present inventors discovered for the first time that intestinal inflammation could be efficiently suppressed by suppressing the production or accumulation of chondroitin sulfate proteoglycans. Specifically, inflammation in the large intestine can be suppressed by using siRNA to suppress the expression of versican, which is one of the chondroitin sulfate... Agent: Bozicevic, Field & Francis LLP

20090202489 - Adenoviruses mutated in the va genes for cancer treatment: This invention refers to the use of an adenovirus for cancer treatment, being this adenovirus defective in its virus-associated (VA) RNAs. Said adenovirus has a mutation in the VAI or VAII gene sequence or both. This adenovirus may also have mutations in the sequences controlling expression of the VA RNAs.... Agent: Fish & Richardson P.C.

20090202523 - Antibodies against a peptide epitope of apoliporotein b: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent: Gauthier & Connors, LLP

20090202521 - Bifunctional polyazamacrocyclic chelating agents: A bifunctional polyazamacrocyclic chelating agent of the formula (I): wherein: and the variables A, L, Q, Q1, X, Y, Z, Z1, m, n and r are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a... Agent: Morgan Lewis & Bockius LLP

20090202519 - Compositions and methods for treating gram positive bacterial infection in a mammalian subject: Compositions and methods are provided for treating Gram positive bacterial infection in a mammalian subject. Compositions and methods are further provided for treating Gram positive bacterial skin infection in the mammalian subject. Compositions and method are provided that comprise administering to the mammalian subject an effective amount of a compound... Agent: The Scripps Research Institute

20090202525 - Dihydroisoindolones as allosteric modulators of glucokinase: m

20090202524 - Pai-1 expression and activity inhibitors for the treatment of ocular disorders: The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 expression or PAI-1 activity. Another embodiment of the present invention is a method of treating a... Agent: Alcon

20090202520 - Treatment and diagnostic methods for fibrosis related disorders: Compositions and methods are provided for the treatment of fibrosis related disorders utilizing the ratio of the concentration of serum amyloid P(SAP) to C-reactive protein (CRP) in a patient. The methods may further comprise determining the R131/H131 polymorphism of FcγRIIA. Diagnostic methods are also provided.... Agent: Ropes & Gray LLP

20090202518 - Treatment of sepsis and inflammation with alpha2a adrenergic antagonists: Provided are methods for treating a mammal undergoing sepsis, or at risk for sepsis. Also provided are methods of preventing or treating a physiological effect of sepsis in a mammal. Additionally provided are methods of inhibiting an inflammatory response in a mammal. Further provided is the use of an α2A-adrenergic... Agent: Amster, Rothstein & Ebenstein LLP

20090202522 - Use of goat serum for veterinary treatment: Methods for veterinary treatment of mammals are described, for treatment of conditions having an inflammatory component. The methods are particularly suited to treatment of cats, dogs, or horses.... Agent: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

20090202526 - Agonist anti-trkc antibodies and methods using same: The invention concerns agonist anti-trkC antibodies, polypeptides, and polynucleotides encoding the same. The invention further concerns use of such antibodies, polypeptides and/or polynucleotides in the treatment and/or prevention of neuropathies, such as sensory neuropathies, including taxol-induced sensory neuropathy, cisplatin-induced sensory neuropathy, and pyridoxine-induced sensory neuropathy.... Agent: Foley & Lardner LLP

20090202536 - Antibody-drug conjugates and methods: where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other... Agent: Genentech, Inc.

20090202541 - Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent: A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) a chemotherapeutic agent selected from antineoplastic agents, especially as defined herein, and agents effective in treating acute... Agent: Novartis Corporate Intellectual Property

20090202534 - Compositions and methods for modulating immune responses: Disclosed is a newly identified CD28 family member that functions as lymphocyte inhibitory receptor termed pG6b, which is expressed on T cells. Methods and compositions for modulating pG6b-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic, and research purposes are also disclosed.... Agent: Zymogenetics, Inc. Intellectual Property Department

20090202538 - F11 receptor (f11r) antagonists as therapeutic agents: The present invention provides a cell adhesion molecule (CAM), designated F11 receptor (F11R) and its use to inhibit platelet aggregation and platelet adhesion for the treatment and prevention of cardiovascular disorders. Cloned F11R cDNA and full length F11R cDNA and amino acid sequences are provided. F11R-antagonists and methods for the... Agent: Scully Scott Murphy & Presser, PC

20090202537 - Fcgammariib specific antibodies and methods of use thereof: The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc... Agent: Edell, Shapiro & Finnan, LLC

20090202532 - High functional bispecific antibody: The present invention is therefore related to a humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of... Agent: Birch Stewart Kolasch & Birch

20090202530 - Identification of tumor-associated antigens for diagnosis and therapy: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.... Agent: Mcandrews Held & Malloy, Ltd

20090202535 - Method for neutralizing effects of spla2: e

20090202539 - Method for treating cancer using anti-wnt2 monoclonal antibodies and sirna: This invention relates to methods of inhibiting the growth of cells, in particular cancer cells, that overexpress Wnt2. The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein, interferes with Wnt2 signaling or inhibits binding of the Wnt2 protein to another protein, such... Agent: Bozicevic, Field & Francis LLP

20090202540 - Substituted oxazaphosphorines: The present invention relates to new oxazaphosphorine alkylating agents and/or immuno-suppressive agents, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20090202528 - Surface-located streptococcus pneumoniae polypeptides: The present invention relates to cell-surface-located polypeptides of Streptococcus pneumoniae and their use in immunisation against Streptococcal infection, in diagnosis of Streptococcus and in identification of compounds with anti-Streptococcus activity. In a further aspect, the invention relates to antibodies capable of recognising cell surface-located polypeptides of Streptococcus pneumoniae and uses... Agent: Davis Wright Tremaine LLP - San Francisco

20090202533 - Treatment and prophylaxis of th2 mediated disorders: The present invention provides a method for the treatment or prophylaxis of T-helper type 2 (Th2)-mediated disorders using antagonists of IL-11.... Agent: Scully Scott Murphy & Presser, PC

20090202527 - Treatment for multiple sclerosis: Methods of treating multiple sclerosis and other disorders are disclosed.... Agent: Lando & Anastasi, LLP B2047

20090202529 - Use of egfr inhibitors to prevent or treat obesity: Methods of treating or preventing obesity or obesity related disorders in a subject are provided, comprising administering to the subject a treatment effective in reducing one or more activities of an epidermal growth factor receptor (EGFR) in the subject. Methods of screening for compositions that can modulate one or more... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090202531 - Uses of anti-cd40 antibodies: Methods for treating a human patient for an inflammatory or autoimmune disease that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who... Agent: Alston & Bird LLP

20090202542 - Rage protein derivatives: The present invention is drawn to fusion proteins comprising a Receptor for Advanced Glycation Endproducts (RAGE) and an immunoglobulin element. The invention also encompasses methods of treating a condition characterized by activation of an inflammatory cytokine cascade comprising administering such fusion proteins. The invention is also drawn to nucleic acids... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090202548 - Antibodies and related molecules that bind to psca proteins: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The... Agent: Agensys C/o Morrison & Foerster LLP

20090202547 - Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof: Molecules comprising the antigen-binding portion of antibodies that block constitutive and/or ligand-dependent activation of a receptor protein tyrosine kinase, such as fibroblast growth factor receptor 3 (FGFR3), are found through screening methods, where a soluble dimeric form of a receptor protein tyrosine kinase is used as target for screening a... Agent: Winston & Strawn LLP Patent Department

20090202546 - Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.... Agent: Genentech, Inc.

20090202543 - Gene and polypeptide relating to breast cancer: The present application provides novel human gene B7330N whose expression is markedly elevated in breast cancers. The gene and polypeptide encoded by the gene can be used, for example, in the diagnosis of breast cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of... Agent: Townsend And Townsend And Crew, LLP

20090202545 - Melanoma biomarker and methods of uses: The present invention relates to the use of TROY, also called tumor necrosis factor receptor superfamily, member 19 (TNFRSF 19) also called toxicity and JNK inducer (TAJ), in diagnosis and therapy of non-epithelial cancers, such as melanoma. Accordingly, the invention provides in vitro and in vivo diagnostic and/or prognostic methods... Agent: Ronald I. Eisenstein

20090202544 - Methods of treating diseases by targeting silt3: This invention provides a method of treating a subject afflicted with a disease, comprising withdrawing blood from the subject, treating the withdrawn blood so as to remove sILT3 from the blood, and returning the treated blood to the subject, thereby treating the subject afflicted with the disease. This invention also... Agent: Ropes & Gray LLP

20090202549 - Anti-il-12 antibodies, epitopes, compositions, methods and uses: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids... Agent: Philip S. Johnson Johnson & Johnson

20090202555 - Antibodies against a peptide epitope of apoliporotein b: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent: Gauthier & Connors, LLP

20090202553 - Antibodies against anthrax protective antigen: A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090202552 - Gene expressed in prostate cancer and methods of use: A new polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Novel Gene Expressed in Prostate (NGEP). Polynucleotides encoding NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies are disclosed that specifically bind NGEP.... Agent: Klarquist Sparkman, LLP

20090202551 - Immunomodulation by altering sphingosine 1-phosphate lyase (spl) activity: Compositions and methods for modulating immune function are provided based on the unexpected discovery that inhibition of sphingosine-1-phosphate lyase (SPL) activity confers useful immunosuppressive effects, for example to modulate immune function in treatment or prevention of inflammation, transplant graft rejection, autoimmune disease, allergy, or other conditions, including therapeutic alteration of... Agent: Seed Intellectual Property Law Group PLLC

20090202554 - Method of modulation of interaction between receptor and ligand: The present invention relates to a method for modulating the interaction between at least two proteins, wherein at least one of the two proteins is a functional cell-surface receptor and the other protein is the receptor ligand. The invention features a binding site of said functional cell-surface receptor on the... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090202550 - Monoclonal antibodies and immunodetection assay specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor: The present invention describes monoclonal antibodies specific for the chemotactic epitope of the uPAR. In particular, the invention comprises monoclonal antibodies against uPAR fragments specifically recognizing in whole or in part the chemotactic sequence of uPAR connecting domain 1 to domain 2.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090202556 - Anti-claudin-4 antibody: An object of the present invention is to provide a monoclonal antibody which is useful as a diagnostic agent or a therapeutic agent for a disease relating to a polypeptide encoded by Claudin-4 (hereinafter referred to as “CLDN4”) gene or a polypeptide encoded by a Claudin-3 (hereinafter referred to as... Agent: Sughrue-265550

20090202557 - Compositions and methods for crystallizing antibody fragments: The invention provides methods of crystallizing antibodies and fragments thereof as well as crystals produced thereby. More particularly, the invention provides methods of crystallizing human and non-human Fab fragments of antibodies, either alone or as co-crystals with their target ligand. For example, a crystal comprising a murine Fab fragment of... Agent: Abbott Bioresearch

20090202558 - Tnfalpha-neutralizing antibodies: The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of... Agent: Bozicevic, Field & Francis LLP

20090202560 - Method for diagnosing efficacy of xenotypic antibody therapy: The invention concerns methods and compositions for intiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen.... Agent: Ropes & Gray LLP

20090202559 - Anti-mesothelin antibodies: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well... Agent: Woodcock Washburn LLP

20090202561 - Novel raag10 cell surface target and a family of antibodies recognizing that target: The invention provides the identification and characterization of disease and cancer-associated antigen, RAAG10. The invention also provides a family of monoclonal antibodies that bind to antigen RAAG10, methods of diagnosing and treating various human cancers and diseases that express RAAG10.... Agent: Morrison & Foerster LLP

20090202562 - Anti-gfralpha3 antibodies: Antibodies and antibody fragments that bind to the receptor GFRalpha3 and inhibit formation of a Neublastin-GFRalpha3-Ret ternary complex are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit phosphorylation of Ret in a cell and treat disorders and in a subject.... Agent: Fish & Richardson P.C.

20090202563 - C20orf23 as modifier of the igfr pathway and methods of use: Human C20ORF23 genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of C20ORF23 are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090202564 - Methods of isolating stem cells: The present inventors discovered for the first time that labeling cell nuclei makes it possible to efficiently isolate stem cells. Namely, it was elucidated that stem cells with labeled nuclei remained labeled even after cell division, and showed self-renewing and long-living abilities characteristic of stem cells. Efficient isolation of stem... Agent: Bozicevic, Field & Francis LLP

20090202565 - Torc polynucleotides and polypeptides and method of use: The present invention relates to a broad range of methods that utilize a transducer of regulated CREB (TORC)-related polynucleotide, polypeptide, or TORC-specific antibody. In addition the invention relates to TORC-related polynucleotide, polypeptide, or TORC-specific antibody compositions, including variants of TORC wild-type sequences. Exemplary methods include a method of stimulating a... Agent: Novartis Corporate Intellectual Property

20090202566 - Use of the endo-180 gene and polypeptide for diagnosis and treatment: This application is directed to a process of identifying a compound capable of modulating activity of a human ENDO180 receptor that comprises the steps of measuring the binding of the ENDO180 receptor to an interactor with which the ENDO180 receptor interacts specifically in vivo, in the absence or presence of... Agent: Cooper & Dunham, LLP

20090202568 - Binding members for interleukin-4 receptor alpha (il-4ra)-173: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4Rα), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4Rα, IL-4 and/or IL-13, examples of which are asthma and COPD.... Agent: Astrazeneca R&d Boston

20090202567 - Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating b cell neoplasm: The invention provides nine oligonucleotides with sequences of SEQ ID NO: 1-9 or their functional homologues or a composition comprising the same and a method for treating B cell neoplasm by using the oligonucleotides or their functional homologues or the composition comprising the oligonucleotides. The oligonucleotides induce the apoptosis of... Agent: Morgan, Lewis & Bockius LLP (sf)

20090202570 - Pm-2 antibodies, functional fragments and methods for treating metastasis: The invention provides PM-2 antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions. Antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions are useful in treatment and diagnostic methods. One method includes treating metastasis of a neoplasia, tumor or cancer in a subject in... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090202569 - Prophylactic/therapeutic agent for cancer: The present invention provides a preventative/therapeutic agent for cancer capable of selectively and effectively killing cancer cells. A medicament of the present invention prepared by combining at least one selected from a substance that inhibits the activity of an enzyme belonging to the acyl-CoA synthase family and a substance that... Agent: Foley And Lardner LLP Suite 500

20090202571 - Bioreductively-activated prodrugs: A compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: —Ar is a substituted heteroaryl group bearing at least one nitro or azido group or is a benzoquinone, naphthoquinone or fused heterocyloquinone; -R1 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090202572 - Compositions and methods for modulating bone mass: The instant invention relates to compositions and methods for treating or preventing bone diseases. In certain aspects, the invention provides compositions comprising a β-adrenergic antagonist or agonist associated to a bone-targeted molecule, as well as methods of modulating bone mass and/or growth in a mammal by administering a composition of... Agent: Dla Piper LLP (us)

20090202573 - Polymeric conjugates containing positively-charged moieties: The present invention provides polymeric conjugates containing positively charged moieties. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed.... Agent: Lucas & Mercanti, LLP

20090202575 - Immunostimulatory nucleic acid molecules: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20090202574 - Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer: The present invention relates to administration of metal ion-saturated lactoferrin, preferably bovine lactoferrin, preferably iron-saturated bovine lactoferrin, or a metal ion-saturated functional variant or fragment thereof to inhibit tumour formation or growth, maintain or improve one or both of the white blood cell count and red blood cell count, stimulate... Agent: Knobbe Martens Olson & Bear LLP

20090202577 - Casb618 polynucleotides and polypeptides and their use: CASB618 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB618 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly ovarian and colon cancers, autoimmune diseases, and related conditions.... Agent: Glaxosmithkline Corporate Intellectual Property

20090202576 - Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides: The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 8, 67, 89, as well as peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, and having cytotoxic T cell inducibility. The present invention also... Agent: Townsend And Townsend And Crew, LLP

20090202578 - Surface proteins from coagulase-negative staphylococci and staphylococcus aureus that generate cross-reactive monoclonal and polyclonal antibodies: Surface proteins are provided which generate polyclonal and monoclonal antibodies which are cross-reactive to both coagulase-positive staphylococcus bacteria, such as S. aureus and to coagulase-negative bacteria, such as S. epidermidis and S. hemolyticus. The antibodies may be generated from surface proteins that have been isolated on the basis of characteristics... Agent: Stites & Harbison PLLC

20090202579 - Methods and compositions for treating and preventing malaria (2): The present invention provides compositions and methods useful in the treatment or prevention of a condition caused by or associated with infection by Plasmodium falciparum, such as malaria. The compositions include various antigens of Plasmodium falciparum, both alone and in combination. The invention further includes fragments of the antigens.... Agent: Birch Stewart Kolasch & Birch

20090202580 - Method for the preparation of specific antibodies against saccharidic antigens: The present invention relates to new compounds useful for the stimulation of the production of antibodies. Said compounds comprises a saccharidic tumor antigen and a polymeric scaffold. The present invention also encompasses conjugated compounds useful in ELISA assay for the selection of antibodies against saccharidic antigens.... Agent: Bracco Research Usa Inc.

20090202581 - Cosmetic formulation: The present invention provides an improved skin care formulation for enhancing the overall quality of the skin and treating aging skin comprising cassia angustilfolia seed polysaccharide, dipeptide-4, glutamylamidoethyl indole, and kluyveromyces extract, in a cosmetically/dermatologically acceptable medium. The formulation improves skin quality by moisturizing and softening the skin, while protecting... Agent: Cislo & Thomas LLP

20090202582 - Water-disposable or water-soluble polymer film as a vehicle for dermatologic and cosmetic active agents: Described are water-dispersible or water-soluble polymer films incorporating at least one cosmetic or dermatologic active agent and a method for the production thereof. The active agents involved are particularly anti-cellulite agents, moisturizers, anti-wrinkle agents and skin smoothing agents.... Agent: Maginot, Moore & Beck, LLP Chase Tower

20090202583 - Rhinovirus vaccines: The present invention relates generally to peptide vaccines. More specifically, the present invention relates to vaccines against rhinoviruses and other related and non-related pathogenic animal viruses. In addition, the present invention relates generally to methods of designing and producing vaccines against viruses and, in certain embodiments, against rhinoviruses and other... Agent: Bryan Cave LLP

20090202585 - Tat-based tolerogen compositions and methods for making and using same: A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune... Agent: K&l Gates LLP

20090202584 - Treatment of epstein-barr virus-associated diseases: The present invention relates to a vaccine for the treatment or prevention of an EBV-associated disease in a subject, wherein said vaccine comprises a synthetic polypeptide comprising a plurality of different segments of at least one parent EBV polypeptide, and wherein the segments are linked together in a different relationship... Agent: Knobbe Martens Olson & Bear LLP

20090202586 - Attenuated vaccine for tularemia: A scan of F. tularensis genome for homology to a regulatory protein that controls virulence identified gene FTL0552. A knock out mutation in FTL0552 was created using reverse transcriptase PCR and the construct inserted into F. tularensis. This mutant was defective for survival in macrophages and found avirulent in in... Agent: Smith Hopen, Pa

20090202587 - Compositions comprising hmw-maa and fragments thereof, and methods of use thereof: This invention provides recombinant polypeptides comprising a fragment of a High Molecular Weight Melanoma-Associated Antigen (HMW-MAA), recombinant Listeria strains comprising same, and methods of inducing an anti-HMW-MAA and anti HER-2/neu immune response thus treating and impeding the growth of tumors, comprising administering same.... Agent: Pearl Cohen Zedek Latzer, LLP

20090202588 - Nucleic acids encoding tgev and prrsv sequences for improved expression of prrsv sequences: i

20090202589 - Fermenter system for biotechnical processes: A fermenter for use in biotechnical processes in particular for culturing cells is disclosed. The object, to provide a fermenter vessel (1) the inner volume of which can be optically monitored and which fermenter vessel can also be efficiently sterilized, is achieved by a fermenter vessel (1) having an outside... Agent: Novartis Vaccines And Diagnostics Inc.

20090202590 - Influenza vaccines extemporaneously adsorbed to aluminium adjuvants: Antigen and adjuvant components of an adjuvanted influenza vaccine are not mixed during manufacture, but are provided as separate components for extemporaneous mixing at the time of use, for example as a kit comprising (i) an antigen component, comprising an influenza virus antigen; and (ii) an adjuvant component, comprising an... Agent: Novartis Vaccines And Diagnostics Inc.

20090202591 - Leucine-based motif and clostridial neurotoxins: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques.... Agent: Allergan, Inc.

20090202592 - Cytolethal distending toxin, inhibition and use thereof: This invention relates to immunotoxins and their use. Specifically, the invention relates to compositions comprising Cdt toxins or their inhibitors and their use in methods for treating infectious and proliferative diseases.... Agent: Pearl Cohen Zedek Latzer, LLP

20090202593 - Novel immunogenic compositions for the prevention and treatment of meningococcal disease: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of... Agent: Wyeth Patent Law Group

20090202594 - Anti-bacterial vaccine compositions: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.... Agent: Pharmacia & Upjohn

20090202595 - Anti-pdef antibodies and uses thereof: The present invention relates to an isolated antibody or antigen-binding fragment thereof that specifically binds with high affinity to at least a portion of a segment of human prostate-derived Ets transcription factor (PDEF). The anti-PDEF antibody of the present invention is effective in prognostic and diagnostic assays for detecting PDEF... Agent: Heslin Rothenberg Farley & Mesiti PC

20090202597 - Ache-nmda combination wafer: Sheet-like pharmaceutical preparations based on hydrophilic polymers, which rapidly disintegrate upon contact with moisture and which are used to treat dementia-related illnesses The dosage form contains an active agent combination of at least two active agents which are suitable for the treatment of dementia (antidementia agents). The antidementia agents should... Agent: D Peter Hochberg D Peter Hochberg Co

20090202596 - Pharmaceutical compositions with biological barriers permeation enhancing properties: Pharmaceutical compositions comprising a water/oil/water (W1/O2/W3) or an oil/water/oil (O1/W2/O3) double microemulsion, with droplets size below one micron, with the drug included in the internal water phase W1 or internal oil phase 01, whereas the external oil 02 and second water phase W3 or the external water phase W2 and... Agent: Young & Thompson

20090202598 - Invert emulsion comprising an aqueous solution of hydrogen peroxide and an inert phase with water solubility of less than 1%: The invention relates to an invert emulsion for bleaching keratin fibres and, in particular, human keratin fibres, such as hair. According to the invention, the emulsion consists of an inert phase comprising at least one non-oxygenated, non-perfluorinated liquid compound having a water solubility at 25° C. of less than 1%... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090202600 - Oil-in-water emulsified milky skin cosmetic preparation: The present invention provides an oil-in-water emulsified milky skin cosmetic preparation, which is able to impart a refreshing feeling, an astringent effect, a moisturizing effect, and a softening effect to skin, when it is singly used, and which is excellent in terms of emulsion stability a